{
  "questions": [
    {
      "id": "65cfae831930410b13000015",
      "type": "summary",
      "body": "What is the use of P85-Ab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
        "http://www.ncbi.nlm.nih.gov/pubmed/16597877",
        "http://www.ncbi.nlm.nih.gov/pubmed/33193880",
        "http://www.ncbi.nlm.nih.gov/pubmed/11316043",
        "http://www.ncbi.nlm.nih.gov/pubmed/17129209",
        "http://www.ncbi.nlm.nih.gov/pubmed/26884888",
        "http://www.ncbi.nlm.nih.gov/pubmed/6299561",
        "http://www.ncbi.nlm.nih.gov/pubmed/7931181",
        "http://www.ncbi.nlm.nih.gov/pubmed/15229902",
        "http://www.ncbi.nlm.nih.gov/pubmed/15195243"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
          "text": "After a retrospective case-control study, the performance of the novel biomarker anti-BNLF2b total antibody (P85-Ab) was validated through a large-scale prospective screening program and compared with that of the standard two-antibody-based screening method (EBV nuclear antigen 1 [EBNA1]-IgA and EBV-specific viral capsid antigen [VCA]-IgA). RESULTS\nP85-Ab was the most promising biomarker for nasopharyngeal carcinoma screening, with high sensitivity (94.4%; 95% confidence interval [CI], 86.4 to 97.8) and specificity (99.6%; 95% CI, 97.8 to 99.9) in the retrospective case-control study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 518,
          "endSection": "abstract",
          "offsetInEndSection": 1111
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
          "text": "After a retrospective case-control study, the performance of the novel biomarker anti-BNLF2b total antibody (P85-Ab) was validated through a large-scale prospective screening program and compared with that of the standard two-antibody-based screening method (EBV nuclear antigen 1 [EBNA1]-IgA and EBV-specific viral capsid antigen [VCA]-IgA). RESULTS\nP85-Ab was the most promising biomarker for nasopharyngeal carcinoma screening, with high sensitivity (94.4%; 95% confidence interval [CI], 86.4 to 97.8) and specificity (99.6%; 95% CI, 97.8 to 99.9) in the retrospective case-control study. Among the 24,852 eligible participants in the prospective cohort, 47 cases of nasopharyngeal carcinoma (38 at an early stage) were identified.",
          "beginSection": "abstract",
          "offsetInBeginSection": 518,
          "endSection": "abstract",
          "offsetInEndSection": 1254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
          "text": "METHODS\nWe designed a peptide library representing highly ranked B-cell epitopes of EBV coding sequences to identify novel serologic biomarkers for nasopharyngeal carcinoma. After a retrospective case-control study, the performance of the novel biomarker anti-BNLF2b total antibody (P85-Ab) was validated through a large-scale prospective screening program and compared with that of the standard two-antibody-based screening method (EBV nuclear antigen 1 [EBNA1]-IgA and EBV-specific viral capsid antigen [VCA]-IgA). RESULTS\nP85-Ab was the most promising biomarker for nasopharyngeal carcinoma screening, with high sensitivity (94.4%; 95% confidence interval [CI], 86.4 to 97.8) and specificity (99.6%; 95% CI, 97.8 to 99.9) in the retrospective case-control study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 344,
          "endSection": "abstract",
          "offsetInEndSection": 1111
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
          "text": "METHODS: We designed a peptide library representing highly ranked B-cell epitopes of EBV coding sequences to identify novel serologic biomarkers for nasopharyngeal carcinoma. After a retrospective case-control study, the performance of the novel biomarker anti-BNLF2b total antibody (P85-Ab) was validated through a large-scale prospective screening program and compared with that of the standard two-antibody-based screening method (EBV nuclear antigen 1 [EBNA1]-IgA and EBV-specific viral capsid antigen [VCA]-IgA).",
          "beginSection": "abstract",
          "offsetInBeginSection": 342,
          "endSection": "abstract",
          "offsetInEndSection": 859
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
          "text": "METHODS\nWe designed a peptide library representing highly ranked B-cell epitopes of EBV coding sequences to identify novel serologic biomarkers for nasopharyngeal carcinoma. After a retrospective case-control study, the performance of the novel biomarker anti-BNLF2b total antibody (P85-Ab) was validated through a large-scale prospective screening program and compared with that of the standard two-antibody-based screening method (EBV nuclear antigen 1 [EBNA1]-IgA and EBV-specific viral capsid antigen [VCA]-IgA).",
          "beginSection": "abstract",
          "offsetInBeginSection": 344,
          "endSection": "abstract",
          "offsetInEndSection": 860
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
          "text": "However, the positive predictive value of current screening strategies is unsatisfactory even in areas where nasopharyngeal carcinoma is endemic. METHODS\nWe designed a peptide library representing highly ranked B-cell epitopes of EBV coding sequences to identify novel serologic biomarkers for nasopharyngeal carcinoma. After a retrospective case-control study, the performance of the novel biomarker anti-BNLF2b total antibody (P85-Ab) was validated through a large-scale prospective screening program and compared with that of the standard two-antibody-based screening method (EBV nuclear antigen 1 [EBNA1]-IgA and EBV-specific viral capsid antigen [VCA]-IgA).",
          "beginSection": "abstract",
          "offsetInBeginSection": 196,
          "endSection": "abstract",
          "offsetInEndSection": 860
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
          "text": "CONCLUSIONS\nOur results suggest that P85-Ab is a promising novel biomarker for nasopharyngeal carcinoma screening, with higher sensitivity, specificity, and positive predictive value than the standard two-antibody method. (Funded by the National Key Research and Development Program of China and others; ClinicalTrials.gov number, NCT04085900. ).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1721,
          "endSection": "abstract",
          "offsetInEndSection": 2066
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
          "text": "CONCLUSIONS\nOur results suggest that P85-Ab is a promising novel biomarker for nasopharyngeal carcinoma screening, with higher sensitivity, specificity, and positive predictive value than the standard two-antibody method. (Funded by the National Key Research and Development Program of China and others; ClinicalTrials.gov number, NCT04085900.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1721,
          "endSection": "abstract",
          "offsetInEndSection": 2064
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33193880",
          "text": "Background: IgA antibodies against Epstein-Barr virus (EBV) capsid antigen (VCA) and nuclear antigen 1 (EBNA1) have been proposed to facilitate the diagnosis and early detection of nasopharyngeal carcinoma (NPC) in high-incidence regions. However, while new methodologies and new platforms for the detection of VCA-IgA and EBNA1-IgA have become available, proper interassay simultaneous comparisons have not been carried out.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 425
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
          "text": "CONCLUSIONS: Our results suggest that P85-Ab is a promising novel biomarker for nasopharyngeal carcinoma screening, with higher sensitivity, specificity, and positive predictive value than the standard two-antibody method. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 1715,
          "endSection": "abstract",
          "offsetInEndSection": 1938
        }
      ],
      "ideal_answer": "P85-Ab is a promising novel biomarker for nasopharyngeal carcinoma screening, with higher sensitivity, specificity, and positive predictive value than the standard two-antibody method (EBV nuclear antigen 1 [EBNA1]-IgA and EBV-specific viral capsid antigen [VCA]-IgA).",
      "exact_answer": "n/a"
    },
    {
      "id": "662fc44b187cba990d000015",
      "type": "list",
      "body": "What are the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
        "http://www.ncbi.nlm.nih.gov/pubmed/34248544",
        "http://www.ncbi.nlm.nih.gov/pubmed/29705823",
        "http://www.ncbi.nlm.nih.gov/pubmed/7446137",
        "http://www.ncbi.nlm.nih.gov/pubmed/17976801",
        "http://www.ncbi.nlm.nih.gov/pubmed/9175606",
        "http://www.ncbi.nlm.nih.gov/pubmed/12900883",
        "http://www.ncbi.nlm.nih.gov/pubmed/30244364",
        "http://www.ncbi.nlm.nih.gov/pubmed/768533",
        "http://www.ncbi.nlm.nih.gov/pubmed/20395092"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "CONCLUSIONS\nLack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic options. The findings support the need for a larger, randomized study to assess and compare these agents with other potential premedications such as scopolamine and atropine in prevention of irinotecan-related cholinergic syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1545,
          "endSection": "abstract",
          "offsetInEndSection": 1970
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "Lack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic options.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1548,
          "endSection": "abstract",
          "offsetInEndSection": 1738
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "To date, no formal studies have compared atropine-diphenoxylate and hyoscyamine as premedications for prophylaxis of the cholinergic syndrome with irinotecan infusion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 191,
          "endSection": "abstract",
          "offsetInEndSection": 358
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "CONCLUSIONS\nLack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic options.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1545,
          "endSection": "abstract",
          "offsetInEndSection": 1747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "To date, no formal studies have compared atropine-diphenoxylate and hyoscyamine as premedications for prophylaxis of the cholinergic syndrome with irinotecan infusion. OBJECTIVES\nTo compare the incidence of cholinergic syndrome with irinotecan using atropine-diphenoxylate or hyoscyamine as premedication.",
          "beginSection": "abstract",
          "offsetInBeginSection": 191,
          "endSection": "abstract",
          "offsetInEndSection": 498
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "LIMITATIONS\nThis study was subjected to vulnerabilities to bias and random error because of its observational retrospective design and small number of participants. CONCLUSIONS\nLack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic options. The findings support the need for a larger, randomized study to assess and compare these agents with other potential premedications such as scopolamine and atropine in prevention of irinotecan-related cholinergic syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1378,
          "endSection": "abstract",
          "offsetInEndSection": 1970
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "LIMITATIONS\nThis study was subjected to vulnerabilities to bias and random error because of its observational retrospective design and small number of participants. CONCLUSIONS\nLack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic options.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1378,
          "endSection": "abstract",
          "offsetInEndSection": 1747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "Cholinergic side effects can be ameliorated or prevented with anticholinergic agents. To date, no formal studies have compared atropine-diphenoxylate and hyoscyamine as premedications for prophylaxis of the cholinergic syndrome with irinotecan infusion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 105,
          "endSection": "abstract",
          "offsetInEndSection": 358
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "To date, no formal studies have compared atropine-diphenoxylate and hyoscyamine as premedications for prophylaxis of the cholinergic syndrome with irinotecan infusion. OBJECTIVES\nTo compare the incidence of cholinergic syndrome with irinotecan using atropine-diphenoxylate or hyoscyamine as premedication. METHODS\nWe conducted a retrospective, single-center, nonrandomized, cohort study of adult patients treated with atropine-diphenoxylate or hyoscyamine as premedication before receiving irinotecan.",
          "beginSection": "abstract",
          "offsetInBeginSection": 191,
          "endSection": "abstract",
          "offsetInEndSection": 696
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "Cholinergic side effects can be ameliorated or prevented with anticholinergic agents. To date, no formal studies have compared atropine-diphenoxylate and hyoscyamine as premedications for prophylaxis of the cholinergic syndrome with irinotecan infusion. OBJECTIVES\nTo compare the incidence of cholinergic syndrome with irinotecan using atropine-diphenoxylate or hyoscyamine as premedication.",
          "beginSection": "abstract",
          "offsetInBeginSection": 105,
          "endSection": "abstract",
          "offsetInEndSection": 498
        }
      ],
      "ideal_answer": "Atropine-diphenoxylate and hyoscyamine are both indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan.",
      "exact_answer": [
        [
          "atropine-diphenoxylate"
        ],
        [
          "hyoscyamine"
        ]
      ]
    },
    {
      "id": "662cf81b187cba990d000001",
      "type": "summary",
      "body": "What is the function of FAM134B (also called JK-1, RETREG1)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31930741",
        "http://www.ncbi.nlm.nih.gov/pubmed/33199694",
        "http://www.ncbi.nlm.nih.gov/pubmed/37813237",
        "http://www.ncbi.nlm.nih.gov/pubmed/37728036",
        "http://www.ncbi.nlm.nih.gov/pubmed/36056188",
        "http://www.ncbi.nlm.nih.gov/pubmed/35477002",
        "http://www.ncbi.nlm.nih.gov/pubmed/35253652",
        "http://www.ncbi.nlm.nih.gov/pubmed/34338405",
        "http://www.ncbi.nlm.nih.gov/pubmed/35436985",
        "http://www.ncbi.nlm.nih.gov/pubmed/32716134"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33199694",
          "text": "FAM134B (also called JK-1, RETREG1), a member of the family with sequence similarity 134, was originally discovered as an oncogene in esophageal squamous cell carcinoma. However, its most famous function is that of an ER-phagy-regulating receptor. Over the decades, the powerful biological functions of FAM134B were gradually revealed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 335
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33199694",
          "text": "FAM134B (also called JK-1, RETREG1), a member of the family with sequence similarity 134, was originally discovered as an oncogene in esophageal squamous cell carcinoma. However, its most famous function is that of an ER-phagy-regulating receptor.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 247
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37813237",
          "text": "FAM134B, the initial endoplasmic reticulum (ER)-phagy receptor identified, facilitates ER-phagy during ER stress.",
          "beginSection": "abstract",
          "offsetInBeginSection": 6,
          "endSection": "abstract",
          "offsetInEndSection": 119
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37813237",
          "text": "AIMS\nFAM134B, the initial endoplasmic reticulum (ER)-phagy receptor identified, facilitates ER-phagy during ER stress. The malfunction of FAM134B has been demonstrated to have a crucial role in the pathological mechanisms of diverse human ailments.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 248
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37813237",
          "text": "AIMS\nFAM134B, the initial endoplasmic reticulum (ER)-phagy receptor identified, facilitates ER-phagy during ER stress. The malfunction of FAM134B has been demonstrated to have a crucial role in the pathological mechanisms of diverse human ailments. However, the role of FAM134B-mediated ER-phagy in ototoxicity, particularly in cisplatin-induced ototoxicity, remains unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 375
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35477002",
          "text": "FAM134B is also known as the reticulophagy regulator 1 (RETREG1) or JK-1. FAM134B consists of two long hydrophobic fragments with a reticulon-homology domain, an N-terminal cytoplasmic domain, and a C-terminal cytoplasmic domain. FAM134B plays an important role in regulating selective ER-phagy, and is related to the occurrence and development of many diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 362
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37813237",
          "text": "AIMS\nFAM134B, the initial endoplasmic reticulum (ER)-phagy receptor identified, facilitates ER-phagy during ER stress.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 118
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33199694",
          "text": "FAM134B (also called JK-1, RETREG1), a member of the family with sequence similarity 134, was originally discovered as an oncogene in esophageal squamous cell carcinoma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 169
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31930741",
          "text": "Here, we show that oligomerization of ER-phagy receptor FAM134B (also referred to as reticulophagy regulator 1 or RETREG1) through its reticulon-homology domain is required for membrane fragmentation in vitro and ER-phagy in vivo. Under ER-stress conditions, activated CAMK2B phosphorylates the reticulon-homology domain of FAM134B, which enhances FAM134B oligomerization and activity in membrane fragmentation to accommodate high demand for ER-phagy. Unexpectedly, FAM134B G216R, a variant derived from a type II hereditary sensory and autonomic neuropathy (HSAN) patient, exhibits gain-of-function defects, such as hyperactive self-association and membrane scission, which results in excessive ER-phagy and sensory neuron death.",
          "beginSection": "abstract",
          "offsetInBeginSection": 235,
          "endSection": "abstract",
          "offsetInEndSection": 965
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31930741",
          "text": "Degradation of endoplasmic reticulum (ER) by selective autophagy (ER-phagy) is crucial for ER homeostasis. However, it remains unclear how ER scission is regulated for subsequent autophagosomal sequestration and lysosomal degradation. Here, we show that oligomerization of ER-phagy receptor FAM134B (also referred to as reticulophagy regulator 1 or RETREG1) through its reticulon-homology domain is required for membrane fragmentation in vitro and ER-phagy in vivo.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 465
        }
      ],
      "ideal_answer": "FAM134B, also known as JK-1 or RETREG1, is an endoplasmic reticulum (ER)-phagy receptor that facilitates ER-phagy during ER stress. It has been identified as an oncogene in esophageal squamous cell carcinoma, and its upregulation inhibits endoplasmic reticulum stress-related degradation protein expression, promoting hepatocellular carcinogenesis.",
      "exact_answer": "n/a"
    },
    {
      "id": "661688cefdcbea915f000053",
      "type": "list",
      "body": "What cancers are associated with human papilloma virus?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
        "http://www.ncbi.nlm.nih.gov/pubmed/36691362",
        "http://www.ncbi.nlm.nih.gov/pubmed/36730877",
        "http://www.ncbi.nlm.nih.gov/pubmed/22154608",
        "http://www.ncbi.nlm.nih.gov/pubmed/18097454",
        "http://www.ncbi.nlm.nih.gov/pubmed/23989943",
        "http://www.ncbi.nlm.nih.gov/pubmed/35176174",
        "http://www.ncbi.nlm.nih.gov/pubmed/21546122",
        "http://www.ncbi.nlm.nih.gov/pubmed/9372384",
        "http://www.ncbi.nlm.nih.gov/pubmed/28351269"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18097454",
          "text": "Human papillomavirus in cervical and head-and-neck cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 58
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35176174",
          "text": "Human papillomavirus (HPV)-positive head and neck cancer (HNC) risk is associated with distinct human leukocyte antigen variants, and some of them are shared by both cervical cancer and HPV-positive HNC. LAY SUMMARY\nCervical cancer studies highlight that human papillomavirus (HPV)-driven cancer risk is linked with human leukocyte antigen (HLA) polymorphism. Hence, the current study was designed to investigate the HLA associations in HPV-positive and HPV-negative head and neck cancer (HNC) and compare these associations with cervical cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1906,
          "endSection": "abstract",
          "offsetInEndSection": 2454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35176174",
          "text": "Human papillomavirus (HPV)-positive head and neck cancer (HNC) risk is associated with distinct human leukocyte antigen variants, and some of them are shared by both cervical cancer and HPV-positive HNC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1906,
          "endSection": "abstract",
          "offsetInEndSection": 2109
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35176174",
          "text": "Human papillomavirus (HPV)-positive head and neck cancer (HNC) risk is associated with distinct human leukocyte antigen variants, and some of them are shared by both cervical cancer and HPV-positive HNC. LAY SUMMARY\nCervical cancer studies highlight that human papillomavirus (HPV)-driven cancer risk is linked with human leukocyte antigen (HLA) polymorphism.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1906,
          "endSection": "abstract",
          "offsetInEndSection": 2267
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35176174",
          "text": "LAY SUMMARY\nCervical cancer studies highlight that human papillomavirus (HPV)-driven cancer risk is linked with human leukocyte antigen (HLA) polymorphism. Hence, the current study was designed to investigate the HLA associations in HPV-positive and HPV-negative head and neck cancer (HNC) and compare these associations with cervical cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2112,
          "endSection": "abstract",
          "offsetInEndSection": 2454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22154608",
          "text": "In addition, human papilloma virus (HPV) has been identified as an important causative factor of tonsillar carcinomas. In contrast, chromosomal instability and aneuploidy identifiable by DNA measurement are predominately associated with cancer progression. This selective review summarizes our studies that aimed to gain a better understanding of the biology and pathology of lung cancer and head and neck cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 248,
          "endSection": "abstract",
          "offsetInEndSection": 661
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22154608",
          "text": "While the vast majority of lung cancers are caused by cigarette smoking alone, smoking together with heavy drinking are the major etiological agents of head and neck cancer. In addition, human papilloma virus (HPV) has been identified as an important causative factor of tonsillar carcinomas. In contrast, chromosomal instability and aneuploidy identifiable by DNA measurement are predominately associated with cancer progression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 74,
          "endSection": "abstract",
          "offsetInEndSection": 504
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35176174",
          "text": "LAY SUMMARY\nCervical cancer studies highlight that human papillomavirus (HPV)-driven cancer risk is linked with human leukocyte antigen (HLA) polymorphism. Hence, the current study was designed to investigate the HLA associations in HPV-positive and HPV-negative head and neck cancer (HNC) and compare these associations with cervical cancer. Several lead signals reported by previous HNC and cervical genome-wide association studies were replicated in the current study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2112,
          "endSection": "abstract",
          "offsetInEndSection": 2583
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35176174",
          "text": "LAY SUMMARY\nCervical cancer studies highlight that human papillomavirus (HPV)-driven cancer risk is linked with human leukocyte antigen (HLA) polymorphism.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2112,
          "endSection": "abstract",
          "offsetInEndSection": 2267
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18097454",
          "text": "Cervical cancer is a major cause of cancer mortality in women worldwide and is initiated by infection with high-risk human papillomaviruses (HPVs). High-risk HPVs, especially HPV-16, are associated with other anogenital cancers and a subgroup of head-and-neck cancers. Indeed, HPV infection could account for the development of head-and-neck cancer in certain individuals that lack the classical risk factors for this disease (tobacco and alcohol abuse).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 454
        }
      ],
      "ideal_answer": "Human papillomavirus (HPV) is associated with cervical cancer, head and neck cancer, esophageal cancer, brain and lung tumors, mouth cancer, throat cancer, anus cancer, and penis cancer.",
      "exact_answer": [
        [
          "cervical cancer"
        ],
        [
          "head and neck cancer"
        ],
        [
          "esophageal cancer"
        ],
        [
          "brain and lung tumours"
        ],
        [
          "mouth cancer"
        ],
        [
          "throat cancer"
        ],
        [
          "anus cancer"
        ],
        [
          "penis cancer"
        ]
      ]
    },
    {
      "id": "662fdb1e187cba990d000019",
      "type": "summary",
      "body": "What is the role of the transcription factor activator protein 2 (AP-2) alpha (TFAP2A) in tumor formation and metastasis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37083077",
        "http://www.ncbi.nlm.nih.gov/pubmed/36831334",
        "http://www.ncbi.nlm.nih.gov/pubmed/34210752",
        "http://www.ncbi.nlm.nih.gov/pubmed/37291585",
        "http://www.ncbi.nlm.nih.gov/pubmed/36410635",
        "http://www.ncbi.nlm.nih.gov/pubmed/35117502",
        "http://www.ncbi.nlm.nih.gov/pubmed/8723999",
        "http://www.ncbi.nlm.nih.gov/pubmed/7555706",
        "http://www.ncbi.nlm.nih.gov/pubmed/12586840",
        "http://www.ncbi.nlm.nih.gov/pubmed/12169772"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37083077",
          "text": "Transcription factor AP‑2 alpha (TFAP2A) is a critical cell growth regulator that is overexpressed in various tumor tissues. However, its role in the development of cervical cancer remains unknown. In the present study, public databases were thus explored and a higher expression of TFAP2A was found in cervical cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 319
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37083077",
          "text": "Transcription factor AP‑2 alpha (TFAP2A) is a critical cell growth regulator that is overexpressed in various tumor tissues. However, its role in the development of cervical cancer remains unknown.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 197
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35117502",
          "text": "BACKGROUND\nTranscription factor AP-2 alpha (TFAP2A) has been reported to participate in various tumors. However, the transcriptional levels and prognostic values of TFAP2A remain elusive in lung adenocarcinoma (LUAD). The purpose of the present study was to investigate the impact of the TFAP2A in LUAD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 303
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35117502",
          "text": "BACKGROUND\nTranscription factor AP-2 alpha (TFAP2A) has been reported to participate in various tumors. However, the transcriptional levels and prognostic values of TFAP2A remain elusive in lung adenocarcinoma (LUAD).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 217
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35117502",
          "text": "BACKGROUND\nTranscription factor AP-2 alpha (TFAP2A) has been reported to participate in various tumors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 103
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37083077",
          "text": "Transcription factor AP‑2 alpha (TFAP2A) is a critical cell growth regulator that is overexpressed in various tumor tissues.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 124
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723999",
          "text": "Activator protein-1 (AP-1) is an inducible transcription factor, and is comprised of multiple protein complexes that include the gene products of the fos and jun gene families. Numerous cellular and viral genes contain AP-1 binding sites within their promoters and, accordingly, AP-1 has been shown to play a role in the regulation of both basal and inducible transcription of these genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723999",
          "text": "They may be constitutively expressed or may only be activated during specific situations. Activator protein-1 (AP-1) is an inducible transcription factor, and is comprised of multiple protein complexes that include the gene products of the fos and jun gene families. Numerous cellular and viral genes contain AP-1 binding sites within their promoters and, accordingly, AP-1 has been shown to play a role in the regulation of both basal and inducible transcription of these genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 63,
          "endSection": "abstract",
          "offsetInEndSection": 542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723999",
          "text": "Activator protein-1 (AP-1) is an inducible transcription factor, and is comprised of multiple protein complexes that include the gene products of the fos and jun gene families. Numerous cellular and viral genes contain AP-1 binding sites within their promoters and, accordingly, AP-1 has been shown to play a role in the regulation of both basal and inducible transcription of these genes. fos-related antigen-2 (fra-2) has been found to have both similar and unique properties to that of other fos gene members in terms of its regulation and expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 707
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723999",
          "text": "Activator protein-1 (AP-1) is an inducible transcription factor, and is comprised of multiple protein complexes that include the gene products of the fos and jun gene families.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 329
        }
      ],
      "ideal_answer": "",
      "exact_answer": "n/a"
    },
    {
      "id": "66300f53187cba990d00001d",
      "type": "list",
      "body": "Which vaccines are safe to be administered for all pregnancies?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
        "http://www.ncbi.nlm.nih.gov/pubmed/21134450",
        "http://www.ncbi.nlm.nih.gov/pubmed/26444109",
        "http://www.ncbi.nlm.nih.gov/pubmed/16382131",
        "http://www.ncbi.nlm.nih.gov/pubmed/16557217",
        "http://www.ncbi.nlm.nih.gov/pubmed/31971933",
        "http://www.ncbi.nlm.nih.gov/pubmed/19838080",
        "http://www.ncbi.nlm.nih.gov/pubmed/22669800",
        "http://www.ncbi.nlm.nih.gov/pubmed/22212127",
        "http://www.ncbi.nlm.nih.gov/pubmed/21949151"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
          "text": "Inactivated vaccines are generally safe. Vaccines safe to be administered to all pregnant ladies are tetanus toxoid (TT; tetanus, diphtheria, acellular pertussis (Tdap) and Flu vaccines. During pre-pregnancy counselling, vaccination for MMR (measles, mumps, and rubella) should be offered, with an advice to avoid pregnancy for a month.",
          "beginSection": "abstract",
          "offsetInBeginSection": 322,
          "endSection": "abstract",
          "offsetInEndSection": 658
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
          "text": "Inactivated vaccines are generally safe. Vaccines safe to be administered to all pregnant ladies are tetanus toxoid (TT; tetanus, diphtheria, acellular pertussis (Tdap) and Flu vaccines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 322,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
          "text": " Vaccines safe to be administered to all pregnant ladies are tetanus toxoid (TT; tetanus, diphtheria, acellular pertussis (Tdap) and Flu vaccines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 362,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
          "text": "Vaccines safe to be administered to all pregnant ladies are tetanus toxoid (TT; tetanus, diphtheria, acellular pertussis (Tdap) and Flu vaccines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 363,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
          "text": "Vaccines safe to be administered to all pregnant ladies are tetanus toxoid (TT; tetanus, diphtheria, acellular pertussis (Tdap) and Flu vaccines. During pre-pregnancy counselling, vaccination for MMR (measles, mumps, and rubella) should be offered, with an advice to avoid pregnancy for a month.",
          "beginSection": "abstract",
          "offsetInBeginSection": 363,
          "endSection": "abstract",
          "offsetInEndSection": 658
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
          "text": "Vaccines safe to be administered to all pregnant ladies are tetanus toxoid (TT; tetanus, diphtheria, acellular pertussis (Tdap) and Flu vaccines. During pre-pregnancy counselling, vaccination for MMR (measles, mumps, and rubella) should be offered, with an advice to avoid pregnancy for a month. All pregnant mothers should receive TT and Tdap vaccination during the third trimester.",
          "beginSection": "abstract",
          "offsetInBeginSection": 363,
          "endSection": "abstract",
          "offsetInEndSection": 746
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
          "text": "As a rule, live vaccines are contraindicated during pregnancy as they may cause fetal viremia/bacteremia. Inactivated vaccines are generally safe. Vaccines safe to be administered to all pregnant ladies are tetanus toxoid (TT; tetanus, diphtheria, acellular pertussis (Tdap) and Flu vaccines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 216,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26444109",
          "text": "OBJECTIVE\nTo evaluate the safety of coadministering tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) and influenza vaccines during pregnancy by comparing adverse events after concomitant and sequential vaccination.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 239
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26444109",
          "text": "OBJECTIVE\nTo evaluate the safety of coadministering tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) and influenza vaccines during pregnancy by comparing adverse events after concomitant and sequential vaccination. METHODS\nWe conducted a retrospective cohort study of pregnant women aged 14-49 years in the Vaccine Safety Datalink from January 1, 2007, to November 15, 2013.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 401
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26444109",
          "text": "Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 117
        }
      ],
      "ideal_answer": "Tdap, Flu, and Tetanus Toxoid vaccines are safe to be administered for all pregnancies.",
      "exact_answer": [
        [
          "Tdap"
        ],
        [
          "Flu"
        ],
        [
          "Tetanus Toxoid"
        ],
        [
          "Inactivated vaccines"
        ]
      ]
    },
    {
      "id": "65d36e761930410b13000044",
      "type": "factoid",
      "body": "What is the use of lebrikizumab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37266844",
        "http://www.ncbi.nlm.nih.gov/pubmed/36994947",
        "http://www.ncbi.nlm.nih.gov/pubmed/37401345",
        "http://www.ncbi.nlm.nih.gov/pubmed/36948491",
        "http://www.ncbi.nlm.nih.gov/pubmed/36630140",
        "http://www.ncbi.nlm.nih.gov/pubmed/32104006",
        "http://www.ncbi.nlm.nih.gov/pubmed/29353026",
        "http://www.ncbi.nlm.nih.gov/pubmed/35702658",
        "http://www.ncbi.nlm.nih.gov/pubmed/37310643",
        "http://www.ncbi.nlm.nih.gov/pubmed/36920778"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36994947",
          "text": "BACKGROUND: Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13.OBJECTIVES: To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36994947",
          "text": "BACKGROUND\nLebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13. OBJECTIVES\nTo evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 356
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36994947",
          "text": "BACKGROUND\nLebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13. OBJECTIVES\nTo evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). METHODS\nPatients who responded to lebrikizumab 250 mg every 2 weeks (Q2W) at the end of the 16-week induction period were re-randomized 2 : 2 : 1 to receive lebrikizumab Q2W, lebrikizumab 250 mg every 4 weeks (Q4W) or placebo Q2W (lebrikizumab withdrawal) for 36 additional weeks.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 639
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29353026",
          "text": "BACKGROUND\nInterleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis (AD). OBJECTIVE\nWe investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS) treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29353026",
          "text": "BACKGROUND\nInterleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis (AD). OBJECTIVE\nWe investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS) treatment. METHODS\nA randomized, placebo-controlled, double-blind, phase 2 study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 364
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29353026",
          "text": "Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 233
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36994947",
          "text": "BACKGROUND\nLebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 116
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32104006",
          "text": "Herein, we review the recent data on lebrikizumab, an interleukin (IL)-13 inhibitor, and its potential role in the treatment of AD. OBJECTIVE\nReview the mechanism of action, and available data on the efficacy and safety of lebrikizumab for the treatment of AD. METHODS\nPubMed, Google Scholar, and clinicaltrials.gov searches were performed with the following terms: \"atopic dermatitis,\" \"dermatitis,\" \"eczema,\" \"lebrikizumab,\" \"IL-4,\" and \"IL-13.\"",
          "beginSection": "abstract",
          "offsetInBeginSection": 454,
          "endSection": "abstract",
          "offsetInEndSection": 905
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29353026",
          "text": "OBJECTIVE\nWe investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS) treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 139,
          "endSection": "abstract",
          "offsetInEndSection": 291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29353026",
          "text": "OBJECTIVE\nWe investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS) treatment. METHODS\nA randomized, placebo-controlled, double-blind, phase 2 study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 139,
          "endSection": "abstract",
          "offsetInEndSection": 364
        }
      ],
      "ideal_answer": "Lebrikizumab is a monoclonal antibody that selectively binds to interleukin (IL)-13, and it is used for the treatment of moderate-to-severe atopic dermatitis (AD).",
      "exact_answer": [
        "lebrikizumab"
      ]
    },
    {
      "id": "662fc981187cba990d000018",
      "type": "yesno",
      "body": "Is CT colonography a cost-effective test for colorectal cancer screening?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16217110",
        "http://www.ncbi.nlm.nih.gov/pubmed/29485322",
        "http://www.ncbi.nlm.nih.gov/pubmed/23006522",
        "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
        "http://www.ncbi.nlm.nih.gov/pubmed/21361717",
        "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
        "http://www.ncbi.nlm.nih.gov/pubmed/20664028",
        "http://www.ncbi.nlm.nih.gov/pubmed/26350285",
        "http://www.ncbi.nlm.nih.gov/pubmed/20003555",
        "http://www.ncbi.nlm.nih.gov/pubmed/19332851"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16217110",
          "text": "Because screening with CT colonography would cost more and result in more deaths overall compared with colonoscopy, the latter remained the dominant strategy. Our results were sensitive to CT colonography's test performance characteristics, the malignant risk of missed adenomas, the risk of perforation and related death, the procedural costs and differences in screening adherence. INTERPRETATION\nAt present, CT colonography cannot be recommended as a primary means of population-based colorectal cancer screening in Canada.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1210,
          "endSection": "abstract",
          "offsetInEndSection": 1738
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16217110",
          "text": "CT colonography would cost more and result in more deaths overall compared with colonoscopy, the latter remained the dominant strategy. Our results were sensitive to CT colonography's test performance characteristics, the malignant risk of missed adenomas, the risk of perforation and related death, the procedural costs and differences in screening adherence.INTERPRETATION: At present, CT colonography cannot be recommended as a primary means of population-based colorectal cancer screening in Canada.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1230,
          "endSection": "abstract",
          "offsetInEndSection": 1733
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16217110",
          "text": "Our results were sensitive to CT colonography's test performance characteristics, the malignant risk of missed adenomas, the risk of perforation and related death, the procedural costs and differences in screening adherence. INTERPRETATION\nAt present, CT colonography cannot be recommended as a primary means of population-based colorectal cancer screening in Canada.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1369,
          "endSection": "abstract",
          "offsetInEndSection": 1738
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
          "text": "CONCLUSIONS\nCT colonography is an effective screening test for colorectal neoplasia. However, it is more expensive and generally less effective than optical colonoscopy. CT colonography can be reasonably cost-effective when the diagnostic accuracy of CT colonography is high, as with primary 3-dimensional technology, and if costs are about 60% of those of optical colonoscopy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1153,
          "endSection": "abstract",
          "offsetInEndSection": 1530
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21361717",
          "text": "RESULTS\nThe most and the least effective methods were CT colonography and fecal occult blood test, respectively. The highest and lowest expenditures in the governmental sector were related to fecal occult blood test and flexible sigmoidoscopy and in the private sector, to CT colonography and fecal occult blood test, respectively. The cost per cancer detected in 20 years of screening in the governmental sector was 0.28, 0.22 and 0.42 billion Rials, respectively for screening by colonoscopy, flexible sigmoidoscopy and fecal occult blood test.",
          "beginSection": "abstract",
          "offsetInBeginSection": 714,
          "endSection": "abstract",
          "offsetInEndSection": 1260
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16217110",
          "text": "RESULTS\nUsing the base-case assumptions, a strategy of CT colonography for colorectal cancer screening would cost 2.27 million dollars extra per 100,000 patients screened; 3.78 perforation-related deaths would be avoided, but 4.11 extra deaths would occur from missed adenomas. Because screening with CT colonography would cost more and result in more deaths overall compared with colonoscopy, the latter remained the dominant strategy. Our results were sensitive to CT colonography's test performance characteristics, the malignant risk of missed adenomas, the risk of perforation and related death, the procedural costs and differences in screening adherence.",
          "beginSection": "abstract",
          "offsetInBeginSection": 932,
          "endSection": "abstract",
          "offsetInEndSection": 1593
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16217110",
          "text": "Because screening with CT colonography would cost more and result in more deaths overall compared with colonoscopy, the latter remained the dominant strategy. Our results were sensitive to CT colonography's test performance characteristics, the malignant risk of missed adenomas, the risk of perforation and related death, the procedural costs and differences in screening adherence.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1210,
          "endSection": "abstract",
          "offsetInEndSection": 1593
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21361717",
          "text": "The cost per cancer detected in 20 years of screening in the governmental sector was 0.28, 0.22 and 0.42 billion Rials, respectively for screening by colonoscopy, flexible sigmoidoscopy and fecal occult blood test. In the private sector, these were 1.54 (colonoscopy), 1.68 (flexible sigmoidoscopy), and 1.60 (fecal occult blood test) billion and 2.58 billion Rials for CT colonography, respectively. CONCLUSIONS\nAlthough CT colonography is the most effective method, it needs a budget of 2.58 billion Rials for each screened patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1046,
          "endSection": "abstract",
          "offsetInEndSection": 1582
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
          "text": "CONCLUSIONS\nCT colonography is an effective screening test for colorectal neoplasia. However, it is more expensive and generally less effective than optical colonoscopy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1153,
          "endSection": "abstract",
          "offsetInEndSection": 1322
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21361717",
          "text": "The cost-effectiveness of each method and the ratio of cost-effectiveness were calculated based on this model. RESULTS\nThe most and the least effective methods were CT colonography and fecal occult blood test, respectively. The highest and lowest expenditures in the governmental sector were related to fecal occult blood test and flexible sigmoidoscopy and in the private sector, to CT colonography and fecal occult blood test, respectively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 601,
          "endSection": "abstract",
          "offsetInEndSection": 1045
        }
      ],
      "ideal_answer": "Yes, CT colonography is a cost-effective test for colorectal cancer screening compared to no screening, flexible sigmoidoscopy, and fecal occult blood testing. However, it is not cost-effective compared to colonoscopy. The cost-effectiveness of CT colonography is sensitive to its test performance characteristics, the malignant risk of missed adenomas, the risk of perforation and related death, the procedural costs, and differences in screening adherence. At present, it cannot be recommended as a primary means of population-based colorectal cancer screening in Canada.",
      "exact_answer": "yes"
    },
    {
      "id": "662cf888187cba990d000002",
      "type": "yesno",
      "body": "is Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), a systemic vasculitis that affects large blood vessels.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
        "http://www.ncbi.nlm.nih.gov/pubmed/36169798",
        "http://www.ncbi.nlm.nih.gov/pubmed/33292799",
        "http://www.ncbi.nlm.nih.gov/pubmed/16344620",
        "http://www.ncbi.nlm.nih.gov/pubmed/10971876",
        "http://www.ncbi.nlm.nih.gov/pubmed/29433114",
        "http://www.ncbi.nlm.nih.gov/pubmed/37476365",
        "http://www.ncbi.nlm.nih.gov/pubmed/23271426",
        "http://www.ncbi.nlm.nih.gov/pubmed/35258723",
        "http://www.ncbi.nlm.nih.gov/pubmed/28514410"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
          "text": "INTRODUCTION\nCryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels. It exhibits a wide range of clinical manifestations, making its treatment a continuing challenge for physicians.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 271
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
          "text": ": Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels.",
          "beginSection": "abstract",
          "offsetInBeginSection": 12,
          "endSection": "abstract",
          "offsetInEndSection": 159
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
          "text": "INTRODUCTION\nCryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 158
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
          "text": "INTRODUCTION\nCryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels. It exhibits a wide range of clinical manifestations, making its treatment a continuing challenge for physicians. AREAS COVERED\nWe conducted a comprehensive review to evaluate the current status of diagnosis, management, and treatment of mixed cryoglobulinemia (MC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 426
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29433114",
          "text": "HCV-induced cryoglobulinemic vasculitis primarily affects small-sized vessels of systemic organs. The most common symptoms are purpura, joint pain, and peripheral neuropathy or Raynaud phenomenon. The blood tests of patients with HCV may exhibit raised erythrocyte sedimentation rate and C-reactive protein levels, positive rheumatoid factor and cryoglobulins, and decreased complement levels.",
          "beginSection": "abstract",
          "offsetInBeginSection": 106,
          "endSection": "abstract",
          "offsetInEndSection": 499
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29433114",
          "text": "HCV-induced cryoglobulinemic vasculitis primarily affects small-sized vessels of systemic organs. The most common symptoms are purpura, joint pain, and peripheral neuropathy or Raynaud phenomenon.",
          "beginSection": "abstract",
          "offsetInBeginSection": 106,
          "endSection": "abstract",
          "offsetInEndSection": 302
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29433114",
          "text": "Cryoglobulins are produced by the over-stimulated immune system of patients with hepatitis C virus (HCV). HCV-induced cryoglobulinemic vasculitis primarily affects small-sized vessels of systemic organs. The most common symptoms are purpura, joint pain, and peripheral neuropathy or Raynaud phenomenon.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 302
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16344620",
          "text": "PURPOSE OF REVIEW\nCryoglobulinemic vasculitis is an immune-complex-mediated systemic vasculitis involving small-medium-sized vessels. A causative role of hepatitis C virus in over 80% patients has been definitively established, with heterogeneous geographical distribution.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16344620",
          "text": "PURPOSE OF REVIEW\nCryoglobulinemic vasculitis is an immune-complex-mediated systemic vasculitis involving small-medium-sized vessels. A causative role of hepatitis C virus in over 80% patients has been definitively established, with heterogeneous geographical distribution. This review focuses on recent etiopathogenetic, clinico-diagnostic, and therapeutical studies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 368
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29433114",
          "text": "HCV-induced cryoglobulinemic vasculitis primarily affects small-sized vessels of systemic organs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 106,
          "endSection": "abstract",
          "offsetInEndSection": 203
        }
      ],
      "ideal_answer": "No, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels, not large blood vessels.",
      "exact_answer": "no"
    },
    {
      "id": "66155e7dfdcbea915f00004c",
      "type": "list",
      "body": "Consequences for the newborn of infection by Zika virus during pregnancy.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36867568",
        "http://www.ncbi.nlm.nih.gov/pubmed/37042942",
        "http://www.ncbi.nlm.nih.gov/pubmed/37458166",
        "http://www.ncbi.nlm.nih.gov/pubmed/37482558",
        "http://www.ncbi.nlm.nih.gov/pubmed/30817677",
        "http://www.ncbi.nlm.nih.gov/pubmed/34999638",
        "http://www.ncbi.nlm.nih.gov/pubmed/27080092",
        "http://www.ncbi.nlm.nih.gov/pubmed/29437050",
        "http://www.ncbi.nlm.nih.gov/pubmed/29561936",
        "http://www.ncbi.nlm.nih.gov/pubmed/31340324"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29561936",
          "text": "Concern for Zika virus infection has been increasing as it is suspected of causing brain defects in newborns such as microcephaly and, more recently, potential neurological and autoimmune complications including Guillian-Barré syndrome and acute disseminated encephalomyelitis. We describe a case of virus infection in a 25-year-old woman during the first trimester of her pregnancy, confirmed by laboratory tests only for the detection of viral particles in maternal urine, with imaging studies demonstrating the progression of cranial and encephalic changes in the fetus and later in the newborn, such as head circumference reduction, cerebral calcifications and ventriculomegaly.",
          "beginSection": "abstract",
          "offsetInBeginSection": 112,
          "endSection": "abstract",
          "offsetInEndSection": 794
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27080092",
          "text": "METHODS\nWe radiologically analyzed 13 cases of newborns with microcephaly born to mothers who were infected by the Zika virus in the early stage of pregnancy. RESULTS\nThe most frequently observed radiological findings were microcephaly and decreased brain parenchymal volume associated with lissencephaly, ventriculomegaly secondary to the lack of brain tissue (not hypertensive), and coarse and anarchic calcifications mainly involving the subcortical cortical transition, and the basal ganglia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 655
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27080092",
          "text": "PURPOSE\nThe aim of this study is to describe some radiological features in the newborns with microcephaly caused by Zika virus infection during pregnancy. METHODS\nWe radiologically analyzed 13 cases of newborns with microcephaly born to mothers who were infected by the Zika virus in the early stage of pregnancy. RESULTS\nThe most frequently observed radiological findings were microcephaly and decreased brain parenchymal volume associated with lissencephaly, ventriculomegaly secondary to the lack of brain tissue (not hypertensive), and coarse and anarchic calcifications mainly involving the subcortical cortical transition, and the basal ganglia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 655
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27080092",
          "text": "METHODS\nWe radiologically analyzed 13 cases of newborns with microcephaly born to mothers who were infected by the Zika virus in the early stage of pregnancy. RESULTS\nThe most frequently observed radiological findings were microcephaly and decreased brain parenchymal volume associated with lissencephaly, ventriculomegaly secondary to the lack of brain tissue (not hypertensive), and coarse and anarchic calcifications mainly involving the subcortical cortical transition, and the basal ganglia. CONCLUSIONS\nAlthough it cannot be concluded that there is a definitive pathognomonic radiographic pattern of microcephaly caused by Zika virus, gross calcifications and anarchic distribution involving the subcortical cortical transition and the basal ganglia, in association with lissencephaly and in the absence of hypertensive ventriculomegaly, are characteristic of this type of infection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 1050
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34999638",
          "text": "The Zika virus crosses the placental barrier and, predominantly, affects neuronal progenitor cells. This disruptive process results in severe cortical developmental disorder, calcifications, cortical and subcortical atrophies, and malformations of the cerebellum, brain stem, and spinal cord. Children with congenital Zika syndrome have a set of clinical findings, such as cerebral palsy, dysphagia, orthopedic deformities, visual and auditory impairment, and, rarely, hydrocephalus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 211,
          "endSection": "abstract",
          "offsetInEndSection": 694
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29561936",
          "text": "Currently Latin America is undergoing a major epidemic of Zika virus, which is transmitted by Aedes mosquitoes. Concern for Zika virus infection has been increasing as it is suspected of causing brain defects in newborns such as microcephaly and, more recently, potential neurological and autoimmune complications including Guillian-Barré syndrome and acute disseminated encephalomyelitis. We describe a case of virus infection in a 25-year-old woman during the first trimester of her pregnancy, confirmed by laboratory tests only for the detection of viral particles in maternal urine, with imaging studies demonstrating the progression of cranial and encephalic changes in the fetus and later in the newborn, such as head circumference reduction, cerebral calcifications and ventriculomegaly.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 794
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34999638",
          "text": "This disruptive process results in severe cortical developmental disorder, calcifications, cortical and subcortical atrophies, and malformations of the cerebellum, brain stem, and spinal cord. Children with congenital Zika syndrome have a set of clinical findings, such as cerebral palsy, dysphagia, orthopedic deformities, visual and auditory impairment, and, rarely, hydrocephalus. Because of the severity of brain lesions, epilepsy is a common finding and a frequent cause of increased morbidity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 311,
          "endSection": "abstract",
          "offsetInEndSection": 810
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34999638",
          "text": "The congenital Zika syndrome is a new entity of a group of etiologies that can lead to microcephaly and other brain damages during pregnancy, such as toxoplasmosis, rubeola, cytomegalovirus, and herpes simplex. The Zika virus crosses the placental barrier and, predominantly, affects neuronal progenitor cells. This disruptive process results in severe cortical developmental disorder, calcifications, cortical and subcortical atrophies, and malformations of the cerebellum, brain stem, and spinal cord.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 503
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29437050",
          "text": "Among infants with clinical findings that are consistent with congenital Zika syndrome, 54% had epilepsy and 100% had motor abnormalities. In these infants, impairments that are consistent with diagnoses of cerebral palsy and epilepsy occur frequently. Pyramidal and extrapyramidal motor abnormalities were notable for their early development and co-occurrence.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1225,
          "endSection": "abstract",
          "offsetInEndSection": 1586
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36867568",
          "text": "In February 2016, the World Health Organization declared Zika virus (ZIKV) infection a public health emergency of international concern because it caused congenital Zika syndrome (CZS). The CZS is considered a specific pattern of birth defects caused by ZIKV infection, which is transmitted by the bite of the Aedes aegypti mosquito. The CZS clinical manifestations are broad and nonspecific, including microcephaly, subcortical calcifications, ocular alterations, congenital contractures, early hypertonia, and pyramidal as well as extrapyramidal symptoms.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 557
        }
      ],
      "ideal_answer": "Newborns infected by Zika virus during pregnancy may suffer from microcephaly, cerebral palsy, epilepsy, ocular alterations, subcortical calcifications, congenital contractures, early hypertonia, and pyramidal as well as extrapyramidal symptoms due to a reduction in neuron numbers and neuronal death, leading to a decrease in neuronal number.",
      "exact_answer": [
        [
          "microcephaly"
        ],
        [
          "cerebral palsy"
        ],
        [
          "epilepsy"
        ],
        [
          "ocular alterations"
        ]
      ]
    },
    {
      "id": "66302090187cba990d00002a",
      "type": "list",
      "body": "Which are the key transcription factors known to drive glioma progression and therapy resistance?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35409080",
        "http://www.ncbi.nlm.nih.gov/pubmed/31070059",
        "http://www.ncbi.nlm.nih.gov/pubmed/20396958",
        "http://www.ncbi.nlm.nih.gov/pubmed/32953933",
        "http://www.ncbi.nlm.nih.gov/pubmed/35994229",
        "http://www.ncbi.nlm.nih.gov/pubmed/31554859",
        "http://www.ncbi.nlm.nih.gov/pubmed/28383481",
        "http://www.ncbi.nlm.nih.gov/pubmed/20232316",
        "http://www.ncbi.nlm.nih.gov/pubmed/37283490",
        "http://www.ncbi.nlm.nih.gov/pubmed/34758200"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35409080",
          "text": "Herein, we describe a selection of oncogenic (GLI-1/2/3, E2F1-8, STAT3, and HIF-1/2) and tumor suppressor (NFI-A/B, TBXT, MYT1, and MYT1L) TFs that are deregulated in gliomas and are subsequently associated with tumor development, progression, and migratory potential. We further discuss the current targeting options against these TFs, including chemical (Bortezomib) and natural (Plumbagin) compounds, small molecules, and inhibitors, and address their potential implications in glioma therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 614,
          "endSection": "abstract",
          "offsetInEndSection": 1110
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35409080",
          "text": "Herein, we describe a selection of oncogenic (GLI-1/2/3, E2F1-8, STAT3, and HIF-1/2) and tumor suppressor (NFI-A/B, TBXT, MYT1, and MYT1L) TFs that are deregulated in gliomas and are subsequently associated with tumor development, progression, and migratory potential.",
          "beginSection": "abstract",
          "offsetInBeginSection": 614,
          "endSection": "abstract",
          "offsetInEndSection": 882
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35409080",
          "text": "A variety of TFs have been detected to be aberrantly expressed in brain tumors, being highly implicated in critical pathological aspects and progression of gliomas. Herein, we describe a selection of oncogenic (GLI-1/2/3, E2F1-8, STAT3, and HIF-1/2) and tumor suppressor (NFI-A/B, TBXT, MYT1, and MYT1L) TFs that are deregulated in gliomas and are subsequently associated with tumor development, progression, and migratory potential. We further discuss the current targeting options against these TFs, including chemical (Bortezomib) and natural (Plumbagin) compounds, small molecules, and inhibitors, and address their potential implications in glioma therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 449,
          "endSection": "abstract",
          "offsetInEndSection": 1110
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35409080",
          "text": "A variety of TFs have been detected to be aberrantly expressed in brain tumors, being highly implicated in critical pathological aspects and progression of gliomas. Herein, we describe a selection of oncogenic (GLI-1/2/3, E2F1-8, STAT3, and HIF-1/2) and tumor suppressor (NFI-A/B, TBXT, MYT1, and MYT1L) TFs that are deregulated in gliomas and are subsequently associated with tumor development, progression, and migratory potential.",
          "beginSection": "abstract",
          "offsetInBeginSection": 449,
          "endSection": "abstract",
          "offsetInEndSection": 882
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35409080",
          "text": "Transcription factors (TFs) are master regulators of gene expression programs, which ultimately shape cell fate and homeostasis. A variety of TFs have been detected to be aberrantly expressed in brain tumors, being highly implicated in critical pathological aspects and progression of gliomas. Herein, we describe a selection of oncogenic (GLI-1/2/3, E2F1-8, STAT3, and HIF-1/2) and tumor suppressor (NFI-A/B, TBXT, MYT1, and MYT1L) TFs that are deregulated in gliomas and are subsequently associated with tumor development, progression, and migratory potential.",
          "beginSection": "abstract",
          "offsetInBeginSection": 320,
          "endSection": "abstract",
          "offsetInEndSection": 882
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35409080",
          "text": "Gliomas portray a large and heterogeneous group of CNS tumors, encompassing a wide range of low- to high-grade tumors, as defined by histological and molecular characteristics. The identification of signature mutations and other molecular abnormalities has largely impacted tumor classification, diagnosis, and therapy. Transcription factors (TFs) are master regulators of gene expression programs, which ultimately shape cell fate and homeostasis. A variety of TFs have been detected to be aberrantly expressed in brain tumors, being highly implicated in critical pathological aspects and progression of gliomas. Herein, we describe a selection of oncogenic (GLI-1/2/3, E2F1-8, STAT3, and HIF-1/2) and tumor suppressor (NFI-A/B, TBXT, MYT1, and MYT1L) TFs that are deregulated in gliomas and are subsequently associated with tumor development, progression, and migratory potential.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 882
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31070059",
          "text": "The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 89
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32953933",
          "text": "E2F transcription factors (E2Fs) were found to be related with cell activities and disease progression among a variety of different tumors, including regulating cell division and cell proliferation. In the analysis, it aimed to focus on transcriptional and survival information of E2Fs in gastric cancer (GC) from Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier plotter, cBioPortal, Database for Annotation, Visualization and Integrated Discovery (DAVID), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, and Oncomine databases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 556
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32953933",
          "text": "E2F transcription factors (E2Fs) were found to be related with cell activities and disease progression among a variety of different tumors, including regulating cell division and cell proliferation. In the analysis, it aimed to focus on transcriptional and survival information of E2Fs in gastric cancer (GC) from Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier plotter, cBioPortal, Database for Annotation, Visualization and Integrated Discovery (DAVID), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, and Oncomine databases. It was found that the expression of E2F1/2/3/5/7/8 in GC tissues was obviously higher than the normal.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 659
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35409080",
          "text": "Transcription factors (TFs) are master regulators of gene expression programs, which ultimately shape cell fate and homeostasis. A variety of TFs have been detected to be aberrantly expressed in brain tumors, being highly implicated in critical pathological aspects and progression of gliomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 320,
          "endSection": "abstract",
          "offsetInEndSection": 613
        }
      ],
      "ideal_answer": "GLI-1/2/3, E2F1-8, STAT3, and HIF-1/2 are key transcription factors known to drive glioma progression and therapy resistance.",
      "exact_answer": [
        [
          "GLI-1/2/3"
        ],
        [
          "E2F1-8"
        ],
        [
          "STAT3"
        ],
        [
          "HIF-1/2"
        ],
        [
          "NFI-A/B"
        ],
        [
          "TBXT"
        ],
        [
          "MYT1"
        ],
        [
          "MYT1L"
        ]
      ]
    },
    {
      "id": "662e29f9187cba990d00000a",
      "type": "list",
      "body": "What are the genotypes of Japanese Encephalitis Virus (JEV)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36450570",
        "http://www.ncbi.nlm.nih.gov/pubmed/30207876",
        "http://www.ncbi.nlm.nih.gov/pubmed/27139722",
        "http://www.ncbi.nlm.nih.gov/pubmed/26866021",
        "http://www.ncbi.nlm.nih.gov/pubmed/25884184",
        "http://www.ncbi.nlm.nih.gov/pubmed/32864366",
        "http://www.ncbi.nlm.nih.gov/pubmed/25787283",
        "http://www.ncbi.nlm.nih.gov/pubmed/10795519",
        "http://www.ncbi.nlm.nih.gov/pubmed/12584335",
        "http://www.ncbi.nlm.nih.gov/pubmed/34696184"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36450570",
          "text": "Japanese encephalitis virus (JEV) is a mosquito-borne virus belonging to the JEV serocomplex within the genus Flavivirus, family Flaviviridae. It has 5 genotypes, G1-G5, based on the envelope (E) protein nucleotide sequence. JEV G3 circulated in Japan until the early 1990s when it was replaced by G1.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 301
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36450570",
          "text": "Japanese encephalitis virus (JEV) is a mosquito-borne virus belonging to the JEV serocomplex within the genus Flavivirus, family Flaviviridae. It has 5 genotypes, G1-G5, based on the envelope (E) protein nucleotide sequence.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 224
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26866021",
          "text": "PURPOSE\nThe Japanese encephalitis virus (JEV) genotype circulating in Korea has changed from G3 to G1.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 102
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26866021",
          "text": "PURPOSE\nThe Japanese encephalitis virus (JEV) genotype circulating in Korea has changed from G3 to G1. Therefore, the purpose of this study was to compare the antigenic relationship between the two genotypes by using antibody tests.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 232
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26866021",
          "text": "PURPOSE\nThe Japanese encephalitis virus (JEV) genotype circulating in Korea has changed from G3 to G1. Therefore, the purpose of this study was to compare the antigenic relationship between the two genotypes by using antibody tests. MATERIALS AND METHODS\nBlood samples from 42 sows and 216 horses were collected, and their seroprevalence was monitored using the hemagglutination inhibition and virus neutralization tests.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 423
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27139722",
          "text": "BACKGROUND\nThe current Japanese encephalitis (JE) vaccine derived from G3 JE virus (JEV) can induce protective immunity against G1-G4 JEV genotypes. However, protective efficacy against the emerging G5 genotype has not been reported.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 233
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27139722",
          "text": "BACKGROUND\nThe current Japanese encephalitis (JE) vaccine derived from G3 JE virus (JEV) can induce protective immunity against G1-G4 JEV genotypes. However, protective efficacy against the emerging G5 genotype has not been reported. METHODS/PRINCIPAL FINDINGS\nUsing in vitro and in vivo tests, biological phenotype and cross-immunoreactions were compared between G3 JEV and G5 JEV (wild strains).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 399
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30207876",
          "text": "Japanese encephalitis virus (JEV) is a representative virus of the JEV serogroup in genus Flavivirus, family Flaviviridae. JEV is a mosquito-borne virus that causes Japanese encephalitis (JE), one of the most severe viral encephalitis diseases in the world. JEV is divided into five genotypes (G1-G5), and each genotype has its own distribution pattern.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 353
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27139722",
          "text": "BACKGROUND\nThe current Japanese encephalitis (JE) vaccine derived from G3 JE virus (JEV) can induce protective immunity against G1-G4 JEV genotypes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 148
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30207876",
          "text": "JEV is a mosquito-borne virus that causes Japanese encephalitis (JE), one of the most severe viral encephalitis diseases in the world. JEV is divided into five genotypes (G1-G5), and each genotype has its own distribution pattern. However, the distribution of different JEV genotypes has changed markedly in recent years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 123,
          "endSection": "abstract",
          "offsetInEndSection": 444
        }
      ],
      "ideal_answer": "The genotypes of Japanese Encephalitis Virus (JEV) are G1, G2, G3, G4, and G5, which are based on the envelope (E) protein nucleotide sequence.",
      "exact_answer": [
        [
          "G1"
        ],
        [
          "G3"
        ]
      ]
    },
    {
      "id": "65d373151930410b13000048",
      "type": "list",
      "body": "What medication were tested in the TRICOTEL trial?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35940183",
        "http://www.ncbi.nlm.nih.gov/pubmed/37459873",
        "http://www.ncbi.nlm.nih.gov/pubmed/34762112",
        "http://www.ncbi.nlm.nih.gov/pubmed/31171876",
        "http://www.ncbi.nlm.nih.gov/pubmed/34904502",
        "http://www.ncbi.nlm.nih.gov/pubmed/32534646",
        "http://www.ncbi.nlm.nih.gov/pubmed/35131452",
        "http://www.ncbi.nlm.nih.gov/pubmed/36460017",
        "http://www.ncbi.nlm.nih.gov/pubmed/31157737",
        "http://www.ncbi.nlm.nih.gov/pubmed/26999478"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940183",
          "text": "Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 154
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940183",
          "text": "We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases. METHODS\nTRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland.",
          "beginSection": "abstract",
          "offsetInBeginSection": 204,
          "endSection": "abstract",
          "offsetInEndSection": 629
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37459873",
          "text": "We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases. METHODS\nTRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland.",
          "beginSection": "abstract",
          "offsetInBeginSection": 204,
          "endSection": "abstract",
          "offsetInEndSection": 629
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37459873",
          "text": "We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases. METHODS\nTRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland. Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, brain metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less.",
          "beginSection": "abstract",
          "offsetInBeginSection": 204,
          "endSection": "abstract",
          "offsetInEndSection": 859
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940183",
          "text": "We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases. METHODS\nTRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland. Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, CNS metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less.",
          "beginSection": "abstract",
          "offsetInBeginSection": 204,
          "endSection": "abstract",
          "offsetInEndSection": 857
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940183",
          "text": "BACKGROUND\nTargeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases. METHODS\nTRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 629
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37459873",
          "text": "BACKGROUND\nTargeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases. METHODS\nTRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 629
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940183",
          "text": "INTERPRETATION\nAdding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAFV600-mutated melanoma with CNS metastases. FUNDING\nF Hoffmann-La Roche.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3436,
          "endSection": "abstract",
          "offsetInEndSection": 3638
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940183",
          "text": "INTERPRETATION\nAdding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAFV600-mutated melanoma with CNS metastases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3436,
          "endSection": "abstract",
          "offsetInEndSection": 3607
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940183",
          "text": "We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 204,
          "endSection": "abstract",
          "offsetInEndSection": 348
        }
      ],
      "ideal_answer": "Atezolizumab, vemurafenib, and cobimetinib were tested in the TRICOTEL trial.",
      "exact_answer": [
        [
          "atezolizumab"
        ],
        [
          "vemurafenib"
        ],
        [
          "cobimetinib"
        ]
      ]
    },
    {
      "id": "66214ff0b9f8b89d7e000006",
      "type": "list",
      "body": "What are the most frequent side effects of regorafenib?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26327919",
        "http://www.ncbi.nlm.nih.gov/pubmed/35716310",
        "http://www.ncbi.nlm.nih.gov/pubmed/37142953",
        "http://www.ncbi.nlm.nih.gov/pubmed/31106665",
        "http://www.ncbi.nlm.nih.gov/pubmed/23700287",
        "http://www.ncbi.nlm.nih.gov/pubmed/33604969",
        "http://www.ncbi.nlm.nih.gov/pubmed/26034039",
        "http://www.ncbi.nlm.nih.gov/pubmed/24980770",
        "http://www.ncbi.nlm.nih.gov/pubmed/25335705",
        "http://www.ncbi.nlm.nih.gov/pubmed/24675266"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327919",
          "text": "The FDA based this approval on data from the CORRECT trial, which showed the efficacy of regorafenib compared with placebo. The most common grade 3-4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue. This review discusses the efficacy data, and the incidence and management of regorafenib's toxicities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 713,
          "endSection": "abstract",
          "offsetInEndSection": 1070
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327919",
          "text": "The FDA based this approval on data from the CORRECT trial, which showed the efficacy of regorafenib compared with placebo. The most common grade 3-4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue.",
          "beginSection": "abstract",
          "offsetInBeginSection": 713,
          "endSection": "abstract",
          "offsetInEndSection": 967
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327919",
          "text": "The most common grade 3-4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue. This review discusses the efficacy data, and the incidence and management of regorafenib's toxicities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 837,
          "endSection": "abstract",
          "offsetInEndSection": 1070
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37142953",
          "text": "BACKGROUND\nRegorafenib, a multikinase inhibitor, causes a high frequency of hand-foot skin reactions (HFSRs).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 109
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37142953",
          "text": "BACKGROUND\nRegorafenib, a multikinase inhibitor, causes a high frequency of hand-foot skin reactions (HFSRs). The present study evaluated the efficacy of topical aluminum chloride, a perspiration suppressant, in reducing the severity of hand-foot skin reactions (HFSRs) caused by regorafenib. METHODS\nThe present single-arm study included patients with metastatic colorectal cancer receiving regorafenib.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 406
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31106665",
          "text": "In contrast, symptom grade of hand-foot skin reaction and regorafenib relative dose intensity showed negative correlation with poor adherence (odds ratio; 0.971, p = 0.012, and 0.485, p < 0.001, respectively).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1190,
          "endSection": "abstract",
          "offsetInEndSection": 1399
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31106665",
          "text": "In contrast, symptom grade of hand-foot skin reaction and regorafenib relative dose intensity showed negative correlation with poor adherence (odds ratio; 0.971, p = 0.012, and 0.485, p < 0.001, respectively). CONCLUSIONS\nThe results suggest that adherence decreases in patients with working.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1190,
          "endSection": "abstract",
          "offsetInEndSection": 1484
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31106665",
          "text": "The relative dose intensity of regorafenib decreased when adherence to topical moisturizing ointments decreased. Severe hand-foot skin reaction could be associated with adherence. Patients consciously might not apply the ointment when hand-foot skin reaction did not become severe.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1485,
          "endSection": "abstract",
          "offsetInEndSection": 1766
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327919",
          "text": "The most common grade 3-4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue.",
          "beginSection": "abstract",
          "offsetInBeginSection": 837,
          "endSection": "abstract",
          "offsetInEndSection": 967
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37142953",
          "text": "BACKGROUND\nRegorafenib, a multikinase inhibitor, causes a high frequency of hand-foot skin reactions (HFSRs). The present study evaluated the efficacy of topical aluminum chloride, a perspiration suppressant, in reducing the severity of hand-foot skin reactions (HFSRs) caused by regorafenib.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 292
        }
      ],
      "ideal_answer": "The most frequent side effects of regorafenib are hand foot skin reactions, diarrhea, hypertension, and fatigue.",
      "exact_answer": [
        [
          "hand foot skin reactions"
        ],
        [
          "diarrhea"
        ],
        [
          "hypertension"
        ],
        [
          "fatigue"
        ]
      ]
    },
    {
      "id": "662cf8db187cba990d000003",
      "type": "yesno",
      "body": "Is Periostin a novel biomarker of TH2-driven asthma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36763690",
        "http://www.ncbi.nlm.nih.gov/pubmed/36753209",
        "http://www.ncbi.nlm.nih.gov/pubmed/37260069",
        "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
        "http://www.ncbi.nlm.nih.gov/pubmed/24759559",
        "http://www.ncbi.nlm.nih.gov/pubmed/27054127",
        "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
        "http://www.ncbi.nlm.nih.gov/pubmed/25037608",
        "http://www.ncbi.nlm.nih.gov/pubmed/25838094",
        "http://www.ncbi.nlm.nih.gov/pubmed/28398635"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36763690",
          "text": "Sputum periostin is worth considering as a phenotype-specific biomarker in asthma as its proximity to the airways may eliminate some of the confounding factors known to affect serum periostin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1623,
          "endSection": "abstract",
          "offsetInEndSection": 1815
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36763690",
          "text": "n. Sputum periostin is worth considering as a phenotype-specific biomarker in asthma as its proximity to the airways may eliminate some of the confounding factors known to affect serum periostin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1615,
          "endSection": "abstract",
          "offsetInEndSection": 1810
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36763690",
          "text": "Using this assay, sputum periostin was detectable and associated with more disease-relevant parameters in asthma than serum periostin. Sputum periostin is worth considering as a phenotype-specific biomarker in asthma as its proximity to the airways may eliminate some of the confounding factors known to affect serum periostin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1488,
          "endSection": "abstract",
          "offsetInEndSection": 1815
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36763690",
          "text": "BACKGROUND\nSerum periostin associates with type-2 inflammation in asthmatic airways, but also reflects whole body periostin levels originating from multiple sources. Less is known about sputum periostin as a biomarker in asthma as detection levels are low using currently available periostin assays.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 299
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36763690",
          "text": "BACKGROUND\nSerum periostin associates with type-2 inflammation in asthmatic airways, but also reflects whole body periostin levels originating from multiple sources. Less is known about sputum periostin as a biomarker in asthma as detection levels are low using currently available periostin assays. We aimed to investigate detection of sputum periostin using ELISA assays targeting different periostin epitopes and relate levels to clinical characteristics.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 458
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36763690",
          "text": "CONCLUSIONS\nWe present an ELISA method for improved analysis of sputum periostin by detecting cleavage products of the periostin protein. Using this assay, sputum periostin was detectable and associated with more disease-relevant parameters in asthma than serum periostin. Sputum periostin is worth considering as a phenotype-specific biomarker in asthma as its proximity to the airways may eliminate some of the confounding factors known to affect serum periostin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1350,
          "endSection": "abstract",
          "offsetInEndSection": 1815
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27054127",
          "text": "INTRODUCTION\nChronic airway inflammation and remodelling are fundamental features of asthma. The molecular phenotypes in asthma are Th2 high and Th2 low. Serum periostin is a biomarker which aid in understanding Th2 high eosinophilic asthma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 241
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
          "text": "Biomarkers are currently being investigated to better characterize the disease phenotypes and to identify the responders to specific targeted therapies. This review focuses on the emerging data surrounding the use of one such biomarker for T helper 2 (TH2)-driven asthma: periostin. RECENT FINDINGS\nPeriostin is an extracellular matrix protein that is induced by interleukin (IL)-4 and IL-13 in airway epithelial cells and lung fibroblasts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 91,
          "endSection": "abstract",
          "offsetInEndSection": 533
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
          "text": "This review focuses on the emerging data surrounding the use of one such biomarker for T helper 2 (TH2)-driven asthma: periostin. RECENT FINDINGS\nPeriostin is an extracellular matrix protein that is induced by interleukin (IL)-4 and IL-13 in airway epithelial cells and lung fibroblasts. It has proven to be an important biomarker of TH2-associated airway inflammation and a potential predictor of airway eosinophilia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 244,
          "endSection": "abstract",
          "offsetInEndSection": 664
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
          "text": "Periostin, a novel biomarker of TH2-driven asthma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 50
        }
      ],
      "ideal_answer": "Yes, periostin is a novel biomarker of TH2-driven asthma. It is associated with type-2 inflammation in asthmatic airways and reflects whole body periostin levels. A novel assay for improved detection of sputum periostin has been developed, and it is worth considering as a phenotype-specific biomarker in asthma as its proximity to the airways may eliminate some of the confounding factors known to affect serum periostin.",
      "exact_answer": "yes"
    },
    {
      "id": "66168a89fdcbea915f000054",
      "type": "summary",
      "body": "Burkitt lymphoma and Epstein-Barr virus.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19165855",
        "http://www.ncbi.nlm.nih.gov/pubmed/19874382",
        "http://www.ncbi.nlm.nih.gov/pubmed/37046794",
        "http://www.ncbi.nlm.nih.gov/pubmed/8057484",
        "http://www.ncbi.nlm.nih.gov/pubmed/37875309",
        "http://www.ncbi.nlm.nih.gov/pubmed/23269792",
        "http://www.ncbi.nlm.nih.gov/pubmed/25418195",
        "http://www.ncbi.nlm.nih.gov/pubmed/16146820",
        "http://www.ncbi.nlm.nih.gov/pubmed/19386607",
        "http://www.ncbi.nlm.nih.gov/pubmed/18628086"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23269792",
          "text": "Epstein-Barr virus (EBV) is present in all cases of endemic Burkitt lymphoma (BL) but in few European/North American sporadic BLs. Gene expression arrays of sporadic tumors have defined a consensus BL profile within which tumors are classifiable as \"molecular BL\" (mBL).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 270
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19165855",
          "text": "Burkitt's lymphoma (BL) was first described as a clinical entity in children in Central Africa by Denis Burkitt in 1958. The particular epidemiological features of this tumor initiated the search for a virus as the causative agent and led to the discovery of Epstein-Barr virus (EBV) by Epstein and coworkers in 1964. It became apparent in the seventies and eighties that the tumor is not restricted to Central Africa, but occurs with lesser incidence all over the world (sporadic BL) and is also particularly frequent in HIV infected individuals, and that not all BL cases are associated with EBV: about 95% of the cases in Central Africa, 40 to 50% of the cases in HIV-infected individuals and 10 to 20% of the sporadic cases harbour the viral information and express at least one viral antigen (EBNA1) and a number of non-coding viral RNAs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 843
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418195",
          "text": "In 1964, a new herpesvirus, Epstein-Barr virus (EBV), was discovered in cultured tumor cells derived from a Burkitt lymphoma (BL) biopsy taken from an African patient. This was a momentous event that reinvigorated research into viruses as a possible cause of human cancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19165855",
          "text": "Burkitt's lymphoma (BL) was first described as a clinical entity in children in Central Africa by Denis Burkitt in 1958. The particular epidemiological features of this tumor initiated the search for a virus as the causative agent and led to the discovery of Epstein-Barr virus (EBV) by Epstein and coworkers in 1964.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 317
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418195",
          "text": "In 1964, a new herpesvirus, Epstein-Barr virus (EBV), was discovered in cultured tumor cells derived from a Burkitt lymphoma (BL) biopsy taken from an African patient. This was a momentous event that reinvigorated research into viruses as a possible cause of human cancers. Subsequent studies demonstrated that EBV was a potent growth-transforming agent for primary B cells, and that all cases of BL carried characteristic chromosomal translocations resulting in constitutive activation of the c-MYC oncogene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 509
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23269792",
          "text": "Epstein-Barr virus (EBV) is present in all cases of endemic Burkitt lymphoma (BL) but in few European/North American sporadic BLs. Gene expression arrays of sporadic tumors have defined a consensus BL profile within which tumors are classifiable as \"molecular BL\" (mBL). Where endemic BLs fall relative to this profile remains unclear, since they not only carry EBV but also display one of two different forms of virus latency.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 427
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23269792",
          "text": "Epstein-Barr virus (EBV) is present in all cases of endemic Burkitt lymphoma (BL) but in few European/North American sporadic BLs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 130
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418195",
          "text": "In 1964, a new herpesvirus, Epstein-Barr virus (EBV), was discovered in cultured tumor cells derived from a Burkitt lymphoma (BL) biopsy taken from an African patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 167
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37875309",
          "text": "Epstein-Barr virus (EBV) is a type of human γ-herpesvirus, and its reactivation plays an important role in the development of EBV-driven Burkitt lymphoma (BL). Despite intensive chemotherapy, the prognosis of relapsed/refractory BL patients remains unfavorable, and a definitive method to completely eliminate latent EBV infection is lacking.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 342
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19165855",
          "text": "The particular epidemiological features of this tumor initiated the search for a virus as the causative agent and led to the discovery of Epstein-Barr virus (EBV) by Epstein and coworkers in 1964. It became apparent in the seventies and eighties that the tumor is not restricted to Central Africa, but occurs with lesser incidence all over the world (sporadic BL) and is also particularly frequent in HIV infected individuals, and that not all BL cases are associated with EBV: about 95% of the cases in Central Africa, 40 to 50% of the cases in HIV-infected individuals and 10 to 20% of the sporadic cases harbour the viral information and express at least one viral antigen (EBNA1) and a number of non-coding viral RNAs. In contrast, all BL cases regardless of their geographical origin exhibit one of three c-myc/Ig chromosomal translocations leading to the activation of the c-myc gene as a crucial event in the development of this disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 121,
          "endSection": "abstract",
          "offsetInEndSection": 1065
        }
      ],
      "ideal_answer": "Burkitt lymphoma (BL) is often associated with Epstein-Barr virus (EBV), but not all cases are linked to the virus. In Central Africa, about 95% of BL cases have EBV, while in HIV-infected individuals, 40 to 50% of BL cases have EBV. In sporadic cases, only 10 to 20% of BL cases have EBV. The precise role of EBV in the development of BL is not well understood, but its presence in all tumor cells provides opportunities for novel therapeutic and diagnostic approaches.",
      "exact_answer": "n/a"
    },
    {
      "id": "663020de187cba990d00002c",
      "type": "list",
      "body": "What tumor suppressor genes are commonly affected by glioblastoma mutations or deletions?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8548755",
        "http://www.ncbi.nlm.nih.gov/pubmed/30899826",
        "http://www.ncbi.nlm.nih.gov/pubmed/10079373",
        "http://www.ncbi.nlm.nih.gov/pubmed/18726148",
        "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
        "http://www.ncbi.nlm.nih.gov/pubmed/11083071",
        "http://www.ncbi.nlm.nih.gov/pubmed/29629647",
        "http://www.ncbi.nlm.nih.gov/pubmed/28483946",
        "http://www.ncbi.nlm.nih.gov/pubmed/9058294",
        "http://www.ncbi.nlm.nih.gov/pubmed/21397855"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
          "text": "In this study we established the simultaneous status of TP53, p16, p14ARF and PTEN tumor suppressor genes in 34 randomly chosen human glioma cell lines. Nine cell lines (26.4%) harbored mutations or deletions in all four tumor suppressor genes and 22 cell lines (64%) had alterations in at least three. Mutations/deletions were found at the following frequencies: TP53 (76.5%), p14ARF (64.7%), p16 (64.7%), PTEN (73.5%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 420
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
          "text": "In this study we established the simultaneous status of TP53, p16, p14ARF and PTEN tumor suppressor genes in 34 randomly chosen human glioma cell lines. Nine cell lines (26.4%) harbored mutations or deletions in all four tumor suppressor genes and 22 cell lines (64%) had alterations in at least three.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 302
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
          "text": "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 108
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11083071",
          "text": "Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 121
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11083071",
          "text": "Taken together, our data indicate that mutations of the PTEN and TP53 tumor suppressor genes, homozygous deletion of the CDKN2A gene as well as overexpression of the EGFR, p53 and Mdm2 proteins lack prognostic significance for overall survival time in patients with GBMs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1118,
          "endSection": "abstract",
          "offsetInEndSection": 1389
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
          "text": "Mutations/deletions were found at the following frequencies: TP53 (76.5%), p14ARF (64.7%), p16 (64.7%), PTEN (73.5%). Thus, there was a high incidence of alterations in the cellular pathways involving the p53 transcription factor (94.1%), the retinoblastoma protein (64.7%) and the PTEN phosphatase (73.5%) and 91% of cell lines carried mutations in two or more pathways. This provides the first clear genetic evidence that these tumor suppressors participate in biological pathways which are functioning separately/independently in glioma cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 303,
          "endSection": "abstract",
          "offsetInEndSection": 849
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
          "text": "Thus, there was a high incidence of alterations in the cellular pathways involving the p53 transcription factor (94.1%), the retinoblastoma protein (64.7%) and the PTEN phosphatase (73.5%) and 91% of cell lines carried mutations in two or more pathways. This provides the first clear genetic evidence that these tumor suppressors participate in biological pathways which are functioning separately/independently in glioma cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 421,
          "endSection": "abstract",
          "offsetInEndSection": 849
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
          "text": "Nine cell lines (26.4%) harbored mutations or deletions in all four tumor suppressor genes and 22 cell lines (64%) had alterations in at least three. Mutations/deletions were found at the following frequencies: TP53 (76.5%), p14ARF (64.7%), p16 (64.7%), PTEN (73.5%). Thus, there was a high incidence of alterations in the cellular pathways involving the p53 transcription factor (94.1%), the retinoblastoma protein (64.7%) and the PTEN phosphatase (73.5%) and 91% of cell lines carried mutations in two or more pathways.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 674
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
          "text": "In this study we established the simultaneous status of TP53, p16, p14ARF and PTEN tumor suppressor genes in 34 randomly chosen human glioma cell lines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 152
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416987",
          "text": "Thus, there was a high incidence of alterations in the cellular pathways involving the p53 transcription factor (94.1%), the retinoblastoma protein (64.7%) and the PTEN phosphatase (73.5%) and 91% of cell lines carried mutations in two or more pathways. This provides the first clear genetic evidence that these tumor suppressors participate in biological pathways which are functioning separately/independently in glioma cells. The status of the gene alterations did not correlate with tumorigenicity in immunocompromized mice or any clinical parameters.",
          "beginSection": "abstract",
          "offsetInBeginSection": 421,
          "endSection": "abstract",
          "offsetInEndSection": 976
        }
      ],
      "ideal_answer": "PTEN, TP53, and RB are commonly affected tumor suppressor genes in glioblastoma.",
      "exact_answer": [
        [
          "PTEN"
        ],
        [
          "TP53"
        ],
        [
          "RB"
        ],
        [
          "p53"
        ],
        [
          "CDKN2/p16"
        ]
      ]
    },
    {
      "id": "6630211d187cba990d00002d",
      "type": "yesno",
      "body": "Is there an association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36565132",
        "http://www.ncbi.nlm.nih.gov/pubmed/36315559",
        "http://www.ncbi.nlm.nih.gov/pubmed/9800909",
        "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
        "http://www.ncbi.nlm.nih.gov/pubmed/35654209",
        "http://www.ncbi.nlm.nih.gov/pubmed/31836945",
        "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
        "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
        "http://www.ncbi.nlm.nih.gov/pubmed/22000308",
        "http://www.ncbi.nlm.nih.gov/pubmed/32616576"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35654209",
          "text": "Duchenne muscular dystrophy (DMD) is a muscle disorder caused by DMD mutations and is characterized by neurobehavioural comorbidities due to dystrophin deficiency in the brain. The lack of Dp140, a dystrophin short isoform, is clinically associated with intellectual disability and autism spectrum disorders (ASDs), but its postnatal functional role is not well understood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 373
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
          "text": "Duchenne muscular dystrophy is an X-Linked neuromuscular disorder, and the most common muscular dystrophy. Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder. These have been observed with higher frequency in mutations that disrupt the short isoforms Dp71 and Dp140.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35654209",
          "text": "Duchenne muscular dystrophy (DMD) is a muscle disorder caused by DMD mutations and is characterized by neurobehavioural comorbidities due to dystrophin deficiency in the brain. The lack of Dp140, a dystrophin short isoform, is clinically associated with intellectual disability and autism spectrum disorders (ASDs), but its postnatal functional role is not well understood. To investigate synaptic function in the presence or absence of brain Dp140, we utilized two DMD mouse models, mdx23 and mdx52 mice, in which Dp140 is preserved or lacking, respectively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 559
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
          "text": "Duchenne muscular dystrophy is an X-Linked neuromuscular disorder, and the most common muscular dystrophy. Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 243
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31836945",
          "text": "Duchenne muscular dystrophy (DMD) is caused by frameshift mutations in the DMD gene that prevent the body-wide translation of its protein product, dystrophin. Besides a severe muscle phenotype, cognitive impairment and neuropsychiatric symptoms are prevalent. Dystrophin protein 71 (Dp71) is the major DMD gene product expressed in the brain and mutations affecting its expression are associated with the DMD neuropsychiatric syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 435
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31836945",
          "text": "Duchenne muscular dystrophy (DMD) is caused by frameshift mutations in the DMD gene that prevent the body-wide translation of its protein product, dystrophin. Besides a severe muscle phenotype, cognitive impairment and neuropsychiatric symptoms are prevalent.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 259
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9800909",
          "text": "Molecular study and neuropsychological analysis were performed concurrently on 49 patients with Duchenne muscular dystrophy (DMD) in order to find a molecular explanation for the cognitive impairment observed in most DMD patients. Complete analysis of the dystrophin gene was performed to define the localization of deletions and duplications in relation to the different DMD promoters. Qualitative analysis of the Dp71 transcript and testing for the specific first exon of Dp140 were also carried out.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 502
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315559",
          "text": "INTRODUCTIONS\nDuchenne muscular dystrophy (DMD) is an X-linked recessive progressive muscular disease marked by developmental delays due to mutations in the DMD gene, which encodes dystrophin. Brain comorbidity adds to the burden of limited mobility and significantly impacts patients' quality of life and their family.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 319
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315559",
          "text": "INTRODUCTIONS\nDuchenne muscular dystrophy (DMD) is an X-linked recessive progressive muscular disease marked by developmental delays due to mutations in the DMD gene, which encodes dystrophin. Brain comorbidity adds to the burden of limited mobility and significantly impacts patients' quality of life and their family. The changes of expression of dystrophin isoforms in the brain due to DMD gene mutations are thought to be related to the cognitive and neurobehavior profiles of DMD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 485
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9800909",
          "text": "Molecular study and neuropsychological analysis were performed concurrently on 49 patients with Duchenne muscular dystrophy (DMD) in order to find a molecular explanation for the cognitive impairment observed in most DMD patients. Complete analysis of the dystrophin gene was performed to define the localization of deletions and duplications in relation to the different DMD promoters.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 386
        }
      ],
      "ideal_answer": "No, there is no association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy. Further research is needed regarding Dp140 and Dp71, especially in DMD for ASD.",
      "exact_answer": "no"
    },
    {
      "id": "65d144b81930410b13000041",
      "type": "factoid",
      "body": "Coffee Bean Sign is characteristic to which disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
        "http://www.ncbi.nlm.nih.gov/pubmed/35773776",
        "http://www.ncbi.nlm.nih.gov/pubmed/36168370",
        "http://www.ncbi.nlm.nih.gov/pubmed/37761402",
        "http://www.ncbi.nlm.nih.gov/pubmed/36779459",
        "http://www.ncbi.nlm.nih.gov/pubmed/35859918",
        "http://www.ncbi.nlm.nih.gov/pubmed/28626382",
        "http://www.ncbi.nlm.nih.gov/pubmed/27444245",
        "http://www.ncbi.nlm.nih.gov/pubmed/11393102",
        "http://www.ncbi.nlm.nih.gov/pubmed/20028915"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28626382",
          "text": "A plain abdominal X-ray demonstrated a coffee bean sign indicating a sigmoid volvulus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 503,
          "endSection": "abstract",
          "offsetInEndSection": 589
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28626382",
          "text": "A plain abdominal X-ray demonstrated a coffee bean sign indicating a sigmoid volvulus. A consequent CT scan of the abdomen revealed a deep outlet obstruction with massively dilated, elongated and twisted loop of the sigmoid colon and no signs of perforation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 503,
          "endSection": "abstract",
          "offsetInEndSection": 761
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28626382",
          "text": "A plain abdominal X-ray demonstrated a coffee bean sign indicating a sigmoid volvulus. A consequent CT scan of the abdomen revealed a deep outlet obstruction with massively dilated, elongated and twisted loop of the sigmoid colon and no signs of perforation. We performed emergency colonoscopy under the assumption of an acute sigmoid volvulus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 503,
          "endSection": "abstract",
          "offsetInEndSection": 847
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
          "text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV). The CT scans disclosed the steel pan sign, the whirl sign, and the beak-shaped transition point, confirming SV.",
          "beginSection": "abstract",
          "offsetInBeginSection": 55,
          "endSection": "abstract",
          "offsetInEndSection": 248
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
          "text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV). The CT scans disclosed the steel pan sign, the whirl sign, and the beak-shaped transition point, confirming SV. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 55,
          "endSection": "abstract",
          "offsetInEndSection": 249
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
          "text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV).",
          "beginSection": "abstract",
          "offsetInBeginSection": 55,
          "endSection": "abstract",
          "offsetInEndSection": 136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
          "text": "A 66-year-old man presented with abdominal distension. A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
          "text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV). The CT scans disclosed the steel pan sign, the whirl sign, and the beak-shaped transition point, confirming SV. He improved with colonoscopic decompression and detorsion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 55,
          "endSection": "abstract",
          "offsetInEndSection": 307
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28626382",
          "text": "He featured large volume diarrhea within the last few hours without signs of bleeding. A plain abdominal X-ray demonstrated a coffee bean sign indicating a sigmoid volvulus. A consequent CT scan of the abdomen revealed a deep outlet obstruction with massively dilated, elongated and twisted loop of the sigmoid colon and no signs of perforation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 416,
          "endSection": "abstract",
          "offsetInEndSection": 761
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
          "text": "A 66-year-old man presented with abdominal distension. A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV). The CT scans disclosed the steel pan sign, the whirl sign, and the beak-shaped transition point, confirming SV.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 248
        }
      ],
      "ideal_answer": "Sigmoid volvulus. The coffee bean sign is a characteristic radiographic finding in sigmoid volvulus, which is a rare condition in children that occurs due to the twisting of the sigmoid colon around its mesentery.",
      "exact_answer": [
        "sigmoid volvulus"
      ]
    },
    {
      "id": "662fc351187cba990d000014",
      "type": "summary",
      "body": "What role does epiregulin and amphiregulin play in the use of EGFR inhibitors for colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17664471",
        "http://www.ncbi.nlm.nih.gov/pubmed/33888518",
        "http://www.ncbi.nlm.nih.gov/pubmed/27344184",
        "http://www.ncbi.nlm.nih.gov/pubmed/23959273",
        "http://www.ncbi.nlm.nih.gov/pubmed/23885463",
        "http://www.ncbi.nlm.nih.gov/pubmed/23099994",
        "http://www.ncbi.nlm.nih.gov/pubmed/37363997",
        "http://www.ncbi.nlm.nih.gov/pubmed/22409860",
        "http://www.ncbi.nlm.nih.gov/pubmed/31519572",
        "http://www.ncbi.nlm.nih.gov/pubmed/26341080"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27344184",
          "text": "Epidermal growth factor receptor (EGFR) and its ligands amphiregulin (AREG) and epiregulin (EREG) play a central role in the development of colorectal cancer, but the prognostic values of AREG and EREG are controversial. We conducted a meta-analysis of studies that investigated AREG and/or EREG mRNA levels in primary tumors to determine their prognostic value in metastatic colorectal cancer (mCRC). In addition, RAS status was assessed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 439
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23959273",
          "text": "However, the potential pharmacogenetic role of other EGFR ligands such as amphiregulin (AREG) and epiregulin (EREG) has not been elucidated. We studied 74 KRAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.",
          "beginSection": "abstract",
          "offsetInBeginSection": 154,
          "endSection": "abstract",
          "offsetInEndSection": 410
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664471",
          "text": "Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 156
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23959273",
          "text": "However, the potential pharmacogenetic role of other EGFR ligands such as amphiregulin (AREG) and epiregulin (EREG) has not been elucidated. We studied 74 KRAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. Twenty-two genetic variants in EGFR, EGF, AREG and EREG genes were selected using HapMap database and literature resources.",
          "beginSection": "abstract",
          "offsetInBeginSection": 154,
          "endSection": "abstract",
          "offsetInEndSection": 534
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664471",
          "text": "RESULTS\nGene expression profiles showed that patients with tumors that express high levels of the EGFR ligands epiregulin and amphiregulin are more likely to have disease control with cetuximab (EREG, P = .000015; AREG, P = .000025). Additionally, patients whose tumors do not have K-ras mutations have a significantly higher disease control rate than patients with K-ras mutations (P = .0003).",
          "beginSection": "abstract",
          "offsetInBeginSection": 729,
          "endSection": "abstract",
          "offsetInEndSection": 1123
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27344184",
          "text": "Epidermal growth factor receptor (EGFR) and its ligands amphiregulin (AREG) and epiregulin (EREG) play a central role in the development of colorectal cancer, but the prognostic values of AREG and EREG are controversial. We conducted a meta-analysis of studies that investigated AREG and/or EREG mRNA levels in primary tumors to determine their prognostic value in metastatic colorectal cancer (mCRC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 401
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23959273",
          "text": "In the epidermal growth factor receptor (EGFR) pathway, polymorphisms in EGFR and its ligand EGF have been studied as biomarkers for anti-EGFR treatment. However, the potential pharmacogenetic role of other EGFR ligands such as amphiregulin (AREG) and epiregulin (EREG) has not been elucidated. We studied 74 KRAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 410
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664471",
          "text": "RESULTS\nGene expression profiles showed that patients with tumors that express high levels of the EGFR ligands epiregulin and amphiregulin are more likely to have disease control with cetuximab (EREG, P = .000015; AREG, P = .000025).",
          "beginSection": "abstract",
          "offsetInBeginSection": 729,
          "endSection": "abstract",
          "offsetInEndSection": 962
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664471",
          "text": "EGFR and K-ras mutation analyses and EGFR gene copy number analyses were performed on DNA from pretreatment biopsies. RESULTS\nGene expression profiles showed that patients with tumors that express high levels of the EGFR ligands epiregulin and amphiregulin are more likely to have disease control with cetuximab (EREG, P = .000015; AREG, P = .000025).",
          "beginSection": "abstract",
          "offsetInBeginSection": 609,
          "endSection": "abstract",
          "offsetInEndSection": 962
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23885463",
          "text": "INTRODUCTION\nProgress has been made in the treatment of metastatic colorectal cancer with the development of biologic agents such as Cetuximab and Panitumumab. These monoclonal antibodies are directed against EGFR and influence cell division, attachment, angiogenesis, migration and apoptosis. Correlation has been found between the presence of mutations in the K-ras gene and resistance to treatment with Cetuximab.New guidelines require K-ras mutation analysis before anti-EGFR treatment is provided.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 502
        }
      ],
      "ideal_answer": "Epiregulin and amphiregulin are EGFR ligands that are associated with anti-EGFR agent response in metastatic colorectal cancer. High tumor mRNA levels of these ligands are associated with disease control in patients treated with cetuximab, particularly in patients with wild-type K-ras.",
      "exact_answer": "n/a"
    },
    {
      "id": "662cfc88187cba990d000008",
      "type": "factoid",
      "body": "What process does tRNA nucleotidyl transferase 1 (TRNT1)  catalyze?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
        "http://www.ncbi.nlm.nih.gov/pubmed/37239403",
        "http://www.ncbi.nlm.nih.gov/pubmed/36121781",
        "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
        "http://www.ncbi.nlm.nih.gov/pubmed/179457",
        "http://www.ncbi.nlm.nih.gov/pubmed/884105",
        "http://www.ncbi.nlm.nih.gov/pubmed/27370603",
        "http://www.ncbi.nlm.nih.gov/pubmed/3552780",
        "http://www.ncbi.nlm.nih.gov/pubmed/10024176",
        "http://www.ncbi.nlm.nih.gov/pubmed/30758723"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
          "text": "tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 206
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
          "text": "tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation. It was recently discovered that partial loss-of-function mutations in TRNT1 are associated with various, seemingly unrelated human diseases including sideroblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD), retinitis pigmentosa with erythrocyte microcytosis, and progressive B-cell immunodeficiency.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 548
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
          "text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria. Exome sequencing revealed TRNT1 mutations in two unrelated subjects with different clinical features.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 356
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
          "text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
          "text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 255
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
          "text": "tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation. It was recently discovered that partial loss-of-function mutations in TRNT1 are associated with various, seemingly unrelated human diseases including sideroblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD), retinitis pigmentosa with erythrocyte microcytosis, and progressive B-cell immunodeficiency. In addition, even within the same disease, the severity and range of the symptoms vary greatly, suggesting a broad, pleiotropic impact of imparting TRNT1 function on diverse cellular systems.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 740
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
          "text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria. Exome sequencing revealed TRNT1 mutations in two unrelated subjects with different clinical features. The first presented with acute lactic acidosis at 3 weeks of age and developed severe developmental delay, hypotonia, microcephaly, seizures, progressive cortical atrophy, neurosensorial deafness, sideroblastic anemia and renal Fanconi syndrome, dying at 21 months.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 622
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370603",
          "text": "BACKGROUND\nTRNT1 (CCA-adding transfer RNA nucleotidyl transferase) enzyme deficiency is a new metabolic disease caused by defective post-transcriptional modification of mitochondrial and cytosolic transfer RNAs (tRNAs).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 219
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/884105",
          "text": "The enzyme tRNA nucleotidyl transferase (EC 2.7.7.25) has been highly purified from whole adult houseflies. A molecular weight of 30 000 has been determined. The enzyme requires Mg2+ and tRNA deprived of the 3' terminal sequence CCA for activity in the incorporation of AMP and CMP onto the tRNA.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 296
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370603",
          "text": "BACKGROUND\nTRNT1 (CCA-adding transfer RNA nucleotidyl transferase) enzyme deficiency is a new metabolic disease caused by defective post-transcriptional modification of mitochondrial and cytosolic transfer RNAs (tRNAs). RESULTS\nWe investigated four patients from two families with infantile-onset cyclical, aseptic febrile episodes with vomiting and diarrhoea, global electrolyte imbalance during these episodes, sideroblastic anaemia, B lymphocyte immunodeficiency, retinitis pigmentosa, hepatosplenomegaly, exocrine pancreatic insufficiency and renal tubulopathy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 567
        }
      ],
      "ideal_answer": "tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs).",
      "exact_answer": [
        "CCA-adding tRNA nucleotidyl transferase"
      ]
    },
    {
      "id": "6614f810fdcbea915f000043",
      "type": "list",
      "body": "What are the causes for heart and lung transplantation in children?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34991964",
        "http://www.ncbi.nlm.nih.gov/pubmed/33849770",
        "http://www.ncbi.nlm.nih.gov/pubmed/32067330",
        "http://www.ncbi.nlm.nih.gov/pubmed/22748904",
        "http://www.ncbi.nlm.nih.gov/pubmed/25650280",
        "http://www.ncbi.nlm.nih.gov/pubmed/8843521",
        "http://www.ncbi.nlm.nih.gov/pubmed/18333354",
        "http://www.ncbi.nlm.nih.gov/pubmed/1637208",
        "http://www.ncbi.nlm.nih.gov/pubmed/26471823",
        "http://www.ncbi.nlm.nih.gov/pubmed/22548028"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1637208",
          "text": "Five children underwent lung transplantation for end-stage pulmonary hypertension and respiratory insufficiency associated with congenital heart disease. One (17 mo) had pulmonary hypertension with a patent ductus arteriosus and required two periods of preoperative extracorporeal membrane oxygenation before successful bilateral sequential lung transplantation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 362
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8843521",
          "text": "Although many of these children will have primary pulmonary hypertension, a substantial number are children whose pulmonary vascular disease is either associated with a congenital heart lesion or secondary to it. Heart-lung transplantation has been performed in these children in the past, but because of the scarcity of availability of donor heart-lung blocks, lung transplantation with repair of associated congenital cardiac lesions has of necessity been performed more frequently.",
          "beginSection": "abstract",
          "offsetInBeginSection": 171,
          "endSection": "abstract",
          "offsetInEndSection": 655
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1637208",
          "text": "Five children underwent lung transplantation for end-stage pulmonary hypertension and respiratory insufficiency associated with congenital heart disease. One (17 mo) had pulmonary hypertension with a patent ductus arteriosus and required two periods of preoperative extracorporeal membrane oxygenation before successful bilateral sequential lung transplantation. One (21 mo) required bilateral lung transplantation for pulmonary hypertension and bronchopulmonary dysplasia associated with iatrogenic injury to the left pulmonary artery.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 536
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8843521",
          "text": "Pulmonary vascular disease with or without associated congenital heart disease is the indication for lung transplantation in 30% of all children requiring this procedure. Although many of these children will have primary pulmonary hypertension, a substantial number are children whose pulmonary vascular disease is either associated with a congenital heart lesion or secondary to it. Heart-lung transplantation has been performed in these children in the past, but because of the scarcity of availability of donor heart-lung blocks, lung transplantation with repair of associated congenital cardiac lesions has of necessity been performed more frequently.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 655
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8843521",
          "text": "Although many of these children will have primary pulmonary hypertension, a substantial number are children whose pulmonary vascular disease is either associated with a congenital heart lesion or secondary to it. Heart-lung transplantation has been performed in these children in the past, but because of the scarcity of availability of donor heart-lung blocks, lung transplantation with repair of associated congenital cardiac lesions has of necessity been performed more frequently. As one might expect, the operative and postoperative management of these patients is a good deal more complex than pulmonary transplantation for primary lung diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 171,
          "endSection": "abstract",
          "offsetInEndSection": 823
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18333354",
          "text": "Congenital heart diseases are the most common congenital malformations and account for about eight cases per 1000 births and are often associated with pulmonary arterial hypertension. Increased shear stress and the excess flow through the pulmonary vascular bed due to a systemic-to-pulmonary shunt lead to the development of pulmonary vascular disease and an increase in pulmonary vascular resistance. Without surgical repair approximately 30% of patients develop pulmonary vascular disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 492
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18333354",
          "text": "Congenital heart diseases are the most common congenital malformations and account for about eight cases per 1000 births and are often associated with pulmonary arterial hypertension. Increased shear stress and the excess flow through the pulmonary vascular bed due to a systemic-to-pulmonary shunt lead to the development of pulmonary vascular disease and an increase in pulmonary vascular resistance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 402
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1637208",
          "text": "Five children underwent lung transplantation for end-stage pulmonary hypertension and respiratory insufficiency associated with congenital heart disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 153
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8843521",
          "text": "Pulmonary vascular disease with or without associated congenital heart disease is the indication for lung transplantation in 30% of all children requiring this procedure. Although many of these children will have primary pulmonary hypertension, a substantial number are children whose pulmonary vascular disease is either associated with a congenital heart lesion or secondary to it.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 383
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1637208",
          "text": "One child underwent right single-lung transplantation and closure of an atrial septal defect for pulmonary hypertension. Two patients had single-lung transplantation for Eisenmenger's syndrome: 1 with muscular inlet ventricular septal defect closure, atrial septal defect closure, and right single-lung transplantation; 1 with ventricular septal defect closure, patent ductus arteriosus ligation, right ventricular outflow tract patch repair, and single-lung transplantation. All patients survived operation, with one late death (lymphoproliferative disease).",
          "beginSection": "abstract",
          "offsetInBeginSection": 745,
          "endSection": "abstract",
          "offsetInEndSection": 1304
        }
      ],
      "ideal_answer": "Heart and lung transplantation in children is primarily caused by congenital heart disease, pulmonary hypertension, and end-stage cardiopulmonary failure. Specific conditions include single-ventricle, tetralogy of Fallot, major aortopulmonary collateral arteries, prior Potts shunt palliation, pulmonary arterial hypertension, primary pulmonary hypertension, congenital heart disease without Eisenmenger's syndrome, and congenital heart disease with Eisenmenger's syndrome.",
      "exact_answer": [
        [
          "congenital heart disease"
        ],
        [
          "pulmonary hypertension"
        ],
        [
          "end-stage cardiopulmonary failure"
        ]
      ]
    },
    {
      "id": "662edc6f187cba990d00000c",
      "type": "yesno",
      "body": "Can enhancer-promoter interactions form independently of genomic distance?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
        "http://www.ncbi.nlm.nih.gov/pubmed/37430091",
        "http://www.ncbi.nlm.nih.gov/pubmed/35418676",
        "http://www.ncbi.nlm.nih.gov/pubmed/25340767",
        "http://www.ncbi.nlm.nih.gov/pubmed/28881991",
        "http://www.ncbi.nlm.nih.gov/pubmed/38062010",
        "http://www.ncbi.nlm.nih.gov/pubmed/27064255",
        "http://www.ncbi.nlm.nih.gov/pubmed/31514731",
        "http://www.ncbi.nlm.nih.gov/pubmed/11742093",
        "http://www.ncbi.nlm.nih.gov/pubmed/19923429"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Enhancer-promoter interactions can form independently of genomic distance and be functional across TAD boundaries",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 113
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Enhancer-promoter interactions can form independently of genomic distance and be functional across TAD boundaries.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 114
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones. These observations suggest that other general mechanisms must exist to establish and maintain specific enhancer-promoter interactions across large distances.",
          "beginSection": "abstract",
          "offsetInBeginSection": 827,
          "endSection": "abstract",
          "offsetInEndSection": 1196
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones.",
          "beginSection": "abstract",
          "offsetInBeginSection": 827,
          "endSection": "abstract",
          "offsetInEndSection": 1038
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "While this developmental gene can establish inter-TAD interactions with its enhancer, the functionality of these interactions remains limited, highlighting the existence of topological constraints. Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones. These observations suggest that other general mechanisms must exist to establish and maintain specific enhancer-promoter interactions across large distances.",
          "beginSection": "abstract",
          "offsetInBeginSection": 629,
          "endSection": "abstract",
          "offsetInEndSection": 1196
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "While this developmental gene can establish inter-TAD interactions with its enhancer, the functionality of these interactions remains limited, highlighting the existence of topological constraints. Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones.",
          "beginSection": "abstract",
          "offsetInBeginSection": 629,
          "endSection": "abstract",
          "offsetInEndSection": 1038
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "We pursued this observation using the twist locus, a master regulator of mesoderm development, and systematically relocated one of its enhancers to various genomic locations. While this developmental gene can establish inter-TAD interactions with its enhancer, the functionality of these interactions remains limited, highlighting the existence of topological constraints. Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones.",
          "beginSection": "abstract",
          "offsetInBeginSection": 454,
          "endSection": "abstract",
          "offsetInEndSection": 1038
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Here, we show that a significant proportion of enhancer-promoter interactions are established across TAD boundaries in Drosophila embryos, but that developmental genes are strikingly enriched in intra- but not inter-TAD interactions. We pursued this observation using the twist locus, a master regulator of mesoderm development, and systematically relocated one of its enhancers to various genomic locations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 220,
          "endSection": "abstract",
          "offsetInEndSection": 628
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Here, we show that a significant proportion of enhancer-promoter interactions are established across TAD boundaries in Drosophila embryos, but that developmental genes are strikingly enriched in intra- but not inter-TAD interactions. We pursued this observation using the twist locus, a master regulator of mesoderm development, and systematically relocated one of its enhancers to various genomic locations. While this developmental gene can establish inter-TAD interactions with its enhancer, the functionality of these interactions remains limited, highlighting the existence of topological constraints.",
          "beginSection": "abstract",
          "offsetInBeginSection": 220,
          "endSection": "abstract",
          "offsetInEndSection": 826
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Here, we show that a significant proportion of enhancer-promoter interactions are established across TAD boundaries in Drosophila embryos, but that developmental genes are strikingly enriched in intra- but not inter-TAD interactions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 220,
          "endSection": "abstract",
          "offsetInEndSection": 453
        }
      ],
      "ideal_answer": "Yes, enhancer-promoter interactions can form independently of genomic distance and be functional across TAD boundaries.",
      "exact_answer": "yes"
    },
    {
      "id": "66300d3e187cba990d00001b",
      "type": "factoid",
      "body": "What is the prevalence of intellectual developmental disorders in Becker Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
        "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
        "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
        "http://www.ncbi.nlm.nih.gov/pubmed/3993293",
        "http://www.ncbi.nlm.nih.gov/pubmed/34782199",
        "http://www.ncbi.nlm.nih.gov/pubmed/37968431",
        "http://www.ncbi.nlm.nih.gov/pubmed/1389764",
        "http://www.ncbi.nlm.nih.gov/pubmed/15269471",
        "http://www.ncbi.nlm.nih.gov/pubmed/7485232",
        "http://www.ncbi.nlm.nih.gov/pubmed/7194435"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
          "text": "Prevalence and incidence of Becker muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 54
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
          "text": "73 patients alive and resident in the Northern Health Region were identified, giving a prevalence rate of 2.38/100,000. This compares with a prevalence of Duchenne muscular dystrophy of 2.48/100,000. The cumulative birth incidence of Becker muscular dystrophy (at least 1 in 18 450 male live births) was about one third that of Duchenne muscular dystrophy (1 in 5618 male live births), suggesting that the disorder is more common than previously thought.",
          "beginSection": "abstract",
          "offsetInBeginSection": 501,
          "endSection": "abstract",
          "offsetInEndSection": 955
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
          "text": "This compares with a prevalence of Duchenne muscular dystrophy of 2.48/100,000. The cumulative birth incidence of Becker muscular dystrophy (at least 1 in 18 450 male live births) was about one third that of Duchenne muscular dystrophy (1 in 5618 male live births), suggesting that the disorder is more common than previously thought.",
          "beginSection": "abstract",
          "offsetInBeginSection": 621,
          "endSection": "abstract",
          "offsetInEndSection": 955
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "Patients with Becker muscular dystrophy demonstrate a less homogeneous cognitive phenotype than that seen in Duchenne muscular dystrophy. Males with Becker muscular dystrophy have a high incidence of learning difficulties. Autism and behavioral and attention problems are also more common in Becker muscular dystrophy than in the general population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1665,
          "endSection": "abstract",
          "offsetInEndSection": 2014
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "The frequency of total behavioral problems in the clinical range was 67%, and the frequency of autism was 8.3%. Patients with Becker muscular dystrophy demonstrate a less homogeneous cognitive phenotype than that seen in Duchenne muscular dystrophy. Males with Becker muscular dystrophy have a high incidence of learning difficulties.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1553,
          "endSection": "abstract",
          "offsetInEndSection": 1887
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "Males with Becker muscular dystrophy have a high incidence of learning difficulties. Autism and behavioral and attention problems are also more common in Becker muscular dystrophy than in the general population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1803,
          "endSection": "abstract",
          "offsetInEndSection": 2014
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "The frequency of total behavioral problems in the clinical range was 67%, and the frequency of autism was 8.3%. Patients with Becker muscular dystrophy demonstrate a less homogeneous cognitive phenotype than that seen in Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1553,
          "endSection": "abstract",
          "offsetInEndSection": 1802
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
          "text": "The cumulative birth incidence of Becker muscular dystrophy (at least 1 in 18 450 male live births) was about one third that of Duchenne muscular dystrophy (1 in 5618 male live births), suggesting that the disorder is more common than previously thought.",
          "beginSection": "abstract",
          "offsetInBeginSection": 701,
          "endSection": "abstract",
          "offsetInEndSection": 955
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "The frequency of learning difficulties for reading was 21%, for spelling was 32%, and for arithmetic was 26%, significantly higher than the frequency in the general population. The frequency of total behavioral problems in the clinical range was 67%, and the frequency of autism was 8.3%. Patients with Becker muscular dystrophy demonstrate a less homogeneous cognitive phenotype than that seen in Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1376,
          "endSection": "abstract",
          "offsetInEndSection": 1802
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34782199",
          "text": "BACKGROUND\nDevelopmental disorders associated with Becker muscular dystrophy (BMD), possibly resulting from a lack of dystrophin in the brain, have been reported, but their importance is not fully understood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 208
        }
      ],
      "ideal_answer": "The prevalence of intellectual developmental disorders in Becker Muscular Dystrophy is 8%.",
      "exact_answer": [
        "8%"
      ]
    },
    {
      "id": "65cfdf1c1930410b13000028",
      "type": "factoid",
      "body": "Mutation of which gene was implicated in Disabling pansclerotic morphea?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37256972",
        "http://www.ncbi.nlm.nih.gov/pubmed/16021158",
        "http://www.ncbi.nlm.nih.gov/pubmed/7356347",
        "http://www.ncbi.nlm.nih.gov/pubmed/20108512",
        "http://www.ncbi.nlm.nih.gov/pubmed/24891683",
        "http://www.ncbi.nlm.nih.gov/pubmed/23716826",
        "http://www.ncbi.nlm.nih.gov/pubmed/28543434",
        "http://www.ncbi.nlm.nih.gov/pubmed/11843172",
        "http://www.ncbi.nlm.nih.gov/pubmed/19250408",
        "http://www.ncbi.nlm.nih.gov/pubmed/6372700"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7356347",
          "text": "Disabling pansclerotic morphea of children.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 43
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11843172",
          "text": "Disabling pansclerotic morphea of childhood and hypogammaglobulinemia: a curious association.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 93
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11843172",
          "text": "Biopsy of the involved areas showed features consistent with pansclerotic morphea. Immunoglobulin estimation revealed hypogammaglobulinemia. This unique combination of pansclerotic morphea with hypogammaglobulinemia has not been reported before.",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 402
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11843172",
          "text": "Biopsy of the involved areas showed features consistent with pansclerotic morphea.",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 239
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11843172",
          "text": "Biopsy of the involved areas showed features consistent with pansclerotic morphea. Immunoglobulin estimation revealed hypogammaglobulinemia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 297
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16021158",
          "text": "Disabling pansclerotic morphea: clinical presentation in two adults.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 68
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7356347",
          "text": "Laboratory data were characterized by a polyclonal elevation of gamma-globulin level and by peripheral eosinophilia. Pulmonary changes in five patients and esophageal changes in one imply that acral pansclerotic morphea may be assoicated with mild nonprogressive visceral change. Although cyclophosphamide may retard the process, no satisfactory treatment for progressive, mutilating acral pansclerotic morphea has been found.",
          "beginSection": "abstract",
          "offsetInBeginSection": 311,
          "endSection": "abstract",
          "offsetInEndSection": 737
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16021158",
          "text": "We describe adult-onset disabling pansclerotic morphea in two previously healthy young men. In both cases, the onset of disease was explosive, with rapid progression, widespread cutaneous involvement, and severe disablement caused by mutilating contracture deformities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 290,
          "endSection": "abstract",
          "offsetInEndSection": 559
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24891683",
          "text": "Disabling pansclerotic morphea (DPM) is a rare, severe, and mutilating form of morphea, involving the dermis, subcutaneous tissue, fat, muscle, and even bone.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 158
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16021158",
          "text": "We describe adult-onset disabling pansclerotic morphea in two previously healthy young men.",
          "beginSection": "abstract",
          "offsetInBeginSection": 290,
          "endSection": "abstract",
          "offsetInEndSection": 381
        }
      ],
      "ideal_answer": "Mutation of the STAT4 gene was implicated in Disabling pansclerotic morphea.",
      "exact_answer": [
        "STAT4"
      ]
    },
    {
      "id": "662fc122187cba990d000012",
      "type": "yesno",
      "body": "Does physical exercise reduce the risk of recurrence from colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30964753",
        "http://www.ncbi.nlm.nih.gov/pubmed/35205748",
        "http://www.ncbi.nlm.nih.gov/pubmed/27364123",
        "http://www.ncbi.nlm.nih.gov/pubmed/23448955",
        "http://www.ncbi.nlm.nih.gov/pubmed/35891576",
        "http://www.ncbi.nlm.nih.gov/pubmed/25918293",
        "http://www.ncbi.nlm.nih.gov/pubmed/24525164",
        "http://www.ncbi.nlm.nih.gov/pubmed/24968815",
        "http://www.ncbi.nlm.nih.gov/pubmed/24644304",
        "http://www.ncbi.nlm.nih.gov/pubmed/34694086"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23448955",
          "text": "BACKGROUND\nPhysical activity (PA) has been associated with lower risk of disease recurrence and longer survival in colorectal cancer (CRC) survivors; however, less than one-third of CRC survivors are meeting PA guidelines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 222
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27364123",
          "text": "PURPOSE\nPhysical activity (PA) is an effective intervention for improving the quality of life of colorectal cancer survivors (CRC) and may reduce the risk of cancer recurrence and cancer specific and all-cause mortality. However, most CRC survivors are not sufficiently active to receive these benefits.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 303
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23448955",
          "text": "BACKGROUND\nPhysical activity (PA) has been associated with lower risk of disease recurrence and longer survival in colorectal cancer (CRC) survivors; however, less than one-third of CRC survivors are meeting PA guidelines. Interventions to promote PA in CRC survivors need to understand the most critical beliefs that influence PA behavior.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 340
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27364123",
          "text": "PURPOSE\nPhysical activity (PA) is an effective intervention for improving the quality of life of colorectal cancer survivors (CRC) and may reduce the risk of cancer recurrence and cancer specific and all-cause mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 220
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35891576",
          "text": "INTRODUCTION\nWhether and to what extent the relationship between physical activity (PA) and colorectal cancer (CRC) differs according to CRC-related genetic risk remains to be determined, and no studies to date have quantified how much genetically determined risk could be compensated for with active exercise.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 310
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27364123",
          "text": "PURPOSE\nPhysical activity (PA) is an effective intervention for improving the quality of life of colorectal cancer survivors (CRC) and may reduce the risk of cancer recurrence and cancer specific and all-cause mortality. However, most CRC survivors are not sufficiently active to receive these benefits. Sedentary behavior (SB) has also been linked to morbidity and mortality risk independent of activity level, thereby presenting an additional opportunity to improve health outcomes of CRC survivors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 501
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25918293",
          "text": "No randomized controlled trials have been completed to confirm that physical activity lowers risk of mortality among colorectal cancer survivors; however, trials have shown that physical activity, including structured exercise, is safe for colorectal cancer survivors (localized to metastatic stage, during and after treatment) and improves cardiorespiratory fitness and physical function.",
          "beginSection": "abstract",
          "offsetInBeginSection": 809,
          "endSection": "abstract",
          "offsetInEndSection": 1198
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25918293",
          "text": "Prospective observational studies have consistently reported that physical activity after colorectal cancer diagnosis reduces mortality. A meta-analysis estimated that each 15 metabolic equivalent task-hour per week increase in physical activity after colorectal cancer diagnosis was associated with a 38% lower risk of mortality. No randomized controlled trials have been completed to confirm that physical activity lowers risk of mortality among colorectal cancer survivors; however, trials have shown that physical activity, including structured exercise, is safe for colorectal cancer survivors (localized to metastatic stage, during and after treatment) and improves cardiorespiratory fitness and physical function.",
          "beginSection": "abstract",
          "offsetInBeginSection": 478,
          "endSection": "abstract",
          "offsetInEndSection": 1198
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23448955",
          "text": "RESULTS\nColorectal cancer survivors identified improved fitness (69.5%), family members (67.3%), and medical/health problems (8.8%) as the most prevalent behavioral, normative, and control beliefs, respectively. All PA beliefs were significantly correlated with all TPB constructs and PA. CONCLUSIONS\nPhysical activity interventions for CRC survivors should target many salient beliefs including behavioral, normative, and control beliefs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 799,
          "endSection": "abstract",
          "offsetInEndSection": 1240
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25918293",
          "text": "A meta-analysis estimated that each 15 metabolic equivalent task-hour per week increase in physical activity after colorectal cancer diagnosis was associated with a 38% lower risk of mortality. No randomized controlled trials have been completed to confirm that physical activity lowers risk of mortality among colorectal cancer survivors; however, trials have shown that physical activity, including structured exercise, is safe for colorectal cancer survivors (localized to metastatic stage, during and after treatment) and improves cardiorespiratory fitness and physical function. In addition, prospective observational studies have suggested that a Western dietary pattern, high carbohydrate intake, and consuming sugar-sweetened beverages after diagnosis may increase risk of colorectal cancer recurrence and mortality, but these data are limited to single analyses from one of two US cohorts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 615,
          "endSection": "abstract",
          "offsetInEndSection": 1513
        }
      ],
      "ideal_answer": "Yes, physical activity (PA) both before and after a colorectal cancer (CRC) diagnosis is associated with a reduced risk of mortality among CRC survivors.",
      "exact_answer": "yes"
    },
    {
      "id": "662a4b08b9f8b89d7e00000b",
      "type": "factoid",
      "body": "Oxysterol is produced by the oxidation of what waxy, fat-like substance made in the liver?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38036887",
        "http://www.ncbi.nlm.nih.gov/pubmed/38036880",
        "http://www.ncbi.nlm.nih.gov/pubmed/38036890",
        "http://www.ncbi.nlm.nih.gov/pubmed/38036882",
        "http://www.ncbi.nlm.nih.gov/pubmed/22884520",
        "http://www.ncbi.nlm.nih.gov/pubmed/32762060",
        "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
        "http://www.ncbi.nlm.nih.gov/pubmed/8399364",
        "http://www.ncbi.nlm.nih.gov/pubmed/10882719",
        "http://www.ncbi.nlm.nih.gov/pubmed/2229319"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Oxysterols are bioactive lipids derived from cholesterol that are linked to inflammatory processes. Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 371
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Oxysterols are bioactive lipids derived from cholesterol that are linked to inflammatory processes. Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma. To this end, we used diet-induced and genetic (ob/ob and db/db) models of obesity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Our data show that, when considering oxysterol metabolism, the high-fat diet and ob/ob models are more closely related when compared to the db/db model. However, we were able to discriminate between lean and obese phenotypes based on liver oxysterol (4β-hydroxycholesterol, 27- hydroxycholesterol, 7-hydroxycholestenone) levels and enzyme (CYP3A11, CYP27A1, CYP7A1) expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1027,
          "endSection": "abstract",
          "offsetInEndSection": 1404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "However, although they are downstream metabolites of oxysterols, the variations in bile acid levels did not reflect the variations of their precursors. Our data show that, when considering oxysterol metabolism, the high-fat diet and ob/ob models are more closely related when compared to the db/db model. However, we were able to discriminate between lean and obese phenotypes based on liver oxysterol (4β-hydroxycholesterol, 27- hydroxycholesterol, 7-hydroxycholestenone) levels and enzyme (CYP3A11, CYP27A1, CYP7A1) expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 875,
          "endSection": "abstract",
          "offsetInEndSection": 1404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma. To this end, we used diet-induced and genetic (ob/ob and db/db) models of obesity. Among the oxysterols measured, we found that 4β-oxysterol levels were consistently decreased in the high-fat diet study, at different time-points, and in the ob/ob model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 625
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Oxysterols are bioactive lipids derived from cholesterol that are linked to inflammatory processes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 371
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma. To this end, we used diet-induced and genetic (ob/ob and db/db) models of obesity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "However, we were able to discriminate between lean and obese phenotypes based on liver oxysterol (4β-hydroxycholesterol, 27- hydroxycholesterol, 7-hydroxycholestenone) levels and enzyme (CYP3A11, CYP27A1, CYP7A1) expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1180,
          "endSection": "abstract",
          "offsetInEndSection": 1404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22884520",
          "text": "LXRs are thought to be activated predominantly by oxysterols generated enzymatically from cholesterol in different cell organelles. Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in sterol-27-hydroxylase activity lead to specific blocks in oxysterol production and impaired LXR-dependent gene activation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 257,
          "endSection": "abstract",
          "offsetInEndSection": 612
        }
      ],
      "ideal_answer": "Oxysterol is produced by the oxidation of cholesterol, a waxy, fat-like substance made in the liver.",
      "exact_answer": [
        "cholesterol"
      ]
    },
    {
      "id": "65f84c78c4010b4d78000049",
      "type": "yesno",
      "body": "Is bowel transplantation commonly performed in patients with severe gastrointestinal disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37495293",
        "http://www.ncbi.nlm.nih.gov/pubmed/36755514",
        "http://www.ncbi.nlm.nih.gov/pubmed/37417206",
        "http://www.ncbi.nlm.nih.gov/pubmed/23730777",
        "http://www.ncbi.nlm.nih.gov/pubmed/16161535",
        "http://www.ncbi.nlm.nih.gov/pubmed/19692189",
        "http://www.ncbi.nlm.nih.gov/pubmed/15751317",
        "http://www.ncbi.nlm.nih.gov/pubmed/10389331",
        "http://www.ncbi.nlm.nih.gov/pubmed/16908253",
        "http://www.ncbi.nlm.nih.gov/pubmed/11151076"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37495293",
          "text": "Intestinal transplantation and multivisceral transplantation are technically challenging and complex procedures mainly performed on patients with irreversible and non-medically manageable end-stage intestinal failure.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 217
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16161535",
          "text": "In adults, the major indication for intestinal transplantation is inadaptable short bowel syndrome after total or subtotal resection. Patients with irreversible intestinal failure and total parenteral nutrition dependency without consistent liver disease must be considered as candidates for isolated small bowel transplantation. Patients with irreversible intestinal failure and end-stage liver diseases are candidates for lifesaving procedure such as combined liver-small bowel transplantation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 410,
          "endSection": "abstract",
          "offsetInEndSection": 906
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16161535",
          "text": "Patients with irreversible intestinal failure and total parenteral nutrition dependency without consistent liver disease must be considered as candidates for isolated small bowel transplantation. Patients with irreversible intestinal failure and end-stage liver diseases are candidates for lifesaving procedure such as combined liver-small bowel transplantation. The appropriate timing for transplantation remains vague.",
          "beginSection": "abstract",
          "offsetInBeginSection": 544,
          "endSection": "abstract",
          "offsetInEndSection": 964
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10389331",
          "text": "Intestinal transplantation is now possible and in some conditions, constitutes the logical treatment option. Since 1985, more than 300 small-bowel grafts have been performed, involving the isolated small bowel with or without the colon (45%), the liver + small bowel (40%) or several organs (15%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 151,
          "endSection": "abstract",
          "offsetInEndSection": 448
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10389331",
          "text": "Intestinal transplantation is now possible and in some conditions, constitutes the logical treatment option. Since 1985, more than 300 small-bowel grafts have been performed, involving the isolated small bowel with or without the colon (45%), the liver + small bowel (40%) or several organs (15%). 2/3 of recipients were under 20 years of age, and indications were short-bowel syndrome (64%), severe intractable diarrhea (13%), abdominal cancer (13%), or chronic intestinal pseudo-obstruction syndrome (8%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 151,
          "endSection": "abstract",
          "offsetInEndSection": 658
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19692189",
          "text": "The work done on short bowel syndrome in the past 20 years should be done in the next years for chronic-intestinal - pseudo-obstruction patients presenting with intestinal failure on a large European scale because chronic-intestinal - pseudo-obstruction is a group of heterogeneous but rare intestinal diseases. Intestinal transplantation is now a mature therapy with formal indication especially in case of Home Parenteral Nutrition failure (mainly Home Parenteral Nutrition-associated severe liver disease) where combined Liver-intestine transplantation is indicated before end-stage liver failure occurs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 842,
          "endSection": "abstract",
          "offsetInEndSection": 1449
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37495293",
          "text": "Intestinal transplantation and multivisceral transplantation are technically challenging and complex procedures mainly performed on patients with irreversible and non-medically manageable end-stage intestinal failure",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 216
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16161535",
          "text": "Patients with irreversible intestinal failure and total parenteral nutrition dependency without consistent liver disease must be considered as candidates for isolated small bowel transplantation. Patients with irreversible intestinal failure and end-stage liver diseases are candidates for lifesaving procedure such as combined liver-small bowel transplantation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 544,
          "endSection": "abstract",
          "offsetInEndSection": 906
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19692189",
          "text": "The work done on short bowel syndrome in the past 20 years should be done in the next years for chronic-intestinal - pseudo-obstruction patients presenting with intestinal failure on a large European scale because chronic-intestinal - pseudo-obstruction is a group of heterogeneous but rare intestinal diseases. Intestinal transplantation is now a mature therapy with formal indication especially in case of Home Parenteral Nutrition failure (mainly Home Parenteral Nutrition-associated severe liver disease) where combined Liver-intestine transplantation is indicated before end-stage liver failure occurs. For high-risk patients, \"preemptive\" indication for intestinal transplantation alone will be discussed before home parenteral nutrition complications occur.",
          "beginSection": "abstract",
          "offsetInBeginSection": 842,
          "endSection": "abstract",
          "offsetInEndSection": 1606
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16161535",
          "text": "In adults, the major indication for intestinal transplantation is inadaptable short bowel syndrome after total or subtotal resection. Patients with irreversible intestinal failure and total parenteral nutrition dependency without consistent liver disease must be considered as candidates for isolated small bowel transplantation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 410,
          "endSection": "abstract",
          "offsetInEndSection": 739
        }
      ],
      "ideal_answer": "No, bowel transplantation is not commonly performed in patients with severe gastrointestinal disease. Only 5% of patients are potentially suitable for intestinal transplantation, and it is a technically challenging and complex procedure mainly performed on patients with irreversible and non-medically manageable end-stage intestinal failure.",
      "exact_answer": "no"
    },
    {
      "id": "6630154c187cba990d000021",
      "type": "factoid",
      "body": "Which chromosome is most commonly affected by loss of heterozygosity in glioblastoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
        "http://www.ncbi.nlm.nih.gov/pubmed/1975968",
        "http://www.ncbi.nlm.nih.gov/pubmed/2544511",
        "http://www.ncbi.nlm.nih.gov/pubmed/8098856",
        "http://www.ncbi.nlm.nih.gov/pubmed/2573417",
        "http://www.ncbi.nlm.nih.gov/pubmed/1320666",
        "http://www.ncbi.nlm.nih.gov/pubmed/11592040",
        "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
        "http://www.ncbi.nlm.nih.gov/pubmed/8546898",
        "http://www.ncbi.nlm.nih.gov/pubmed/10850866"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
          "text": "Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested.",
          "beginSection": "abstract",
          "offsetInBeginSection": 439,
          "endSection": "abstract",
          "offsetInEndSection": 631
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
          "text": "Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas;",
          "beginSection": "abstract",
          "offsetInBeginSection": 439,
          "endSection": "abstract",
          "offsetInEndSection": 551
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1975968",
          "text": "Loss of constitutional heterozygosity in chromosome 10 in human glioblastoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 77
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
          "text": "Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 111
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8098856",
          "text": "Loss of heterozygosity on chromosome 10 was seen in 16 tumours (13 glioblastoma multiforme, 2 anaplastic astrocytomas, and 1 anaplastic oligoastrocytoma), but not in any of the low-grade astrocytomas examined.",
          "beginSection": "abstract",
          "offsetInBeginSection": 293,
          "endSection": "abstract",
          "offsetInEndSection": 502
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
          "text": "Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested. We carried out deletion mappings on chromosome 10, using PCR-based microsatellite analysis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 439,
          "endSection": "abstract",
          "offsetInEndSection": 723
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2544511",
          "text": "Loss of heterozygosity on chromosome 10 in human glioblastoma multiforme.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 73
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2573417",
          "text": "Loss of constitutional heterozygosity for loci on chromosome 17 was found in both anaplastic astrocytoma and glioblastoma patients with equal frequency (40% of cases). Our mapping data revealed a region of loss on chromosome 17p between physical loci p11.2 and pter that was common to both patient groups.",
          "beginSection": "abstract",
          "offsetInBeginSection": 847,
          "endSection": "abstract",
          "offsetInEndSection": 1152
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
          "text": "Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested. We carried out deletion mappings on chromosome 10, using PCR-based microsatellite analysis. LOH#10 was detected at similar frequencies in primary (8/17; 47%) and secondary glioblastomas (7/13; 54%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 439,
          "endSection": "abstract",
          "offsetInEndSection": 830
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2573417",
          "text": "Loss of constitutional heterozygosity for loci on chromosome 17 was found in both anaplastic astrocytoma and glioblastoma patients with equal frequency (40% of cases).",
          "beginSection": "abstract",
          "offsetInBeginSection": 847,
          "endSection": "abstract",
          "offsetInEndSection": 1014
        }
      ],
      "ideal_answer": "Chromosome 10 is the most commonly affected chromosome by loss of heterozygosity in glioblastoma.",
      "exact_answer": [
        "chromosome 10"
      ]
    },
    {
      "id": "663023f3187cba990d000030",
      "type": "summary",
      "body": "What is KineDMD?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
        "http://www.ncbi.nlm.nih.gov/pubmed/21724396",
        "http://www.ncbi.nlm.nih.gov/pubmed/35032073",
        "http://www.ncbi.nlm.nih.gov/pubmed/36749302",
        "http://www.ncbi.nlm.nih.gov/pubmed/26870665",
        "http://www.ncbi.nlm.nih.gov/pubmed/31429914",
        "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
        "http://www.ncbi.nlm.nih.gov/pubmed/31792454",
        "http://www.ncbi.nlm.nih.gov/pubmed/21315399",
        "http://www.ncbi.nlm.nih.gov/pubmed/27858763"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 950,
          "endSection": "abstract",
          "offsetInEndSection": 1367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 912,
          "endSection": "abstract",
          "offsetInEndSection": 1367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Then, we used machine learning algorithms that combined the behavioral fingerprints to make cross-sectional and longitudinal disease course predictions, which outperformed predictions derived from currently used clinical assessments. Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 678,
          "endSection": "abstract",
          "offsetInEndSection": 1367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form.",
          "beginSection": "abstract",
          "offsetInBeginSection": 912,
          "endSection": "abstract",
          "offsetInEndSection": 1146
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "We first defined new movement behavioral fingerprints capable of distinguishing DMD from controls. Then, we used machine learning algorithms that combined the behavioral fingerprints to make cross-sectional and longitudinal disease course predictions, which outperformed predictions derived from currently used clinical assessments. Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form.",
          "beginSection": "abstract",
          "offsetInBeginSection": 579,
          "endSection": "abstract",
          "offsetInEndSection": 1146
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Then, we used machine learning algorithms that combined the behavioral fingerprints to make cross-sectional and longitudinal disease course predictions, which outperformed predictions derived from currently used clinical assessments. Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form.",
          "beginSection": "abstract",
          "offsetInBeginSection": 678,
          "endSection": "abstract",
          "offsetInEndSection": 1146
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1147,
          "endSection": "abstract",
          "offsetInEndSection": 1367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26870665",
          "text": "Statistical analysis revealed correlations between the serum concentrations and certain clinical endpoints including forced vital capacity in DMD patients and the time to walk ten meters in LGMD2B patients. Serum concentrations of these proteins were also elevated in two preclinical models of muscular dystrophy, the mdx mouse and the golden-retriever muscular dystrophy dog. CONCLUSIONS\nThese proteins, therefore, are potential muscular dystrophy biomarkers for monitoring disease progression and therapeutic response in both preclinical and clinical studies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1187,
          "endSection": "abstract",
          "offsetInEndSection": 1750
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21724396",
          "text": "To identify serum biomarkers that allow monitoring of disease progression and treatment effects in Duchenne muscular dystrophy (DMD) patients, levels of matrix metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase-1 (TIMP-1) and osteopontin (OPN) were determined in 63 DMD patients on corticosteroid therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 322
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21724396",
          "text": "Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 128
        }
      ],
      "ideal_answer": "KineDMD is a behavioral biomarker that is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. It can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
      "exact_answer": "n/a"
    },
    {
      "id": "65d12a181930410b1300002f",
      "type": "yesno",
      "body": "Can fluoroquinolones be used for patient with myasthenia gravis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19232642",
        "http://www.ncbi.nlm.nih.gov/pubmed/21879778",
        "http://www.ncbi.nlm.nih.gov/pubmed/24029473",
        "http://www.ncbi.nlm.nih.gov/pubmed/33719062",
        "http://www.ncbi.nlm.nih.gov/pubmed/36373673",
        "http://www.ncbi.nlm.nih.gov/pubmed/32922263",
        "http://www.ncbi.nlm.nih.gov/pubmed/7481384",
        "http://www.ncbi.nlm.nih.gov/pubmed/24935165",
        "http://www.ncbi.nlm.nih.gov/pubmed/17763602",
        "http://www.ncbi.nlm.nih.gov/pubmed/32700310"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7481384",
          "text": "The report of exacerbation of myasthenia gravis with other antibiotic belonging to the group of fluoroquinolones (ciprofloxacin, norfloxacin and ofloxacin) prompt us to recommend caution with the use of all fluoroquinolones in myasthenic patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 536,
          "endSection": "abstract",
          "offsetInEndSection": 783
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24029473",
          "text": "CONCLUSION\nFluoroquinolone exposure may result in myasthenia gravis exacerbations in patients with underlying diseases. Healthcare professionals should be aware of this serious drug-disease association.",
          "beginSection": "abstract",
          "offsetInBeginSection": 881,
          "endSection": "abstract",
          "offsetInEndSection": 1083
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21879778",
          "text": "CONCLUSIONS\nFluoroquinolone exposure may result in potentially life-threatening myasthenia gravis exacerbations in patients with underlying disease. Healthcare professionals should be aware of this serious drug-disease association and carefully weigh the benefit-risks of fluoroquinolones when treating infections in non-ventilated myasthenic patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2024,
          "endSection": "abstract",
          "offsetInEndSection": 2376
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24029473",
          "text": "All patients improved upon the withdrawal of fluoroquinolone in conjunctions with other interventions. CONCLUSION\nFluoroquinolone exposure may result in myasthenia gravis exacerbations in patients with underlying diseases. Healthcare professionals should be aware of this serious drug-disease association.",
          "beginSection": "abstract",
          "offsetInBeginSection": 776,
          "endSection": "abstract",
          "offsetInEndSection": 1083
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24029473",
          "text": "All patients improved upon the withdrawal of fluoroquinolone in conjunctions with other interventions. CONCLUSION\nFluoroquinolone exposure may result in myasthenia gravis exacerbations in patients with underlying diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 776,
          "endSection": "abstract",
          "offsetInEndSection": 1000
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19232642",
          "text": "Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG). We present a case of MG following a treatment with prulifloxacin, a new broad-spectrum oral fluoroquinolone.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 197
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19232642",
          "text": "Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 88
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19232642",
          "text": "Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG). ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 89
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24029473",
          "text": "CONCLUSION: Fluoroquinolone exposure may result in myasthenia gravis exacerbations in patients with underlying diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 875,
          "endSection": "abstract",
          "offsetInEndSection": 995
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19232642",
          "text": "Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG). We present a case of MG following a treatment with prulifloxacin, a new broad-spectrum oral fluoroquinolone. Fluoroquinolones of any generation may interfere with neuromuscular transmission and should be avoided in patients with MG.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 321
        }
      ],
      "ideal_answer": "Fluoroquinolones should be avoided in patients with myasthenia gravis as they have been associated with exacerbation of the disease.",
      "exact_answer": "no"
    },
    {
      "id": "66099eb9fdcbea915f000026",
      "type": "yesno",
      "body": "Are BRAF V600E mutation associated to worse prognosis in colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16024606",
        "http://www.ncbi.nlm.nih.gov/pubmed/21285991",
        "http://www.ncbi.nlm.nih.gov/pubmed/25367198",
        "http://www.ncbi.nlm.nih.gov/pubmed/27404270",
        "http://www.ncbi.nlm.nih.gov/pubmed/27672042",
        "http://www.ncbi.nlm.nih.gov/pubmed/26376292",
        "http://www.ncbi.nlm.nih.gov/pubmed/33330032",
        "http://www.ncbi.nlm.nih.gov/pubmed/24861115",
        "http://www.ncbi.nlm.nih.gov/pubmed/30635874",
        "http://www.ncbi.nlm.nih.gov/pubmed/20501503"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16024606",
          "text": "We conclude that the BRAF V600E mutation in microsatellite-stable colon cancer is associated with a significantly poorer survival in stages 2 to 4 colon cancer but has no effect on the excellent prognosis of microsatellite-unstable tumors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1269,
          "endSection": "abstract",
          "offsetInEndSection": 1508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16024606",
          "text": "Microsatellite-unstable tumors were associated with an excellent 5-year survival whether the V600E mutation was present or absent (76.2% and 75.0%, respectively). We conclude that the BRAF V600E mutation in microsatellite-stable colon cancer is associated with a significantly poorer survival in stages 2 to 4 colon cancer but has no effect on the excellent prognosis of microsatellite-unstable tumors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1106,
          "endSection": "abstract",
          "offsetInEndSection": 1508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27404270",
          "text": "In stage IV cancers, the survival rates of patients at 2 years were 8.5, 50.0, and 68.2% in the BRAF V600E mutation, BRAF D594G mutation, and BRAF wild-type groups, respectively. CONCLUSION\nColorectal cancers with BRAF D594G mutations exhibit similar clinicopathological features, microsatellite instability status, and prognosis as those with BRAF wild-type.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1026,
          "endSection": "abstract",
          "offsetInEndSection": 1387
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27404270",
          "text": "METHODS\nWe selected 908 colorectal cancer patients who underwent surgical resection from January 2008 to January 2013, and assessed BRAF, KRAS, microsatellite instability, and CpG island methylator phenotype (CIMP). RESULTS\nWe detected BRAF D594G in 7 patients and BRAF V600E in 45 patients. The clinicopathological features of cancers with BRAF D594G mutation were similar to those with BRAF wild-type, but differed from those with BRAF V600E mutations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 205,
          "endSection": "abstract",
          "offsetInEndSection": 661
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27404270",
          "text": "There were no CIMP-positive tumors in cancers with BRAF D594G mutations, whereas 67.8% of tumors with BRAF V600E mutations were CIMP-positive. In stage IV cancers, the survival rates of patients at 2 years were 8.5, 50.0, and 68.2% in the BRAF V600E mutation, BRAF D594G mutation, and BRAF wild-type groups, respectively. CONCLUSION\nColorectal cancers with BRAF D594G mutations exhibit similar clinicopathological features, microsatellite instability status, and prognosis as those with BRAF wild-type.",
          "beginSection": "abstract",
          "offsetInBeginSection": 883,
          "endSection": "abstract",
          "offsetInEndSection": 1387
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27672042",
          "text": "Consistent with other published series, patients with BRAF V600E mutation exhibited a significantly shorter overall survival (hazard ratio = 1.500, P = 0.0432). In particular, the microsatellite stable/BRAF mutation group had inferior prognosis compared with the MSI-H/BRAF wild-type group (hazard ratio = 2.621, P = 0.0004).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1085,
          "endSection": "abstract",
          "offsetInEndSection": 1410
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27672042",
          "text": "PURPOSE\nIn colorectal cancer (CRC), the BRAF V600E mutation is an important biomarker for poor prognosis, while high microsatellite instability (MSI-H) indicates good prognosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 177
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27404270",
          "text": "CONCLUSION\nColorectal cancers with BRAF D594G mutations exhibit similar clinicopathological features, microsatellite instability status, and prognosis as those with BRAF wild-type.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1207,
          "endSection": "abstract",
          "offsetInEndSection": 1387
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25367198",
          "text": "BRAF V600E was associated with advanced TNM (P < 0.001), more distant metastases (P = 0.025), and worse overall survival (OS, P < 0.001; multivariate HR = 4.2, P = 0.004) in colon cancer patients. Compared with KRAS wt/BRAF wt CRC patients (N = 109), those with KRAS codon 13 mutations (N = 25) had significantly worse OS (P = 0.016; multivariate HR = 2.7, P = 0.011), whereas KRAS codon 12-mutated cases were not significantly associated with survival.",
          "beginSection": "abstract",
          "offsetInBeginSection": 963,
          "endSection": "abstract",
          "offsetInEndSection": 1416
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27672042",
          "text": "Consistent with other published series, patients with BRAF V600E mutation exhibited a significantly shorter overall survival (hazard ratio = 1.500, P = 0.0432). In particular, the microsatellite stable/BRAF mutation group had inferior prognosis compared with the MSI-H/BRAF wild-type group (hazard ratio = 2.621, P = 0.0004). CONCLUSIONS\nIHC using a BRAF V600E-specific antibody was useful for diagnosis and concurred with direct sequencing results.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1085,
          "endSection": "abstract",
          "offsetInEndSection": 1536
        }
      ],
      "ideal_answer": "Yes, the BRAF V600E mutation is associated with worse prognosis in colorectal cancer patients, particularly in microsatellite-stable colon cancer stages 2 to 4. The median overall survival for BRAF mutation-positive patients is significantly worse than that for patients with wild-type KRAS and BRAF.",
      "exact_answer": "yes"
    },
    {
      "id": "662cfadc187cba990d000006",
      "type": "summary",
      "body": "Circular RNAs (circRNAs) are a distinct family of RNAs, how are they derived?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32972011",
        "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
        "http://www.ncbi.nlm.nih.gov/pubmed/37762282",
        "http://www.ncbi.nlm.nih.gov/pubmed/33634138",
        "http://www.ncbi.nlm.nih.gov/pubmed/29182528",
        "http://www.ncbi.nlm.nih.gov/pubmed/31001302",
        "http://www.ncbi.nlm.nih.gov/pubmed/29625140",
        "http://www.ncbi.nlm.nih.gov/pubmed/31102674",
        "http://www.ncbi.nlm.nih.gov/pubmed/33537235",
        "http://www.ncbi.nlm.nih.gov/pubmed/30259367"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33537235",
          "text": "Circular RNAs (circRNAs) are a class of endogenous single-stranded covalently closed RNAs, primarily produced from pre-mRNAs via non-canonical back-splicing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 157
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33537235",
          "text": "Circular RNAs (circRNAs) are a class of endogenous single-stranded covalently closed RNAs, primarily produced from pre-mRNAs via non-canonical back-splicing. circRNAs are highly conserved, stable, and expressed in tissue- and development-specific pattern.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 255
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33537235",
          "text": "Circular RNAs (circRNAs) are a class of endogenous single-stranded covalently closed RNAs, primarily produced from pre-mRNAs via non-canonical back-splicing. circRNAs are highly conserved, stable, and expressed in tissue- and development-specific pattern. circRNAs play essential roles in physiological process as well as cancer biology.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 337
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29182528",
          "text": "Circular RNAs (circRNAs) are a class of RNA that are emerging as key new members of the gene regulatory milieu, which are produced by back-splicing events within genes. In circRNA formation, rather than being spliced in a linear fashion, exons can be circularised by use of the 3' acceptor splice site of an upstream exon, leading to the formation of a circular RNA species. circRNAs have been demonstrated across species and have the potential to present genetic information in new orientations distinct from their parent transcript.",
          "beginSection": "abstract",
          "offsetInBeginSection": 59,
          "endSection": "abstract",
          "offsetInEndSection": 593
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29182528",
          "text": "Circular RNAs (circRNAs) are a class of RNA that are emerging as key new members of the gene regulatory milieu, which are produced by back-splicing events within genes. In circRNA formation, rather than being spliced in a linear fashion, exons can be circularised by use of the 3' acceptor splice site of an upstream exon, leading to the formation of a circular RNA species.",
          "beginSection": "abstract",
          "offsetInBeginSection": 59,
          "endSection": "abstract",
          "offsetInEndSection": 433
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31001302",
          "text": "Circular RNAs (circRNAs) are new endogenous non-coding RNA family members that arise during pre-mRNA splicing in a reversed order in which the 3' and 5' ends are covalently closed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 180
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31001302",
          "text": "Circular RNAs (circRNAs) are new endogenous non-coding RNA family members that arise during pre-mRNA splicing in a reversed order in which the 3' and 5' ends are covalently closed. Compared to the comprehensive investigation of circRNAs in animals, circRNA research in plants is still in its infancy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 300
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29182528",
          "text": "Splicing events do not always produce a linear transcript. Circular RNAs (circRNAs) are a class of RNA that are emerging as key new members of the gene regulatory milieu, which are produced by back-splicing events within genes. In circRNA formation, rather than being spliced in a linear fashion, exons can be circularised by use of the 3' acceptor splice site of an upstream exon, leading to the formation of a circular RNA species.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 433
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29182528",
          "text": "Circular RNAs (circRNAs) are a class of RNA that are emerging as key new members of the gene regulatory milieu, which are produced by back-splicing events within genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 59,
          "endSection": "abstract",
          "offsetInEndSection": 227
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31001302",
          "text": "Circular RNAs (circRNAs) are new endogenous non-coding RNA family members that arise during pre-mRNA splicing in a reversed order in which the 3' and 5' ends are covalently closed. Compared to the comprehensive investigation of circRNAs in animals, circRNA research in plants is still in its infancy. Genome-wide identification and characterization of circRNAs have recently been performed in several plant species.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 415
        }
      ],
      "ideal_answer": "Circular RNAs (circRNAs) are derived from back-splicing of pre-mRNA, forming a single-stranded continuous circular structure. They are a distinct family of RNAs and are produced from exonic regions, termed canonical circRNAs.",
      "exact_answer": "n/a"
    },
    {
      "id": "66169f9bfdcbea915f000057",
      "type": "summary",
      "body": "Transgender identity and mortality.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
        "http://www.ncbi.nlm.nih.gov/pubmed/36716027",
        "http://www.ncbi.nlm.nih.gov/pubmed/33544021",
        "http://www.ncbi.nlm.nih.gov/pubmed/32798005",
        "http://www.ncbi.nlm.nih.gov/pubmed/34481559",
        "http://www.ncbi.nlm.nih.gov/pubmed/33438880",
        "http://www.ncbi.nlm.nih.gov/pubmed/29947478",
        "http://www.ncbi.nlm.nih.gov/pubmed/35981277",
        "http://www.ncbi.nlm.nih.gov/pubmed/29062859",
        "http://www.ncbi.nlm.nih.gov/pubmed/35548863"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "transgender individuals had significantly higher rates of suicide attempt, suicide mortality, suicide-unrelated mortality, and all-cause mortality compared with the nontransgender population",
          "beginSection": "abstract",
          "offsetInBeginSection": 2594,
          "endSection": "abstract",
          "offsetInEndSection": 2784
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Conclusions and Relevance\nIn this Danish population-based, retrospective cohort study, results suggest that transgender individuals had significantly higher rates of suicide attempt, suicide mortality, suicide-unrelated mortality, and all-cause mortality compared with the nontransgender population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2497,
          "endSection": "abstract",
          "offsetInEndSection": 2796
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Importance\nPrior studies have suggested that transgender individuals may be a high-risk group with respect to suicide attempt and mortality, but large-scale, population-based investigations are lacking. Objective\nTo examine in a national setting whether transgender individuals have higher rates of suicide attempt and mortality than nontransgender individuals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 363
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Objective\nTo examine in a national setting whether transgender individuals have higher rates of suicide attempt and mortality than nontransgender individuals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 205,
          "endSection": "abstract",
          "offsetInEndSection": 363
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Standardized suicide-unrelated mortality rates per 100 000 person-years were 2380 for transgender vs 1310 for nontransgender individuals (aIRR, 1.9; 95% CI, 1.6-2.2), and standardized all-cause mortality rates per 100 000 person-years were 2559 for transgender vs 1331 for nontransgender individuals (aIRR, 2.0; 95% CI, 1.7-2.4). Despite declining rates of suicide attempts and mortality during the 42 years covered, aIRRs remained significantly elevated in recent calendar periods up to and including 2021 for suicide attempts (aIRR, 6.6; 95% CI, 4.5-9.5), suicide mortality (aIRR, 2.8; 95% CI, 1.3-5.9), suicide-unrelated mortality (aIRR, 1.7; 95% CI, 1.5-2.1), and all-cause mortality (aIRR, 1.7; 95% CI, 1.4-2.1). Conclusions and Relevance\nIn this Danish population-based, retrospective cohort study, results suggest that transgender individuals had significantly higher rates of suicide attempt, suicide mortality, suicide-unrelated mortality, and all-cause mortality compared with the nontransgender population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1777,
          "endSection": "abstract",
          "offsetInEndSection": 2796
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Importance\nPrior studies have suggested that transgender individuals may be a high-risk group with respect to suicide attempt and mortality, but large-scale, population-based investigations are lacking. Objective\nTo examine in a national setting whether transgender individuals have higher rates of suicide attempt and mortality than nontransgender individuals. Design, Setting, and Participants\nNationwide, register-based, retrospective cohort study on all 6 657 456 Danish-born individuals aged 15 years or older who lived in Denmark between January 1, 1980, and December 31, 2021.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 587
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Standardized suicide-unrelated mortality rates per 100 000 person-years were 2380 for transgender vs 1310 for nontransgender individuals (aIRR, 1.9; 95% CI, 1.6-2.2), and standardized all-cause mortality rates per 100 000 person-years were 2559 for transgender vs 1331 for nontransgender individuals (aIRR, 2.0; 95% CI, 1.7-2.4).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1777,
          "endSection": "abstract",
          "offsetInEndSection": 2106
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Standardized suicide-unrelated mortality rates per 100 000 person-years were 2380 for transgender vs 1310 for nontransgender individuals (aIRR, 1.9; 95% CI, 1.6-2.2), and standardized all-cause mortality rates per 100 000 person-years were 2559 for transgender vs 1331 for nontransgender individuals (aIRR, 2.0; 95% CI, 1.7-2.4). Despite declining rates of suicide attempts and mortality during the 42 years covered, aIRRs remained significantly elevated in recent calendar periods up to and including 2021 for suicide attempts (aIRR, 6.6; 95% CI, 4.5-9.5), suicide mortality (aIRR, 2.8; 95% CI, 1.3-5.9), suicide-unrelated mortality (aIRR, 1.7; 95% CI, 1.5-2.1), and all-cause mortality (aIRR, 1.7; 95% CI, 1.4-2.1).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1777,
          "endSection": "abstract",
          "offsetInEndSection": 2494
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Standardized suicide mortality rates per 100 000 person-years were 75 for transgender vs 21 for nontransgender individuals (aIRR, 3.5; 95% CI, 2.0-6.3). Standardized suicide-unrelated mortality rates per 100 000 person-years were 2380 for transgender vs 1310 for nontransgender individuals (aIRR, 1.9; 95% CI, 1.6-2.2), and standardized all-cause mortality rates per 100 000 person-years were 2559 for transgender vs 1331 for nontransgender individuals (aIRR, 2.0; 95% CI, 1.7-2.4). Despite declining rates of suicide attempts and mortality during the 42 years covered, aIRRs remained significantly elevated in recent calendar periods up to and including 2021 for suicide attempts (aIRR, 6.6; 95% CI, 4.5-9.5), suicide mortality (aIRR, 2.8; 95% CI, 1.3-5.9), suicide-unrelated mortality (aIRR, 1.7; 95% CI, 1.5-2.1), and all-cause mortality (aIRR, 1.7; 95% CI, 1.4-2.1).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1624,
          "endSection": "abstract",
          "offsetInEndSection": 2494
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Despite declining rates of suicide attempts and mortality during the 42 years covered, aIRRs remained significantly elevated in recent calendar periods up to and including 2021 for suicide attempts (aIRR, 6.6; 95% CI, 4.5-9.5), suicide mortality (aIRR, 2.8; 95% CI, 1.3-5.9), suicide-unrelated mortality (aIRR, 1.7; 95% CI, 1.5-2.1), and all-cause mortality (aIRR, 1.7; 95% CI, 1.4-2.1). Conclusions and Relevance\nIn this Danish population-based, retrospective cohort study, results suggest that transgender individuals had significantly higher rates of suicide attempt, suicide mortality, suicide-unrelated mortality, and all-cause mortality compared with the nontransgender population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2107,
          "endSection": "abstract",
          "offsetInEndSection": 2796
        }
      ],
      "ideal_answer": "Transgender individuals have been found to have significantly higher rates of suicide attempt, suicide mortality, suicide-unrelated mortality, and all-cause mortality compared with the nontransgender population. Limited research also suggests that transgender and gender diverse people may have higher mortality rates than cisgender people.",
      "exact_answer": "n/a"
    },
    {
      "id": "663016bb187cba990d000023",
      "type": "factoid",
      "body": "Which genetic alteration is most commonly associated with the classical subtype of glioblastoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33435537",
        "http://www.ncbi.nlm.nih.gov/pubmed/37446288",
        "http://www.ncbi.nlm.nih.gov/pubmed/30680510",
        "http://www.ncbi.nlm.nih.gov/pubmed/16033132",
        "http://www.ncbi.nlm.nih.gov/pubmed/24457079",
        "http://www.ncbi.nlm.nih.gov/pubmed/31273577",
        "http://www.ncbi.nlm.nih.gov/pubmed/26136784",
        "http://www.ncbi.nlm.nih.gov/pubmed/30509096",
        "http://www.ncbi.nlm.nih.gov/pubmed/1320666",
        "http://www.ncbi.nlm.nih.gov/pubmed/22323597"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30680510",
          "text": "EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 118
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31273577",
          "text": "Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 129
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16033132",
          "text": "Primary glioblastoma multiforme (GBM) commonly overexpresses the epidermal growth factor receptor (EGFR) gene and its ligand-independent mutant, EGFRvIII. Amplification of the EGFR gene has been implicated in the pathogenesis of primary GBM, in particular the small cell phenotype, and this finding may contribute to its aggressive clinical behavior. Anti-EGFR clinical trials for GBM are being conducted, and it would be useful to identify a rapid technique to determine whether EGFR expression and the small cell phenotype are associated with a response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 567
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16033132",
          "text": "Primary glioblastoma multiforme (GBM) commonly overexpresses the epidermal growth factor receptor (EGFR) gene and its ligand-independent mutant, EGFRvIII. Amplification of the EGFR gene has been implicated in the pathogenesis of primary GBM, in particular the small cell phenotype, and this finding may contribute to its aggressive clinical behavior.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 350
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31273577",
          "text": "PURPOSE\nEpidermal growth factor receptor (EGFR) amplification has been reported to occur in ~ 50% of glioblastomas (GBMs).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 122
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31273577",
          "text": "PURPOSE\nEpidermal growth factor receptor (EGFR) amplification has been reported to occur in ~ 50% of glioblastomas (GBMs). We are conducting several global studies that require central testing for EGFR amplification during screening, representing an opportunity to confirm the frequency of amplification in GBM in a large cohort and to evaluate whether EGFR amplification differs by region of the world.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 403
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16033132",
          "text": "Primary glioblastoma multiforme (GBM) commonly overexpresses the epidermal growth factor receptor (EGFR) gene and its ligand-independent mutant, EGFRvIII.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 154
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26136784",
          "text": "However, this method does not conserve amplification of the Epidermal Growth Factor Receptor (EGFR) gene, which is present in over 50% of all newly diagnosed GBM cases. GS-cells with retained EGFR amplification could overcome the limitations of current in vitro model systems and contribute significantly to preclinical research on EGFR-targeted therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 292,
          "endSection": "abstract",
          "offsetInEndSection": 646
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26136784",
          "text": "However, this method does not conserve amplification of the Epidermal Growth Factor Receptor (EGFR) gene, which is present in over 50% of all newly diagnosed GBM cases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 292,
          "endSection": "abstract",
          "offsetInEndSection": 460
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30680510",
          "text": "Classical subtype and EGFR gene amplification were significantly associated with a shorter time to progression both in univariate (p < 0.001 and p = 0.007, respectively) and multivariate analysis (both p = 0.010). CONCLUSION\nEGFR gene amplification and classical subtype by TCGA analysis are associated with significantly shorter time to progression for patients with recurrent GBM when treated with bevacizumab. These findings can have a significant impact on decision-making and should be further validated prospectively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1179,
          "endSection": "abstract",
          "offsetInEndSection": 1704
        }
      ],
      "ideal_answer": "Epidermal growth factor receptor (EGFR) amplification is most commonly associated with the classical subtype of glioblastoma.",
      "exact_answer": [
        "EGFR amplification"
      ]
    },
    {
      "id": "66302487187cba990d000031",
      "type": "factoid",
      "body": "What is PUL-2 in Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37066919",
        "http://www.ncbi.nlm.nih.gov/pubmed/26342193",
        "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
        "http://www.ncbi.nlm.nih.gov/pubmed/31538331",
        "http://www.ncbi.nlm.nih.gov/pubmed/23902233",
        "http://www.ncbi.nlm.nih.gov/pubmed/37612177",
        "http://www.ncbi.nlm.nih.gov/pubmed/36793650",
        "http://www.ncbi.nlm.nih.gov/pubmed/25642376",
        "http://www.ncbi.nlm.nih.gov/pubmed/32718814",
        "http://www.ncbi.nlm.nih.gov/pubmed/33656143"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "The Performance of the Upper Limb (PUL) module is an externally-assessed clinical scale, initially designed for the Duchenne muscular dystrophy population. It provides an upper extremity functional score suitable for both weaker ambulatory and non-ambulatory phases up to the severely impaired patients. It is capable of characterizing overall progression and severity of disease and of tracking the stereotypical proximal-to-distal progressive loss of upper limb function in muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 495
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "The Performance of the Upper Limb (PUL) module is an externally-assessed clinical scale, initially designed for the Duchenne muscular dystrophy population. It provides an upper extremity functional score suitable for both weaker ambulatory and non-ambulatory phases up to the severely impaired patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 303
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23902233",
          "text": "We report the steps leading to the development of the Performance of the Upper Limb (PUL), a tool specifically designed for assessing upper limb function in ambulant and non-ambulant patients with Duchenne muscular dystrophy (DMD).",
          "beginSection": "abstract",
          "offsetInBeginSection": 201,
          "endSection": "abstract",
          "offsetInEndSection": 432
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23902233",
          "text": "We report the steps leading to the development of the Performance of the Upper Limb (PUL), a tool specifically designed for assessing upper limb function in ambulant and non-ambulant patients with Duchenne muscular dystrophy (DMD). METHOD\nThe development of the PUL followed a number of steps, from the systematic review and a preliminary study exploring the suitability of the existing measures, to the application of a pilot version in a multicentric setting, with Rasch analysis of the preliminary results, leading to a revised pro forma. RESULTS\nThe PUL was specifically designed for DMD, with a conceptual framework reflecting the progression of weakness and natural history of functional decline in DMD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 201,
          "endSection": "abstract",
          "offsetInEndSection": 914
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23902233",
          "text": "We report the steps leading to the development of the Performance of the Upper Limb (PUL), a tool specifically designed for assessing upper limb function in ambulant and non-ambulant patients with Duchenne muscular dystrophy (DMD). METHOD\nThe development of the PUL followed a number of steps, from the systematic review and a preliminary study exploring the suitability of the existing measures, to the application of a pilot version in a multicentric setting, with Rasch analysis of the preliminary results, leading to a revised pro forma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 201,
          "endSection": "abstract",
          "offsetInEndSection": 744
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31538331",
          "text": "AIM\nTo report the differences between Performance of Upper Limb (PUL) versions 1.2 and 2.0, compare the measurement ability of the two versions, and compare their longitudinal performance in Duchenne muscular dystrophy. METHOD\nRasch analysis was performed on the dual data from three centres to confirm whether the two scales measure the same construct.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "It is capable of characterizing overall progression and severity of disease and of tracking the stereotypical proximal-to-distal progressive loss of upper limb function in muscular dystrophy. Since the PUL module has been validated only with Duchenne patients, its use also for Becker and Limb-Girdle muscular dystrophy patients has been here evaluated, to verify its reliability and extend its use. In particular, two different assessors performed this scale on 32 dystrophic subjects in two consecutive days.",
          "beginSection": "abstract",
          "offsetInBeginSection": 304,
          "endSection": "abstract",
          "offsetInEndSection": 814
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "The Performance of the Upper Limb (PUL) module is an externally-assessed clinical scale, initially designed for the Duchenne muscular dystrophy population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 155
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31538331",
          "text": "AIM\nTo report the differences between Performance of Upper Limb (PUL) versions 1.2 and 2.0, compare the measurement ability of the two versions, and compare their longitudinal performance in Duchenne muscular dystrophy. METHOD\nRasch analysis was performed on the dual data from three centres to confirm whether the two scales measure the same construct. Change scores in natural history for the different domains were compared for the two versions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "It is capable of characterizing overall progression and severity of disease and of tracking the stereotypical proximal-to-distal progressive loss of upper limb function in muscular dystrophy. Since the PUL module has been validated only with Duchenne patients, its use also for Becker and Limb-Girdle muscular dystrophy patients has been here evaluated, to verify its reliability and extend its use.",
          "beginSection": "abstract",
          "offsetInBeginSection": 304,
          "endSection": "abstract",
          "offsetInEndSection": 703
        }
      ],
      "ideal_answer": "PUL-2 is a component of the Performance of Upper Limb 2.0 (PUL) assessment tool, which is used to evaluate upper limb function in patients with Duchenne Muscular Dystrophy (DMD).",
      "exact_answer": [
        "PUL-2"
      ]
    },
    {
      "id": "65cfac201930410b13000013",
      "type": "summary",
      "body": "What is the mechanism of action of Mezigdomide?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
        "http://www.ncbi.nlm.nih.gov/pubmed/37705327",
        "http://www.ncbi.nlm.nih.gov/pubmed/36342226",
        "http://www.ncbi.nlm.nih.gov/pubmed/37906232",
        "http://www.ncbi.nlm.nih.gov/pubmed/37694945",
        "http://www.ncbi.nlm.nih.gov/pubmed/33676183",
        "http://www.ncbi.nlm.nih.gov/pubmed/31187860",
        "http://www.ncbi.nlm.nih.gov/pubmed/24987056",
        "http://www.ncbi.nlm.nih.gov/pubmed/25181509",
        "http://www.ncbi.nlm.nih.gov/pubmed/36139651"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37705327",
          "text": "Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced autonomous cell-killing activity in multiple myeloma (MM) cells, and promising immunomodulatory and antitumor activity in patients with MM.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 220
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37705327",
          "text": "Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced autonomous cell-killing activity in multiple myeloma (MM) cells, and promising immunomodulatory and antitumor activity in patients with MM. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 221
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37705327",
          "text": "Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced autonomous cell-killing activity in multiple myeloma (MM) cells, and promising immunomodulatory and antitumor activity in patients with MM. We developed a population pharmacokinetics (PKs) model for mezigdomide in healthy subjects (HSs), and quantified effects of high-fat meal and proton pump inhibitor (PPI) on human disposition parameters.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 423
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
          "text": "Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
          "text": "Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide.",
          "beginSection": "abstract",
          "offsetInBeginSection": 73,
          "endSection": "abstract",
          "offsetInEndSection": 292
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37705327",
          "text": "Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced autonomous cell-killing activity in multiple myeloma (MM) cells, and promising immunomodulatory and antitumor activity in patients with MM. We developed a population pharmacokinetics (PKs) model for mezigdomide in healthy subjects (HSs), and quantified effects of high-fat meal and proton pump inhibitor (PPI) on human disposition parameters. Plasma concentrations from 64 HS in two phase I clinical studies (NCT03803644 and NCT04211545) were used to develop a population PK model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 562
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
          "text": "Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide. METHODS\nIn this phase 1-2 study, we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 443
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
          "text": "BACKGROUND\nDespite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
          "text": "Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide. METHODS\nIn this phase 1-2 study, we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma. The primary objectives of phase 1 (dose-escalation cohort) were to assess safety and pharmacokinetics and to identify the dose and schedule for phase 2.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 596
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
          "text": "BACKGROUND\nDespite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide. METHODS\nIn this phase 1-2 study, we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 443
        }
      ],
      "ideal_answer": "Mezigdomide is a novel cereblon E3 ligase modulator that has potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma. It works by enhancing autonomous cell-killing activity in multiple myeloma cells and has promising immunomodulatory and antitumor activity in patients with multiple myeloma.",
      "exact_answer": "n/a"
    },
    {
      "id": "66099907fdcbea915f000015",
      "type": "factoid",
      "body": "What is the average median survival for advanced colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36781990",
        "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
        "http://www.ncbi.nlm.nih.gov/pubmed/16334762",
        "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
        "http://www.ncbi.nlm.nih.gov/pubmed/12091066",
        "http://www.ncbi.nlm.nih.gov/pubmed/22763194",
        "http://www.ncbi.nlm.nih.gov/pubmed/15865040",
        "http://www.ncbi.nlm.nih.gov/pubmed/15547753",
        "http://www.ncbi.nlm.nih.gov/pubmed/18386570",
        "http://www.ncbi.nlm.nih.gov/pubmed/15214592"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
          "text": "At 5 years after the initial diagnosis, the remaining median survival was longest for patients with colorectal carcinoma, almost 6 years (71.5 months), followed by patients with lung carcinoma (52.5 months), breast carcinoma (42.5 months), and prostate carcinoma (34.5 months).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1278,
          "endSection": "abstract",
          "offsetInEndSection": 1555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
          "text": "Conversely, there was a rapid increase in the conditional median survival according to the amount of time since diagnosis for patients with lung and colorectal carcinoma. The trend was most pronounced for patients with colorectal carcinoma. At 5 years after the initial diagnosis, the remaining median survival was longest for patients with colorectal carcinoma, almost 6 years (71.5 months), followed by patients with lung carcinoma (52.5 months), breast carcinoma (42.5 months), and prostate carcinoma (34.5 months).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1037,
          "endSection": "abstract",
          "offsetInEndSection": 1555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
          "text": "The trend was most pronounced for patients with colorectal carcinoma. At 5 years after the initial diagnosis, the remaining median survival was longest for patients with colorectal carcinoma, almost 6 years (71.5 months), followed by patients with lung carcinoma (52.5 months), breast carcinoma (42.5 months), and prostate carcinoma (34.5 months).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1208,
          "endSection": "abstract",
          "offsetInEndSection": 1555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
          "text": "At 5 years after the initial diagnosis, the remaining median survival was longest for patients with colorectal carcinoma, almost 6 years (71.5 months), followed by patients with lung carcinoma (52.5 months), breast carcinoma (42.5 months), and prostate carcinoma (34.5 months). Although race was a correlate with initial survival, gender and age had more impact on late conditional survival.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1278,
          "endSection": "abstract",
          "offsetInEndSection": 1669
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
          "text": "The trend was most pronounced for patients with colorectal carcinoma. At 5 years after the initial diagnosis, the remaining median survival was longest for patients with colorectal carcinoma, almost 6 years (71.5 months), followed by patients with lung carcinoma (52.5 months), breast carcinoma (42.5 months), and prostate carcinoma (34.5 months). Although race was a correlate with initial survival, gender and age had more impact on late conditional survival.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1208,
          "endSection": "abstract",
          "offsetInEndSection": 1669
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
          "text": "At 5 years after the initial diagnosis, the remaining median survival was longest for patients with colorectal carcinoma, almost 6 years (71.5 months), followed by patients with lung carcinoma (52.5 months), breast carcinoma (42.5 months), and prostate carcinoma (34.5 months). Although race was a correlate with initial survival, gender and age had more impact on late conditional survival. CONCLUSIONS\nThe conditional median survival provides useful and encouraging information for patients who survive with advanced disease and for healthcare professionals who treat these patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1278,
          "endSection": "abstract",
          "offsetInEndSection": 1865
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
          "text": "One-year survival was found to be 65% while the 2-year survival was found to be 25%. A satisfactory quality of life was also observed. In conclusion, colorectal cancer is a slow-going malignancy, as indicated by the long-term survival of patients and the biological characteristics of the tumor.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1100,
          "endSection": "abstract",
          "offsetInEndSection": 1395
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16334762",
          "text": "The median survival from the diagnosis of advanced/metastatic disease was 34.3 months.",
          "beginSection": "abstract",
          "offsetInBeginSection": 748,
          "endSection": "abstract",
          "offsetInEndSection": 834
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
          "text": "The results showed the median survival of patients to be 24 months (range 16-42).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1018,
          "endSection": "abstract",
          "offsetInEndSection": 1099
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16334762",
          "text": "METHODOLOGY\nWe have analyzed retrospectively the survival of 77 consecutive advanced colorectal cancer patients treated with OHP after previous CPT therapy. Multivariate analysis was performed by Cox regression method, with the results expressed as hazard ratio (HR). RESULTS\nThe median survival from the start of OHP therapy was 10.7 months (1-year survival 43%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 270,
          "endSection": "abstract",
          "offsetInEndSection": 636
        }
      ],
      "ideal_answer": "The average median survival for advanced colorectal cancer patients is 32.4 months.",
      "exact_answer": [
        "32.4 months"
      ]
    },
    {
      "id": "662cfa24187cba990d000005",
      "type": "summary",
      "body": "What is the function of the mTORC1 kinase?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37274127",
        "http://www.ncbi.nlm.nih.gov/pubmed/36434160",
        "http://www.ncbi.nlm.nih.gov/pubmed/37057673",
        "http://www.ncbi.nlm.nih.gov/pubmed/35822019",
        "http://www.ncbi.nlm.nih.gov/pubmed/28813526",
        "http://www.ncbi.nlm.nih.gov/pubmed/31451768",
        "http://www.ncbi.nlm.nih.gov/pubmed/21795849",
        "http://www.ncbi.nlm.nih.gov/pubmed/36099296",
        "http://www.ncbi.nlm.nih.gov/pubmed/23863160",
        "http://www.ncbi.nlm.nih.gov/pubmed/28835610"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37274127",
          "text": "The mTOR pathway, particularly mTOR complex 1 (mTORC1), has been shown to control aging, lifespan, and healthspan through the regulation of protein synthesis, autophagy, mitochondrial function, and metabolic health. The mTOR pathway also plays critical roles in the heart, from cardiac development, growth and maturation, and maintenance of cardiac homeostasis. Hyperactivation of mTORC1 signaling is well documented in aging and many age-related pathologies, including age-related cardiac dysfunction and heart failure.",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 677
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37274127",
          "text": "The mTOR pathway, particularly mTOR complex 1 (mTORC1), has been shown to control aging, lifespan, and healthspan through the regulation of protein synthesis, autophagy, mitochondrial function, and metabolic health. The mTOR pathway also plays critical roles in the heart, from cardiac development, growth and maturation, and maintenance of cardiac homeostasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 518
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37274127",
          "text": "The mammalian target of rapamycin (mTOR) is one of the most important signaling pathways that regulate nutrient sensing, cell growth, metabolism, and aging. The mTOR pathway, particularly mTOR complex 1 (mTORC1), has been shown to control aging, lifespan, and healthspan through the regulation of protein synthesis, autophagy, mitochondrial function, and metabolic health.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 372
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37274127",
          "text": "The mammalian target of rapamycin (mTOR) is one of the most important signaling pathways that regulate nutrient sensing, cell growth, metabolism, and aging. The mTOR pathway, particularly mTOR complex 1 (mTORC1), has been shown to control aging, lifespan, and healthspan through the regulation of protein synthesis, autophagy, mitochondrial function, and metabolic health. The mTOR pathway also plays critical roles in the heart, from cardiac development, growth and maturation, and maintenance of cardiac homeostasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 518
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813526",
          "text": "The mammalian target of rapamycin (mTOR), present in mTOR complex 1 (mTORC1) and mTORC2, is a serine/threonine kinase that integrates nutrients, growth factors, and cellular energy status to control protein synthesis, cell growth, survival and metabolism. However, it remains elusive whether mTOR plays a developmental stage-specific role in tissue development and whether mTOR can function independent of its complexes and kinase activity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 440
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35822019",
          "text": "In fact, mTORC1 functions as a molecular sensor for amino acids, linking the cellular demand to the nutritional supply. Notably, dietary restriction (DR), a nutritional regimen that has been shown to extend lifespan and improve healthspan in a broad spectrum of organisms, works via limiting nutrient uptake and changes in mTORC1 activity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 489,
          "endSection": "abstract",
          "offsetInEndSection": 828
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37274127",
          "text": "The mTOR pathway, particularly mTOR complex 1 (mTORC1), has been shown to control aging, lifespan, and healthspan through the regulation of protein synthesis, autophagy, mitochondrial function, and metabolic health.",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 372
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813526",
          "text": "The mammalian target of rapamycin (mTOR), present in mTOR complex 1 (mTORC1) and mTORC2, is a serine/threonine kinase that integrates nutrients, growth factors, and cellular energy status to control protein synthesis, cell growth, survival and metabolism. However, it remains elusive whether mTOR plays a developmental stage-specific role in tissue development and whether mTOR can function independent of its complexes and kinase activity. In this study, by inducible genetic manipulation approach, we investigated the role of mTOR and its dependence on mTOR complexes and kinase activity in mitochondrial fitness of early, progenitor stage (lineage-negative; Lin-) versus later, lineage-committed stage (lineage-positive; Lin+) of hematopoietic cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 753
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813526",
          "text": "The mammalian target of rapamycin (mTOR), present in mTOR complex 1 (mTORC1) and mTORC2, is a serine/threonine kinase that integrates nutrients, growth factors, and cellular energy status to control protein synthesis, cell growth, survival and metabolism.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 255
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35822019",
          "text": "Presumably the most important stimulus that regulates mTORC1 activity is nutrient sufficiency, whereby amino acids play a predominant role. In fact, mTORC1 functions as a molecular sensor for amino acids, linking the cellular demand to the nutritional supply. Notably, dietary restriction (DR), a nutritional regimen that has been shown to extend lifespan and improve healthspan in a broad spectrum of organisms, works via limiting nutrient uptake and changes in mTORC1 activity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 349,
          "endSection": "abstract",
          "offsetInEndSection": 828
        }
      ],
      "ideal_answer": "The mTORC1 kinase is a nutrient-sensing kinase that regulates cell growth in response to nutritional status. It plays a key role in controlling protein synthesis, autophagy, mitochondrial function, and metabolic health, thereby contributing to aging, lifespan, and healthspan.",
      "exact_answer": "n/a"
    },
    {
      "id": "6616a122fdcbea915f000058",
      "type": "yesno",
      "body": "Has statin use been associated with a higher risk of dementia?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34871380",
        "http://www.ncbi.nlm.nih.gov/pubmed/34756134",
        "http://www.ncbi.nlm.nih.gov/pubmed/24578458",
        "http://www.ncbi.nlm.nih.gov/pubmed/16009757",
        "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
        "http://www.ncbi.nlm.nih.gov/pubmed/25203109",
        "http://www.ncbi.nlm.nih.gov/pubmed/24681022",
        "http://www.ncbi.nlm.nih.gov/pubmed/35305172",
        "http://www.ncbi.nlm.nih.gov/pubmed/31107515",
        "http://www.ncbi.nlm.nih.gov/pubmed/30045255"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24578458",
          "text": "CONCLUSION\nOur results suggest that long-term use of statin is associated with a reduced dementia risk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1248,
          "endSection": "abstract",
          "offsetInEndSection": 1351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
          "text": "CONCLUSION\nIn this nationwide cohort study, statin use was associated with decreased risk of dementia among patients with stroke.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1379,
          "endSection": "abstract",
          "offsetInEndSection": 1508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
          "text": "Some studies have found that statin use might lower the risk of incident dementia; however, there is still a lack of data from patients with stroke. Therefore, the aim of our study was to investigate the impact of statin use on the risk of dementia in patients with stroke.",
          "beginSection": "abstract",
          "offsetInBeginSection": 68,
          "endSection": "abstract",
          "offsetInEndSection": 341
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
          "text": "Some studies have found that statin use might lower the risk of incident dementia; however, there is still a lack of data from patients with stroke.",
          "beginSection": "abstract",
          "offsetInBeginSection": 68,
          "endSection": "abstract",
          "offsetInEndSection": 216
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24578458",
          "text": "Fibrates or other lipid-lowering agents had no significant association with dementia risk. CONCLUSION\nOur results suggest that long-term use of statin is associated with a reduced dementia risk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1155,
          "endSection": "abstract",
          "offsetInEndSection": 1351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24578458",
          "text": "BACKGROUND\nThe effect of statin use on dementia risk remains unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 69
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
          "text": "BACKGROUND\nPatients with stroke have an increased risk of dementia. Some studies have found that statin use might lower the risk of incident dementia; however, there is still a lack of data from patients with stroke. Therefore, the aim of our study was to investigate the impact of statin use on the risk of dementia in patients with stroke.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 341
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
          "text": "No significant effect modification for the relationship between statin use and the risk of dementia was found for either age or sex. CONCLUSION\nIn this nationwide cohort study, statin use was associated with decreased risk of dementia among patients with stroke. The use of high-potency statins, lipophilic statins, and prolonged exposure to statins may be associated with greater benefits.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1244,
          "endSection": "abstract",
          "offsetInEndSection": 1636
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24578458",
          "text": "BACKGROUND\nThe effect of statin use on dementia risk remains unclear. This study aims to examine the association between long-term statin use and dementia risk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 160
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24578458",
          "text": "However, there was no significant difference in dementia risks between lipophilic and hydrophilic statins. Fibrates or other lipid-lowering agents had no significant association with dementia risk. CONCLUSION\nOur results suggest that long-term use of statin is associated with a reduced dementia risk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1048,
          "endSection": "abstract",
          "offsetInEndSection": 1351
        }
      ],
      "ideal_answer": "No, statin use has not been associated with a higher risk of dementia. In fact, there is some evidence to suggest a potential favorable role of statins in preventing or delaying the progression of dementia.",
      "exact_answer": "no"
    },
    {
      "id": "6630254b187cba990d000032",
      "type": "yesno",
      "body": "Is DNA methylation always associated with gene silencing?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31914996",
        "http://www.ncbi.nlm.nih.gov/pubmed/29958539",
        "http://www.ncbi.nlm.nih.gov/pubmed/22641018",
        "http://www.ncbi.nlm.nih.gov/pubmed/10754536",
        "http://www.ncbi.nlm.nih.gov/pubmed/15756280",
        "http://www.ncbi.nlm.nih.gov/pubmed/18407786",
        "http://www.ncbi.nlm.nih.gov/pubmed/11228434",
        "http://www.ncbi.nlm.nih.gov/pubmed/17058541",
        "http://www.ncbi.nlm.nih.gov/pubmed/16341240",
        "http://www.ncbi.nlm.nih.gov/pubmed/12087472"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31914996",
          "text": "Especially datasets on DNA methylation, the most commonly studied epigenetic marker, have recently been measured and analysed in several PCa patient cohorts. DNA methylation is most commonly associated with downregulation of gene expression. However, positive associations of DNA methylation to gene expression have also been reported, suggesting a more diverse mechanism of epigenetic regulation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 300,
          "endSection": "abstract",
          "offsetInEndSection": 697
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10754536",
          "text": "DNA methylation is associated with the silencing of gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 68
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10754536",
          "text": "DNA methylation is associated with the silencing of gene expression. The predominant mechanism involves the methylation of DNA and the subsequent recruitment of binding proteins that preferentially recognize methylated DNA. In turn, these proteins associate with histone deacetylase and chromatin remodelling complexes to cause the stabilization of condensed chromatin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 369
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11228434",
          "text": "Epigenetic gene silencing results from the inhibition of transcription or from posttranscriptional RNA degradation. DNA methylation is one of the most central and frequently discussed elements of gene silencing in both plants and mammals. Because DNA methylation has not been detected in yeast, Drosophila or Caenorhabditis elegans, the standard genetic workhorses, plants are important models for revealing the role of DNA methylation in the epigenetic regulation of genes in vivo.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 482
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11228434",
          "text": "Epigenetic gene silencing results from the inhibition of transcription or from posttranscriptional RNA degradation. DNA methylation is one of the most central and frequently discussed elements of gene silencing in both plants and mammals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 238
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10754536",
          "text": "DNA methylation is associated with the silencing of gene expression. The predominant mechanism involves the methylation of DNA and the subsequent recruitment of binding proteins that preferentially recognize methylated DNA.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 223
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10754536",
          "text": "DNA methylation and silencing of gene expression.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 49
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11228434",
          "text": "DNA methylation is one of the most central and frequently discussed elements of gene silencing in both plants and mammals. Because DNA methylation has not been detected in yeast, Drosophila or Caenorhabditis elegans, the standard genetic workhorses, plants are important models for revealing the role of DNA methylation in the epigenetic regulation of genes in vivo.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 482
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18407786",
          "text": "While some studies suggest that DNA methylation patterns guide histone modifications (including histone acetylation and methylation) during gene silencing, other studies argue that DNA methylation takes its cues primarily from histone modification states. In this review, we summarize current knowledge on the interplay between DNA methylation and histone modifications during gene silencing and its importance in the integration of environmental and intrinsic stimuli in the control of gene expression. We also discuss the importance of an epigenetic cross-talk in the protection against genetic changes in response to environmental genotoxins as well as the implication for cancer therapy and prevention.",
          "beginSection": "abstract",
          "offsetInBeginSection": 991,
          "endSection": "abstract",
          "offsetInEndSection": 1697
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18407786",
          "text": "Accumulating evidence suggests that an epigenetic cross-talk, i.e. interplay between DNA methylation and histone acetylation, may be involved in the process of gene transcription and aberrant gene silencing in tumours. Although the molecular mechanism of gene activation is relatively well understood, the hierarchical order of events and dependencies leading to gene silencing in the course of cancer development remain largely unknown.",
          "beginSection": "abstract",
          "offsetInBeginSection": 553,
          "endSection": "abstract",
          "offsetInEndSection": 990
        }
      ],
      "ideal_answer": "No, DNA methylation is not always associated with gene silencing. It is most commonly associated with downregulation of gene expression, but positive associations of DNA methylation to gene expression have also been reported, suggesting a more diverse mechanism of epigenetic regulation.",
      "exact_answer": "no"
    },
    {
      "id": "66302174187cba990d00002e",
      "type": "yesno",
      "body": "Are there any digital biomarkers for Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
        "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
        "http://www.ncbi.nlm.nih.gov/pubmed/32024675",
        "http://www.ncbi.nlm.nih.gov/pubmed/34533053",
        "http://www.ncbi.nlm.nih.gov/pubmed/26039989",
        "http://www.ncbi.nlm.nih.gov/pubmed/30050384",
        "http://www.ncbi.nlm.nih.gov/pubmed/37545256",
        "http://www.ncbi.nlm.nih.gov/pubmed/35386072",
        "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
        "http://www.ncbi.nlm.nih.gov/pubmed/21724396"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1147,
          "endSection": "abstract",
          "offsetInEndSection": 1367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 124
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Then, we used machine learning algorithms that combined the behavioral fingerprints to make cross-sectional and longitudinal disease course predictions, which outperformed predictions derived from currently used clinical assessments. Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 678,
          "endSection": "abstract",
          "offsetInEndSection": 1367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
          "text": "This review will illustrate known circulating biomarkers that could track disease progression and response to therapy in patients affected by Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 561,
          "endSection": "abstract",
          "offsetInEndSection": 731
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
          "text": "This review will illustrate known circulating biomarkers that could track disease progression and response to therapy in patients affected by Duchenne muscular dystrophy. We present an overview of the transcriptomic, proteomic, metabolomics and lipidomic biomarkers described in literature.",
          "beginSection": "abstract",
          "offsetInBeginSection": 561,
          "endSection": "abstract",
          "offsetInEndSection": 851
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
          "text": "This review will illustrate known circulating biomarkers that could track disease progression and response to therapy in patients affected by Duchenne muscular dystrophy. We present an overview of the transcriptomic, proteomic, metabolomics and lipidomic biomarkers described in literature. We show how studies in muscle tissue have led to the identification of serum and urine biomarkers and we highlight the importance of evaluating biomarkers as possible surrogate endpoints to facilitate regulatory processes for new medicinal products.",
          "beginSection": "abstract",
          "offsetInBeginSection": 561,
          "endSection": "abstract",
          "offsetInEndSection": 1101
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
          "text": "Murine and canine animal models have been a valuable source to profile muscles and body fluids, thus providing candidate biomarkers that can be evaluated in patients. This review will illustrate known circulating biomarkers that could track disease progression and response to therapy in patients affected by Duchenne muscular dystrophy. We present an overview of the transcriptomic, proteomic, metabolomics and lipidomic biomarkers described in literature.",
          "beginSection": "abstract",
          "offsetInBeginSection": 394,
          "endSection": "abstract",
          "offsetInEndSection": 851
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 912,
          "endSection": "abstract",
          "offsetInEndSection": 1367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
          "text": "Murine and canine animal models have been a valuable source to profile muscles and body fluids, thus providing candidate biomarkers that can be evaluated in patients. This review will illustrate known circulating biomarkers that could track disease progression and response to therapy in patients affected by Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 394,
          "endSection": "abstract",
          "offsetInEndSection": 731
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26039989",
          "text": "Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs of drug effects, and be useful as surrogate outcome measures to predict later clinical benefit. In this study a large-scale biomarker discovery was performed on serum samples from patients with DMD and age-matched healthy volunteers using a modified aptamer-based proteomics technology.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 456
        }
      ],
      "ideal_answer": "Yes, there are digital biomarkers for Duchenne Muscular Dystrophy. Wearable full-body motion tracking of activities of daily living can predict disease trajectory and a behavioral biomarker, termed the KineDMD ethomic biomarker, can predict disease progression and potentially track the response to therapy.",
      "exact_answer": "yes"
    },
    {
      "id": "65cfd2681930410b1300001e",
      "type": "summary",
      "body": "How should Insulin icodec be administered?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37313230",
        "http://www.ncbi.nlm.nih.gov/pubmed/37354562",
        "http://www.ncbi.nlm.nih.gov/pubmed/37249450",
        "http://www.ncbi.nlm.nih.gov/pubmed/36631720",
        "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
        "http://www.ncbi.nlm.nih.gov/pubmed/34413118",
        "http://www.ncbi.nlm.nih.gov/pubmed/37748181",
        "http://www.ncbi.nlm.nih.gov/pubmed/37356066",
        "http://www.ncbi.nlm.nih.gov/pubmed/33944562",
        "http://www.ncbi.nlm.nih.gov/pubmed/37694740"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
          "text": "BACKGROUND AND AIMS\nInsulin icodec is currently the most advanced candidate insulin suitable for once-weekly administration. We aim to conduct a systematic review of the literature to find out the efficacy and safety of insulin icodec in patients with diabetes mellitus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 270
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
          "text": "BACKGROUND AND AIMS\nInsulin icodec is currently the most advanced candidate insulin suitable for once-weekly administration.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 124
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413118",
          "text": "The clinical pharmacology trial in people with type 2 diabetes showed that insulin icodec was well tolerated and has pharmacokinetic/pharmacodynamic properties that are suited for once-weekly dosing, with a mean half-life of 196 hours and close to even distribution of glucose-lowering effect over the entire dosing interval of 1 week.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1644,
          "endSection": "abstract",
          "offsetInEndSection": 1979
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37748181",
          "text": "Once-weekly insulin icodec (icodec) is a basal insulin analogue that is in development and is aimed at reducing treatment burden. OBJECTIVE\nTo compare the effectiveness and safety of icodec titrated with a dosing guide app (icodec with app) versus once-daily basal insulin analogues (OD analogues) dosed per standard practice. DESIGN\n52-week, randomized, open-label, parallel-group, phase 3a trial with real-world elements.",
          "beginSection": "abstract",
          "offsetInBeginSection": 152,
          "endSection": "abstract",
          "offsetInEndSection": 579
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
          "text": "RESULTS\nPhase 1 study showed insulin icodec having a half-life of 196 h (>1 week) while a steady state is achieved after 3 to 4 weekly injections. Phase 2 studies compared once-weekly icodec to insulin glargine (U-100) and found a similar glucose control with no significantly greater hypoglycemia risks.",
          "beginSection": "abstract",
          "offsetInBeginSection": 644,
          "endSection": "abstract",
          "offsetInEndSection": 948
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37748181",
          "text": "Once-weekly insulin icodec (icodec) is a basal insulin analogue that is in development and is aimed at reducing treatment burden.",
          "beginSection": "abstract",
          "offsetInBeginSection": 152,
          "endSection": "abstract",
          "offsetInEndSection": 281
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
          "text": "RESULTS\nPhase 1 study showed insulin icodec having a half-life of 196 h (>1 week) while a steady state is achieved after 3 to 4 weekly injections. Phase 2 studies compared once-weekly icodec to insulin glargine (U-100) and found a similar glucose control with no significantly greater hypoglycemia risks. Top-line results from the five phase 3 studies reported better glucose control with once-weekly icodec compared to both once-daily insulin glargine (ONWARDS 1) and once-daily degludec (in both ONWARDS 2 and 4) with similar rates of hypoglycemia in type 2 diabetes, although there was a higher hypoglycemic event with insulin icodec in type 1 diabetes (ONWARDS 6) compared to once-daily degludec despite a similar glycemic control.",
          "beginSection": "abstract",
          "offsetInBeginSection": 644,
          "endSection": "abstract",
          "offsetInEndSection": 1379
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
          "text": "RESULTS\nPhase 1 study showed insulin icodec having a half-life of 196 h (>1 week) while a steady state is achieved after 3 to 4 weekly injections.",
          "beginSection": "abstract",
          "offsetInBeginSection": 644,
          "endSection": "abstract",
          "offsetInEndSection": 790
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413118",
          "text": "The clinical pharmacology trial in people with type 2 diabetes showed that insulin icodec was well tolerated and has pharmacokinetic/pharmacodynamic properties that are suited for once-weekly dosing, with a mean half-life of 196 hours and close to even distribution of glucose-lowering effect over the entire dosing interval of 1 week. CONCLUSIONS\nThe molecular modifications introduced into insulin icodec provide a novel basal insulin with biological and pharmacokinetic/pharmacodynamic properties suitable for once-weekly dosing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1644,
          "endSection": "abstract",
          "offsetInEndSection": 2178
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37748181",
          "text": "Once-weekly insulin icodec (icodec) is a basal insulin analogue that is in development and is aimed at reducing treatment burden. OBJECTIVE\nTo compare the effectiveness and safety of icodec titrated with a dosing guide app (icodec with app) versus once-daily basal insulin analogues (OD analogues) dosed per standard practice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 152,
          "endSection": "abstract",
          "offsetInEndSection": 480
        }
      ],
      "ideal_answer": "Insulin icodec should be administered once a week.",
      "exact_answer": "n/a"
    },
    {
      "id": "66099ba9fdcbea915f000022",
      "type": "yesno",
      "body": "Is FOLFIRI plus Aflibercept a cost-effective treatment in patients with advanced colorectal caner?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36110513",
        "http://www.ncbi.nlm.nih.gov/pubmed/25616671",
        "http://www.ncbi.nlm.nih.gov/pubmed/32616433",
        "http://www.ncbi.nlm.nih.gov/pubmed/35248464",
        "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
        "http://www.ncbi.nlm.nih.gov/pubmed/38050741",
        "http://www.ncbi.nlm.nih.gov/pubmed/31520559",
        "http://www.ncbi.nlm.nih.gov/pubmed/36706629",
        "http://www.ncbi.nlm.nih.gov/pubmed/24045663",
        "http://www.ncbi.nlm.nih.gov/pubmed/30117334"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
          "text": "[Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31520559",
          "text": "Aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) is a second-line treatment for metastatic colorectal cancer. This ancillary exploratory analysis of data in Japanese people was aimed at exploring the relationship between a set of potential prognostic biomarkers and efficacy endpoints following aflibercept plus FOLFIRI therapy. Sixty-two patients with metastatic colorectal cancer received aflibercept (4 mg/kg) plus FOLFIRI every 2 weeks.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 457
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35248464",
          "text": "AIM\nTo compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy. MATERIALS AND METHODS\nWe analysed the treatment outcomes of patients receiving FOLFIRI in combination with bevacizumab or aflibercept as second-line treatment for mCRC between October 2017 and March 2020. This analysis included 67 patients receiving FOLFIRI plus aflibercept and 83 receiving FOLFIRI plus bevacizumab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 541
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31520559",
          "text": "Aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) is a second-line treatment for metastatic colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 126
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31520559",
          "text": "Aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) is a second-line treatment for metastatic colorectal cancer. This ancillary exploratory analysis of data in Japanese people was aimed at exploring the relationship between a set of potential prognostic biomarkers and efficacy endpoints following aflibercept plus FOLFIRI therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 345
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35248464",
          "text": "AIM\nTo compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy. MATERIALS AND METHODS\nWe analysed the treatment outcomes of patients receiving FOLFIRI in combination with bevacizumab or aflibercept as second-line treatment for mCRC between October 2017 and March 2020.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 428
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35248464",
          "text": "A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 172
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38050741",
          "text": "Aim: To investigate the impact of natremia in metastatic colorectal cancer (mCRC) patients treated with aflibercept plus folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRI). Patients & methods: A total of 84 mCRC patients receiving aflibercept plus FOLFIRI as second-line treatment were enrolled and divided into two groups based on their median sodium value. Progression-free survival and overall survival were analyzed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 436
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
          "text": "In the cost-effectiveness analysis Euros 38,931/LYG was obtained with aflibercept in combination with FOLFIRI versus FOLFIRI. CONCLUSION\nAflibercept in combination with FOLFIRI increased overall survival versus FOLFIRI, so it is an effective strategy in the treatment of patients with mCRC. Aflibercept in combination with FOLFIRI is an efficient strategy for second-line mCRC treatment from the National Health System perspective.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1216,
          "endSection": "abstract",
          "offsetInEndSection": 1649
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38050741",
          "text": "Aim: To investigate the impact of natremia in metastatic colorectal cancer (mCRC) patients treated with aflibercept plus folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRI). Patients & methods: A total of 84 mCRC patients receiving aflibercept plus FOLFIRI as second-line treatment were enrolled and divided into two groups based on their median sodium value.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 374
        }
      ],
      "ideal_answer": "No, FOLFIRI plus Aflibercept is not a cost-effective treatment in patients with advanced colorectal cancer.",
      "exact_answer": "no"
    },
    {
      "id": "662cf96f187cba990d000004",
      "type": "list",
      "body": "Please list some treatment options for bone marrow edema syndrome,",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37047734",
        "http://www.ncbi.nlm.nih.gov/pubmed/36573724",
        "http://www.ncbi.nlm.nih.gov/pubmed/33413520",
        "http://www.ncbi.nlm.nih.gov/pubmed/33880304",
        "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
        "http://www.ncbi.nlm.nih.gov/pubmed/36370218",
        "http://www.ncbi.nlm.nih.gov/pubmed/19358909",
        "http://www.ncbi.nlm.nih.gov/pubmed/35987803",
        "http://www.ncbi.nlm.nih.gov/pubmed/15847192",
        "http://www.ncbi.nlm.nih.gov/pubmed/12043991"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
          "text": "This paper reviews the literature and summarizes the treatment options for bone marrow edema syndrome, such as symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed electromagnetic fields (PEFs), hyperbaric oxygen (HBO), vitamin D, iloprost, bisphosphonates, denosumab, and surgery, etc. This informs clinicians in treating bone marrow edema syndrome, hopefully improving patients' quality of life and shortening the duration of their disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 359,
          "endSection": "abstract",
          "offsetInEndSection": 821
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
          "text": "This paper reviews the literature and summarizes the treatment options for bone marrow edema syndrome, such as symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed electromagnetic fields (PEFs), hyperbaric oxygen (HBO), vitamin D, iloprost, bisphosphonates, denosumab, and surgery, etc.",
          "beginSection": "abstract",
          "offsetInBeginSection": 359,
          "endSection": "abstract",
          "offsetInEndSection": 665
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37047734",
          "text": "BME can be related to trauma or a variety of non-traumatic diseases, and current treatment modalities include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 219,
          "endSection": "abstract",
          "offsetInEndSection": 520
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37047734",
          "text": "BME can be related to trauma or a variety of non-traumatic diseases, and current treatment modalities include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 219,
          "endSection": "abstract",
          "offsetInEndSection": 521
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37047734",
          "text": "Bone marrow edema (BME), also termed bone marrow lesions, is a syndrome characterized by bone pain and the appearance of high signal intensity on T2 fat-suppressed and short tau inversion recovery (STIR) MRI sequences. BME can be related to trauma or a variety of non-traumatic diseases, and current treatment modalities include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 520
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37047734",
          "text": "Bone marrow edema (BME), also termed bone marrow lesions, is a syndrome characterized by bone pain and the appearance of high signal intensity on T2 fat-suppressed and short tau inversion recovery (STIR) MRI sequences. BME can be related to trauma or a variety of non-traumatic diseases, and current treatment modalities include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression. Spontaneous BME is a subset that has been observed with no apparent causative conditions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 610
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
          "text": "Hence, doctors are not sufficiently aware of the disease and are prone to misdiagnosis and mistreatment, which can undoubtedly prolong the course of the disease, reduce the quality of life of patients and even affect their function. This paper reviews the literature and summarizes the treatment options for bone marrow edema syndrome, such as symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed electromagnetic fields (PEFs), hyperbaric oxygen (HBO), vitamin D, iloprost, bisphosphonates, denosumab, and surgery, etc.",
          "beginSection": "abstract",
          "offsetInBeginSection": 126,
          "endSection": "abstract",
          "offsetInEndSection": 665
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
          "text": "Hence, doctors are not sufficiently aware of the disease and are prone to misdiagnosis and mistreatment, which can undoubtedly prolong the course of the disease, reduce the quality of life of patients and even affect their function. This paper reviews the literature and summarizes the treatment options for bone marrow edema syndrome, such as symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed electromagnetic fields (PEFs), hyperbaric oxygen (HBO), vitamin D, iloprost, bisphosphonates, denosumab, and surgery, etc. This informs clinicians in treating bone marrow edema syndrome, hopefully improving patients' quality of life and shortening the duration of their disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 126,
          "endSection": "abstract",
          "offsetInEndSection": 821
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37047734",
          "text": "BME can be related to trauma or a variety of non-traumatic diseases, and current treatment modalities include non-steroidal anti-inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression. Spontaneous BME is a subset that has been observed with no apparent causative conditions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 219,
          "endSection": "abstract",
          "offsetInEndSection": 610
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
          "text": "It has been poorly reported in the literature. Hence, doctors are not sufficiently aware of the disease and are prone to misdiagnosis and mistreatment, which can undoubtedly prolong the course of the disease, reduce the quality of life of patients and even affect their function. This paper reviews the literature and summarizes the treatment options for bone marrow edema syndrome, such as symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed electromagnetic fields (PEFs), hyperbaric oxygen (HBO), vitamin D, iloprost, bisphosphonates, denosumab, and surgery, etc.",
          "beginSection": "abstract",
          "offsetInBeginSection": 79,
          "endSection": "abstract",
          "offsetInEndSection": 665
        }
      ],
      "ideal_answer": "Treatment options for bone marrow edema syndrome include NSAIDS, bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression.",
      "exact_answer": [
        [
          "NSAIDS"
        ],
        [
          "bisphosphonates"
        ],
        [
          "denosumab"
        ],
        [
          "ESWT"
        ],
        [
          "iloprost"
        ]
      ]
    },
    {
      "id": "66150639fdcbea915f000047",
      "type": "list",
      "body": "What is the immediate treatment after a sexual assault?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37977653",
        "http://www.ncbi.nlm.nih.gov/pubmed/36940194",
        "http://www.ncbi.nlm.nih.gov/pubmed/24981399",
        "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
        "http://www.ncbi.nlm.nih.gov/pubmed/34533583",
        "http://www.ncbi.nlm.nih.gov/pubmed/26527554",
        "http://www.ncbi.nlm.nih.gov/pubmed/34725910",
        "http://www.ncbi.nlm.nih.gov/pubmed/12603187",
        "http://www.ncbi.nlm.nih.gov/pubmed/28605228",
        "http://www.ncbi.nlm.nih.gov/pubmed/14631520"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
          "text": "Availability of emergency contraception may vary between districts and countries, depending on local laws and cultural or religious beliefs. Sexually transmitted infections, including gonorrhoea, chlamydia, hepatitis B and human immunodeficiency virus, represent an important part of management of victims of sexual assault. They can be prevented immediately by offering bacterial and viral prophylaxis followed by sexual health screening 2 weeks later unless symptomatic.",
          "beginSection": "abstract",
          "offsetInBeginSection": 463,
          "endSection": "abstract",
          "offsetInEndSection": 935
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
          "text": "Sexually transmitted infections, including gonorrhoea, chlamydia, hepatitis B and human immunodeficiency virus, represent an important part of management of victims of sexual assault. They can be prevented immediately by offering bacterial and viral prophylaxis followed by sexual health screening 2 weeks later unless symptomatic.",
          "beginSection": "abstract",
          "offsetInBeginSection": 604,
          "endSection": "abstract",
          "offsetInEndSection": 935
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
          "text": "Sexually transmitted infections, including gonorrhoea, chlamydia, hepatitis B and human immunodeficiency virus, represent an important part of management of victims of sexual assault. They can be prevented immediately by offering bacterial and viral prophylaxis followed by sexual health screening 2 weeks later unless symptomatic. In deciding what antibiotics to use as prophylaxis, local prevalence of infections and resistance to antibiotics should be considered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 604,
          "endSection": "abstract",
          "offsetInEndSection": 1070
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34533583",
          "text": "Relevant exposure to important infectious pathogens can occur during sexual assault. If there is a latent period between exposure and illness due to an infection with pathogens, a postexposure prophylaxis can effectively inhibit the infection. In the present review article possible postexposure prophylaxis treatment for tetanus, hepatitis B, HIV and hepatitis A are discussed with a focus on the time window within which a specific regimen should be started and in which temporal order.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 488
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34533583",
          "text": "In the present review article possible postexposure prophylaxis treatment for tetanus, hepatitis B, HIV and hepatitis A are discussed with a focus on the time window within which a specific regimen should be started and in which temporal order. These recommendations are based on the epidemiologic conditions in Germany. Moreover, the two most frequent sexually transmitted bacterial infections, namely Neisseria gonorrhoea and Chlamydia trachomatis are presented, as victims of sexual assault in particular often do not return for control investigations in an outpatient setting.",
          "beginSection": "abstract",
          "offsetInBeginSection": 244,
          "endSection": "abstract",
          "offsetInEndSection": 824
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981399",
          "text": "Current practice of HIV postexposure prophylaxis treatment for sexual assault patients in an emergency department.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 114
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981399",
          "text": "BACKGROUND\nComprehensive data that address current HIV nonoccupational postexposure prophylaxis (nPEP) practices in the emergency care of sexual assault patients are limited. The U.S. Centers for Disease Control and Prevention released HIV nPEP guidelines in 2005 and updated guidelines for Sexually Transmitted Disease Treatment in 2006 and 2010, each of which support providing nPEP to sexual assault patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 412
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981399",
          "text": "BACKGROUND\nComprehensive data that address current HIV nonoccupational postexposure prophylaxis (nPEP) practices in the emergency care of sexual assault patients are limited. The U.S. Centers for Disease Control and Prevention released HIV nPEP guidelines in 2005 and updated guidelines for Sexually Transmitted Disease Treatment in 2006 and 2010, each of which support providing nPEP to sexual assault patients. This study examined the offer, acceptance, and adherence rates of nPEP among sexual assault patients treated at an emergency department (ED).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 554
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
          "text": "Pregnancy prevention can be achieved through oral or mechanical methods of emergency contraception. Availability of emergency contraception may vary between districts and countries, depending on local laws and cultural or religious beliefs. Sexually transmitted infections, including gonorrhoea, chlamydia, hepatitis B and human immunodeficiency virus, represent an important part of management of victims of sexual assault.",
          "beginSection": "abstract",
          "offsetInBeginSection": 363,
          "endSection": "abstract",
          "offsetInEndSection": 787
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
          "text": "Availability of emergency contraception may vary between districts and countries, depending on local laws and cultural or religious beliefs. Sexually transmitted infections, including gonorrhoea, chlamydia, hepatitis B and human immunodeficiency virus, represent an important part of management of victims of sexual assault.",
          "beginSection": "abstract",
          "offsetInBeginSection": 463,
          "endSection": "abstract",
          "offsetInEndSection": 787
        }
      ],
      "ideal_answer": "The immediate treatment after a sexual assault includes emergency contraception to prevent pregnancy, postexposure prophylaxis (PEP) for HIV, Hepatitis B vaccination, and presumptive treatment for gonorrhea and chlamydia.",
      "exact_answer": [
        [
          "emergency contraception"
        ],
        [
          "HIV PEP"
        ],
        [
          "Hepatitis B vaccination"
        ]
      ]
    },
    {
      "id": "6630562c187cba990d000036",
      "type": "summary",
      "body": "What is the potential role of the tumor microenvironment and factors like stem cells in contributing to the recurrence of glioblastoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36968288",
        "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
        "http://www.ncbi.nlm.nih.gov/pubmed/33544755",
        "http://www.ncbi.nlm.nih.gov/pubmed/33177991",
        "http://www.ncbi.nlm.nih.gov/pubmed/32038644",
        "http://www.ncbi.nlm.nih.gov/pubmed/29566069",
        "http://www.ncbi.nlm.nih.gov/pubmed/29204831",
        "http://www.ncbi.nlm.nih.gov/pubmed/34185283",
        "http://www.ncbi.nlm.nih.gov/pubmed/22996727",
        "http://www.ncbi.nlm.nih.gov/pubmed/33668200"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
          "text": "The continuous cross-talk between glioma stem cells (GSCs) and the tumor microenvironment (TME) contributes to disease progression, which renders research in this field difficult and challenging. The main aim of the review was to assess the different possible mechanisms that could explain resistance to treatment promoted by TME and GSCs in glioblastoma, including the role of M2 macrophages, micro RNAs (miRNAs), and long non-coding RNAs (lncRNAs) from exosomes from the TME. A systematic review of the literature on the role of the TME in developing and promoting radioresistance and chemoresistance of GBM was performed according to PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) guidelines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 273,
          "endSection": "abstract",
          "offsetInEndSection": 1008
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
          "text": "The continuous cross-talk between glioma stem cells (GSCs) and the tumor microenvironment (TME) contributes to disease progression, which renders research in this field difficult and challenging. The main aim of the review was to assess the different possible mechanisms that could explain resistance to treatment promoted by TME and GSCs in glioblastoma, including the role of M2 macrophages, micro RNAs (miRNAs), and long non-coding RNAs (lncRNAs) from exosomes from the TME.",
          "beginSection": "abstract",
          "offsetInBeginSection": 273,
          "endSection": "abstract",
          "offsetInEndSection": 750
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
          "text": "In order to create new therapeutic strategies, it is imperative to have a better understanding of the mechanisms behind tumor growth and invasion. The continuous cross-talk between glioma stem cells (GSCs) and the tumor microenvironment (TME) contributes to disease progression, which renders research in this field difficult and challenging. The main aim of the review was to assess the different possible mechanisms that could explain resistance to treatment promoted by TME and GSCs in glioblastoma, including the role of M2 macrophages, micro RNAs (miRNAs), and long non-coding RNAs (lncRNAs) from exosomes from the TME.",
          "beginSection": "abstract",
          "offsetInBeginSection": 126,
          "endSection": "abstract",
          "offsetInEndSection": 750
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968288",
          "text": "Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex system, which in addition to cancer cells, consists of various resident brain and immune cells as well as cells in transit through the tumor such as marrow-derived immune cells. The TME is a dynamic environment which is heavily influenced by alterations in cellular composition, cell-to-cell contact and cellular metabolic products as well as other chemical factors, such as pH and oxygen levels. Emerging evidence suggests that GBM cells appear to reprogram their the TME, and hijack microenvironmental elements to facilitate rapid proliferation, invasion, migration, and survival thus generating treatment resistance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 705
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968288",
          "text": "Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex system, which in addition to cancer cells, consists of various resident brain and immune cells as well as cells in transit through the tumor such as marrow-derived immune cells. The TME is a dynamic environment which is heavily influenced by alterations in cellular composition, cell-to-cell contact and cellular metabolic products as well as other chemical factors, such as pH and oxygen levels.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 482
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33177991",
          "text": "A major difficulty in eradicating GBM is the presence of microscopic residual infiltrating disease remaining after multimodality treatment. Glioma cancer stem cells (CSCs) have been pinpointed as the treatment-resistant tumor component that seeds ultimate tumor progression. Despite the key role of CSCs, the ideal preclinical model to study the genetic and epigenetic landmarks driving their malignant behavior while simulating an accurate interaction with the tumor microenvironment (TME) is still missing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 122,
          "endSection": "abstract",
          "offsetInEndSection": 630
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32038644",
          "text": "Glioblastomas (GBM) are highly aggressive primary brain tumors. Complex and dynamic tumor microenvironment (TME) plays a crucial role in the sustained growth, proliferation, and invasion of GBM. Several means of intercellular communication have been documented between glioma cells and the TME, including growth factors, cytokines, chemokines as well as extracellular vesicles (EVs).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 383
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968288",
          "text": "Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex system, which in addition to cancer cells, consists of various resident brain and immune cells as well as cells in transit through the tumor such as marrow-derived immune cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 263
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
          "text": "In order to create new therapeutic strategies, it is imperative to have a better understanding of the mechanisms behind tumor growth and invasion. The continuous cross-talk between glioma stem cells (GSCs) and the tumor microenvironment (TME) contributes to disease progression, which renders research in this field difficult and challenging.",
          "beginSection": "abstract",
          "offsetInBeginSection": 126,
          "endSection": "abstract",
          "offsetInEndSection": 468
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
          "text": "The invasive nature of glioblastoma is problematic in a radical surgery approach and can be responsible for tumor recurrence. In order to create new therapeutic strategies, it is imperative to have a better understanding of the mechanisms behind tumor growth and invasion. The continuous cross-talk between glioma stem cells (GSCs) and the tumor microenvironment (TME) contributes to disease progression, which renders research in this field difficult and challenging.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 468
        }
      ],
      "ideal_answer": "The tumor microenvironment (TME) of glioblastoma (GBM) is a complex system that includes various cells and chemical factors. GBM cells can reprogram the TME to facilitate rapid proliferation, invasion, migration, and survival, leading to treatment resistance. Glioma stem cells (GSCs) and their continuous cross-talk with the TME contribute to disease progression, making research in this field challenging and potentially impacting tumor recurrence.",
      "exact_answer": "n/a"
    },
    {
      "id": "663020d7187cba990d00002b",
      "type": "yesno",
      "body": "Is there an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36565132",
        "http://www.ncbi.nlm.nih.gov/pubmed/36315559",
        "http://www.ncbi.nlm.nih.gov/pubmed/22560791",
        "http://www.ncbi.nlm.nih.gov/pubmed/31836945",
        "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
        "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
        "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
        "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
        "http://www.ncbi.nlm.nih.gov/pubmed/28954035",
        "http://www.ncbi.nlm.nih.gov/pubmed/8344426"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31836945",
          "text": "We review genotype-phenotype correlations and discuss emerging cellular/tissue evidence for the involvement of Dp71 in the neuropathophysiology of DMD. The literature suggests changes observed in the DMD brain are neurodevelopmental in origin and that their risk and severity is associated with a cumulative loss of distal DMD gene products such as Dp71. The high risk of neuropsychiatric syndromes in Duchenne patients warrants early intervention to achieve the best possible quality of life.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1074,
          "endSection": "abstract",
          "offsetInEndSection": 1567
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31836945",
          "text": "Duchenne muscular dystrophy (DMD) is caused by frameshift mutations in the DMD gene that prevent the body-wide translation of its protein product, dystrophin. Besides a severe muscle phenotype, cognitive impairment and neuropsychiatric symptoms are prevalent. Dystrophin protein 71 (Dp71) is the major DMD gene product expressed in the brain and mutations affecting its expression are associated with the DMD neuropsychiatric syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 435
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31836945",
          "text": "Duchenne muscular dystrophy (DMD) is caused by frameshift mutations in the DMD gene that prevent the body-wide translation of its protein product, dystrophin. Besides a severe muscle phenotype, cognitive impairment and neuropsychiatric symptoms are prevalent.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 259
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315559",
          "text": "INTRODUCTIONS\nDuchenne muscular dystrophy (DMD) is an X-linked recessive progressive muscular disease marked by developmental delays due to mutations in the DMD gene, which encodes dystrophin. Brain comorbidity adds to the burden of limited mobility and significantly impacts patients' quality of life and their family. The changes of expression of dystrophin isoforms in the brain due to DMD gene mutations are thought to be related to the cognitive and neurobehavior profiles of DMD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 485
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560791",
          "text": "OBJECTIVES\nTo assess attention deficit hyperactivity disorder (ADHD) in boys affected by Duchenne muscular dystrophy (DMD) and to explore the relationship with cognitive abilities and genetic findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 201
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315559",
          "text": "INTRODUCTIONS\nDuchenne muscular dystrophy (DMD) is an X-linked recessive progressive muscular disease marked by developmental delays due to mutations in the DMD gene, which encodes dystrophin. Brain comorbidity adds to the burden of limited mobility and significantly impacts patients' quality of life and their family.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 319
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560791",
          "text": "OBJECTIVES\nTo assess attention deficit hyperactivity disorder (ADHD) in boys affected by Duchenne muscular dystrophy (DMD) and to explore the relationship with cognitive abilities and genetic findings. STUDY DESIGN\nBoys with DMD (n = 103; 4-17 years of age, mean: 12.6) were assessed using a cognitive test (Wechsler scales).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 327
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560791",
          "text": "OBJECTIVES\nTo assess attention deficit hyperactivity disorder (ADHD) in boys affected by Duchenne muscular dystrophy (DMD) and to explore the relationship with cognitive abilities and genetic findings. STUDY DESIGN\nBoys with DMD (n = 103; 4-17 years of age, mean: 12.6) were assessed using a cognitive test (Wechsler scales). Assessment of ADHD was based on the Diagnostic Statistical Manual, Fourth Edition, Text Revision criteria and on the long version of the Conners Parents and Teachers Rating Scales.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315559",
          "text": "INTRODUCTIONS\nDuchenne muscular dystrophy (DMD) is an X-linked recessive progressive muscular disease marked by developmental delays due to mutations in the DMD gene, which encodes dystrophin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 192
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31836945",
          "text": "Duchenne muscular dystrophy (DMD) is caused by frameshift mutations in the DMD gene that prevent the body-wide translation of its protein product, dystrophin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 158
        }
      ],
      "ideal_answer": "Yes, there is an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy. ADHD might be associated with the Dp71 genotype in DMD.",
      "exact_answer": "yes"
    },
    {
      "id": "65cfd8551930410b13000023",
      "type": "yesno",
      "body": "Is vemurafenib–cobimetinib promising for craniopharyngioma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37477404",
        "http://www.ncbi.nlm.nih.gov/pubmed/37437144",
        "http://www.ncbi.nlm.nih.gov/pubmed/35169097",
        "http://www.ncbi.nlm.nih.gov/pubmed/31171876",
        "http://www.ncbi.nlm.nih.gov/pubmed/26984388",
        "http://www.ncbi.nlm.nih.gov/pubmed/25265494",
        "http://www.ncbi.nlm.nih.gov/pubmed/34904502",
        "http://www.ncbi.nlm.nih.gov/pubmed/25037139",
        "http://www.ncbi.nlm.nih.gov/pubmed/30018526",
        "http://www.ncbi.nlm.nih.gov/pubmed/26999478"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37477404",
          "text": "Vemurafenib plus cobimetinib is effective in patients with BRAF-mutant papillary craniopharyngioma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34904502",
          "text": "AREAS COVERED\nThis review covers the efficacy and safety of atezolizumab, cobimetinib and vemurafenib for patients with advanced or metastatic BRAF mutant melanoma. The combination is compared with the current standard of care including BRAF/MEK inhibition and treatment with immune checkpoint inhibitors. EXPERT OPINION\nAtezolizumab plus cobimetinib and vemurafenib showed superior progression-free survival in metastatic melanoma compared to cobimetinib and vemurafenib alone.",
          "beginSection": "abstract",
          "offsetInBeginSection": 519,
          "endSection": "abstract",
          "offsetInEndSection": 999
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34904502",
          "text": "AREAS COVERED\nThis review covers the efficacy and safety of atezolizumab, cobimetinib and vemurafenib for patients with advanced or metastatic BRAF mutant melanoma. The combination is compared with the current standard of care including BRAF/MEK inhibition and treatment with immune checkpoint inhibitors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 519,
          "endSection": "abstract",
          "offsetInEndSection": 824
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265494",
          "text": "This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. METHODS\nWe randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group).",
          "beginSection": "abstract",
          "offsetInBeginSection": 209,
          "endSection": "abstract",
          "offsetInEndSection": 587
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265494",
          "text": "This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. METHODS\nWe randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group). The primary end point was investigator-assessed progression-free survival.",
          "beginSection": "abstract",
          "offsetInBeginSection": 209,
          "endSection": "abstract",
          "offsetInEndSection": 662
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34904502",
          "text": "The IMspire150 trial investigated the combination of atezolizumab, cobimetinib and vemurafenib versus cobimetinib and vemurafenib alone. AREAS COVERED\nThis review covers the efficacy and safety of atezolizumab, cobimetinib and vemurafenib for patients with advanced or metastatic BRAF mutant melanoma. The combination is compared with the current standard of care including BRAF/MEK inhibition and treatment with immune checkpoint inhibitors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 380,
          "endSection": "abstract",
          "offsetInEndSection": 824
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26984388",
          "text": "The MEK inhibitor cobimetinib (Cotellic(®)) is indicated for the treatment of patients with BRAF (V600) mutation-positive unresectable or metastatic melanoma, in combination with the BRAF inhibitor vemurafenib (Zelboraf(®)). In the pivotal coBRIM trial, previously untreated patients with BRAF (V600) mutation-positive unresectable, stage IIIC or stage IV melanoma received cobimetinib 60 mg once daily for the first 21 days of each 28-day cycle plus vemurafenib 960 mg twice daily or vemurafenib alone. Compared with vemurafenib alone, cobimetinib plus vemurafenib significantly prolonged progression-free survival (primary endpoint) and was associated with a significantly higher overall response rate and significantly prolonged overall survival.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 749
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34904502",
          "text": "The combination of BRAF/MEK and immune checkpoint inhibition might achieve higher response rates and improve long-term disease control. The IMspire150 trial investigated the combination of atezolizumab, cobimetinib and vemurafenib versus cobimetinib and vemurafenib alone. AREAS COVERED\nThis review covers the efficacy and safety of atezolizumab, cobimetinib and vemurafenib for patients with advanced or metastatic BRAF mutant melanoma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 244,
          "endSection": "abstract",
          "offsetInEndSection": 683
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26984388",
          "text": "The MEK inhibitor cobimetinib (Cotellic(®)) is indicated for the treatment of patients with BRAF (V600) mutation-positive unresectable or metastatic melanoma, in combination with the BRAF inhibitor vemurafenib (Zelboraf(®)). In the pivotal coBRIM trial, previously untreated patients with BRAF (V600) mutation-positive unresectable, stage IIIC or stage IV melanoma received cobimetinib 60 mg once daily for the first 21 days of each 28-day cycle plus vemurafenib 960 mg twice daily or vemurafenib alone.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 503
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265494",
          "text": "BACKGROUND\nThe combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone. This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. METHODS\nWe randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 587
        }
      ],
      "ideal_answer": "Yes, vemurafenib–cobimetinib is promising for craniopharyngioma. In a study of 16 patients with papillary craniopharyngiomas, 15 of them had a partial response or better to the BRAF-MEK inhibitor combination vemurafenib-cobimetinib. This suggests that vemurafenib plus cobimetinib is effective in patients with BRAF-mutant papillary craniopharyngioma.",
      "exact_answer": "yes"
    },
    {
      "id": "66214db9b9f8b89d7e000004",
      "type": "summary",
      "body": "What is the molecular mechanism by which Bacteroides Fragilis is associated to colorectal cancer development?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25105360",
        "http://www.ncbi.nlm.nih.gov/pubmed/37644520",
        "http://www.ncbi.nlm.nih.gov/pubmed/32038097",
        "http://www.ncbi.nlm.nih.gov/pubmed/33126615",
        "http://www.ncbi.nlm.nih.gov/pubmed/19366918",
        "http://www.ncbi.nlm.nih.gov/pubmed/21876161",
        "http://www.ncbi.nlm.nih.gov/pubmed/32863742",
        "http://www.ncbi.nlm.nih.gov/pubmed/26173688",
        "http://www.ncbi.nlm.nih.gov/pubmed/35453577",
        "http://www.ncbi.nlm.nih.gov/pubmed/12476774"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876161",
          "text": "In the context of gastrointestinal disease, the bacterium enterotoxigenic Bacteroides fragilis (ETBF) is a significant source of chronic inflammation and has been implicated as a risk factor for colorectal cancer. Spermine oxidase (SMO) is a polyamine catabolic enzyme that is highly inducible by inflammatory stimuli resulting in increased reactive oxygen species (ROS) and DNA damage. We now demonstrate that purified B. fragilis toxin (BFT) up-regulates SMO in HT29/c1 and T84 colonic epithelial cells, resulting in SMO-dependent generation of ROS and induction of γ-H2A.x, a marker of DNA damage.",
          "beginSection": "abstract",
          "offsetInBeginSection": 205,
          "endSection": "abstract",
          "offsetInEndSection": 805
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33126615",
          "text": "Enterotoxigenic Bacteroides fragilis (ETBF) is a gut commensal bacterium and reported to be a potent initiator of colitis via secretion of the Bacteroides fragilis toxin (BFT). BFT induces ectodomain cleavage of E-cadherin in colonic epithelial cells, consequently leading to cell rounding, epithelial barrier disruption, and the secretion of IL-8, which promotes tumorigenesis in mice via IL-17A-mediated inflammation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 275,
          "endSection": "abstract",
          "offsetInEndSection": 694
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366918",
          "text": "Enterotoxigenic Bacteroides fragilis (ETBF) strains are strains of B. fragilis that secrete a 20-kDa heat-labile zinc-dependent metalloprotease toxin termed the B. fragilis toxin (BFT). BFT is the only recognized virulence factor specific for ETBF. ETBF strains are associated with inflammatory diarrheal disease in children older than 1 year of age and in adults; limited data suggest an association of ETBF colonization with inflammatory bowel disease flare-ups and colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 486
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33126615",
          "text": "Enterotoxigenic Bacteroides fragilis (ETBF) is a gut commensal bacterium and reported to be a potent initiator of colitis via secretion of the Bacteroides fragilis toxin (BFT). BFT induces ectodomain cleavage of E-cadherin in colonic epithelial cells, consequently leading to cell rounding, epithelial barrier disruption, and the secretion of IL-8, which promotes tumorigenesis in mice via IL-17A-mediated inflammation. A HSD is characteristic of the Western-type diet and can exhibit inflammatory effects.",
          "beginSection": "abstract",
          "offsetInBeginSection": 275,
          "endSection": "abstract",
          "offsetInEndSection": 781
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32038097",
          "text": "The human commensal bacterium, enterotoxigenic Bacteroides fragilis (ETBF) secretes the Bacteroides fragilis toxin (BFT) which is necessary and sufficient to cause colitis. We report that BALB/c mice infected with WT-ETBF and administered three cycles of AOM/DSS developed numerous, large-sized polyps predominantly in the colorectal region.",
          "beginSection": "abstract",
          "offsetInBeginSection": 118,
          "endSection": "abstract",
          "offsetInEndSection": 459
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32038097",
          "text": "The human commensal bacterium, enterotoxigenic Bacteroides fragilis (ETBF) secretes the Bacteroides fragilis toxin (BFT) which is necessary and sufficient to cause colitis. We report that BALB/c mice infected with WT-ETBF and administered three cycles of AOM/DSS developed numerous, large-sized polyps predominantly in the colorectal region. In addition, AOM/DSS-treated BALB/c mice orally inoculated with wild-type nontoxigenic Bacteroides fragilis (WT-NTBF) overexpressing bft (rETBF) developed numerous polyps whereas mice infected with WT-NTBF overexpressing a biologically inactive bft (rNTBF) did not promote polyp formation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 118,
          "endSection": "abstract",
          "offsetInEndSection": 749
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33126615",
          "text": "A high salt diet (HSD) exacerbates IL-17A-induced inflammation in inflammatory bowel disease and other autoimmune diseases. Enterotoxigenic Bacteroides fragilis (ETBF) is a gut commensal bacterium and reported to be a potent initiator of colitis via secretion of the Bacteroides fragilis toxin (BFT). BFT induces ectodomain cleavage of E-cadherin in colonic epithelial cells, consequently leading to cell rounding, epithelial barrier disruption, and the secretion of IL-8, which promotes tumorigenesis in mice via IL-17A-mediated inflammation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 151,
          "endSection": "abstract",
          "offsetInEndSection": 694
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876161",
          "text": "In the context of gastrointestinal disease, the bacterium enterotoxigenic Bacteroides fragilis (ETBF) is a significant source of chronic inflammation and has been implicated as a risk factor for colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 205,
          "endSection": "abstract",
          "offsetInEndSection": 418
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366918",
          "text": "Enterotoxigenic Bacteroides fragilis (ETBF) strains are strains of B. fragilis that secrete a 20-kDa heat-labile zinc-dependent metalloprotease toxin termed the B. fragilis toxin (BFT). BFT is the only recognized virulence factor specific for ETBF.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 248
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876161",
          "text": "It is estimated that the etiology of 20-30% of epithelial cancers is directly associated with inflammation, although the direct molecular events linking inflammation and carcinogenesis are poorly defined. In the context of gastrointestinal disease, the bacterium enterotoxigenic Bacteroides fragilis (ETBF) is a significant source of chronic inflammation and has been implicated as a risk factor for colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 418
        }
      ],
      "ideal_answer": "Bacteroides Fragilis is associated with colorectal cancer development by changing signaling pathways, specifically the WNT/β-catenin pathway. This is mediated by BFT, the only known virulence factor of Enterotoxigenic Bacteroides Fragilis (ETBF), which leads to intestinal inflammation and promotes colon tumorigenesis.",
      "exact_answer": "n/a"
    },
    {
      "id": "662cfbf5187cba990d000007",
      "type": "factoid",
      "body": "Where in the body would the globus pallidus be found?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36719479",
        "http://www.ncbi.nlm.nih.gov/pubmed/36378365",
        "http://www.ncbi.nlm.nih.gov/pubmed/36309960",
        "http://www.ncbi.nlm.nih.gov/pubmed/36724759",
        "http://www.ncbi.nlm.nih.gov/pubmed/36418626",
        "http://www.ncbi.nlm.nih.gov/pubmed/22866355",
        "http://www.ncbi.nlm.nih.gov/pubmed/803514",
        "http://www.ncbi.nlm.nih.gov/pubmed/25190203",
        "http://www.ncbi.nlm.nih.gov/pubmed/7279302",
        "http://www.ncbi.nlm.nih.gov/pubmed/17349144"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/803514",
          "text": "The radial fibers in the globus pallidus.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 41
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22866355",
          "text": "Bilateral globus pallidus lesions.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 34
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/803514",
          "text": "The radial fibers converging in the globus pallidus pursue many radii and there is little coincidence between the plane of section and the planes in which they travel. At most only severed radial fiber segments 100-150 microns in length can be found in the horizontal sections needed to observe the collaterals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 880,
          "endSection": "abstract",
          "offsetInEndSection": 1191
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25190203",
          "text": "RESULTS\nGlobus pallidus infarcts were present in 19 patients; all were bilateral, and most were left-dominant.",
          "beginSection": "abstract",
          "offsetInBeginSection": 718,
          "endSection": "abstract",
          "offsetInEndSection": 828
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25190203",
          "text": "RESULTS\nGlobus pallidus infarcts were present in 19 patients; all were bilateral, and most were left-dominant. A neuroanatomic scoring system based on the infarct patterns was devised; this revealed a 5-stage hierarchical susceptibility to metabolic infarct, with the posterior portion of the globus pallidus externa being the most vulnerable.",
          "beginSection": "abstract",
          "offsetInBeginSection": 718,
          "endSection": "abstract",
          "offsetInEndSection": 1061
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7279302",
          "text": "These results suggest that the caudate is the sole source of pallidal enkephalin and that the innervation diffusely converges on the smaller globus pallidus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 850,
          "endSection": "abstract",
          "offsetInEndSection": 1007
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25190203",
          "text": "CONCLUSIONS\nThe staged pattern of globus pallidus infarcts in isolated methylmalonic acidemia suggests a nonuniform, regionally specific cellular susceptibility to metabolic injury, even for patients having milder biochemical phenotypes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1421,
          "endSection": "abstract",
          "offsetInEndSection": 1658
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/803514",
          "text": "The radial fibers converging in the globus pallidus pursue many radii and there is little coincidence between the plane of section and the planes in which they travel.",
          "beginSection": "abstract",
          "offsetInBeginSection": 880,
          "endSection": "abstract",
          "offsetInEndSection": 1047
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25190203",
          "text": "Infarcted globus pallidus segments were neuroanatomically characterized, and infarct volumes were measured. RESULTS\nGlobus pallidus infarcts were present in 19 patients; all were bilateral, and most were left-dominant.",
          "beginSection": "abstract",
          "offsetInBeginSection": 608,
          "endSection": "abstract",
          "offsetInEndSection": 828
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7279302",
          "text": "The source of enkephalin in neuronal terminals of the rat globus pallidus was evaluated with electrolytic and knife cut lesions. Straight knife cuts medial to the globus pallidus or a curved knife cut just below the corpus callosum do not reduce immunofluorescence staining in the globus pallidus, indicating that cerebral cortex is not a major source of pallidal enkephalin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 375
        }
      ],
      "ideal_answer": "The globus pallidus is a structure found in the brain.",
      "exact_answer": [
        "globus pallidus"
      ]
    },
    {
      "id": "66151045fdcbea915f000048",
      "type": "factoid",
      "body": "What is the approximate prevalence of autoimmune diseases?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37156255",
        "http://www.ncbi.nlm.nih.gov/pubmed/16477262",
        "http://www.ncbi.nlm.nih.gov/pubmed/20521924",
        "http://www.ncbi.nlm.nih.gov/pubmed/36041475",
        "http://www.ncbi.nlm.nih.gov/pubmed/15550215",
        "http://www.ncbi.nlm.nih.gov/pubmed/22396771",
        "http://www.ncbi.nlm.nih.gov/pubmed/17582741",
        "http://www.ncbi.nlm.nih.gov/pubmed/33151588",
        "http://www.ncbi.nlm.nih.gov/pubmed/37582563",
        "http://www.ncbi.nlm.nih.gov/pubmed/24129899"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15550215",
          "text": "Autoimmune diseases affect approximately 8% of the population, 78% of whom are women. The reasons for the high prevalence in women are unknown, but circumstantial evidence links autoimmune diseases with preceding infections. Animal models of autoimmune diseases have shown that infections can induce autoimmune disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 319
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15550215",
          "text": "Autoimmune diseases affect approximately 8% of the population, 78% of whom are women. The reasons for the high prevalence in women are unknown, but circumstantial evidence links autoimmune diseases with preceding infections.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 224
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15550215",
          "text": "Autoimmune diseases affect approximately 8% of the population, 78% of whom are women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 85
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16477262",
          "text": "We determined the prevalence of comorbid autoimmune disease according to index disease and then compiled summary statistics.",
          "beginSection": "abstract",
          "offsetInBeginSection": 859,
          "endSection": "abstract",
          "offsetInEndSection": 983
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36041475",
          "text": "Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 163
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16477262",
          "text": "We determined the prevalence of comorbid autoimmune disease according to index disease and then compiled summary statistics. Heterogeneity among studies was assessed by exact likelihood ratio tests and Monte Carlo inference. RESULTS\nWe found 54 studies that met the eligibility criteria.",
          "beginSection": "abstract",
          "offsetInBeginSection": 859,
          "endSection": "abstract",
          "offsetInEndSection": 1148
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36041475",
          "text": "In the autoimmune cohort, mean age at diagnosis was 46·2 years (SD 19·8), and 271 410 (60·8%) were women and 175 039 (39·2%) were men. 68 413 (15·3%) people with and 231 410 (11·0%) without autoimmune diseases developed incident cardiovascular disease during a median of 6·2 years (IQR 2·7-10·8) of follow-up. The incidence rate of cardiovascular disease was 23·3 events per 1000 patient-years among patients with autoimmune disease and 15·0 events per 1000 patient-years among those without an autoimmune disease (hazard ratio [HR] 1·56 [95% CI 1·52-1·59]).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1278,
          "endSection": "abstract",
          "offsetInEndSection": 1836
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36041475",
          "text": "In the autoimmune cohort, mean age at diagnosis was 46·2 years (SD 19·8), and 271 410 (60·8%) were women and 175 039 (39·2%) were men. 68 413 (15·3%) people with and 231 410 (11·0%) without autoimmune diseases developed incident cardiovascular disease during a median of 6·2 years (IQR 2·7-10·8) of follow-up.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1278,
          "endSection": "abstract",
          "offsetInEndSection": 1587
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36041475",
          "text": "FINDINGS\nOf 22 009 375 individuals identified from the CPRD databases, we identified 446 449 eligible individuals with autoimmune diseases and 2 102 830 matched controls. In the autoimmune cohort, mean age at diagnosis was 46·2 years (SD 19·8), and 271 410 (60·8%) were women and 175 039 (39·2%) were men.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1107,
          "endSection": "abstract",
          "offsetInEndSection": 1412
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20521924",
          "text": "However, patients with autoimmune diseases have an approximately double risk than the general population of developing infections.",
          "beginSection": "abstract",
          "offsetInBeginSection": 369,
          "endSection": "abstract",
          "offsetInEndSection": 499
        }
      ],
      "ideal_answer": "Approximately one in ten individuals is affected by autoimmune diseases.",
      "exact_answer": [
        "approximately one in ten individuals"
      ]
    },
    {
      "id": "662ee24a187cba990d00000d",
      "type": "summary",
      "body": "What is the role of Isocitrate dehydrogenase (IDH) mutations in glioma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31263678",
        "http://www.ncbi.nlm.nih.gov/pubmed/35670952",
        "http://www.ncbi.nlm.nih.gov/pubmed/32825279",
        "http://www.ncbi.nlm.nih.gov/pubmed/21955197",
        "http://www.ncbi.nlm.nih.gov/pubmed/35769466",
        "http://www.ncbi.nlm.nih.gov/pubmed/27355333",
        "http://www.ncbi.nlm.nih.gov/pubmed/28980701",
        "http://www.ncbi.nlm.nih.gov/pubmed/35854925",
        "http://www.ncbi.nlm.nih.gov/pubmed/25078896",
        "http://www.ncbi.nlm.nih.gov/pubmed/20692206"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32825279",
          "text": "Mutations in isocitrate dehydrogenase (IDH) are commonly observed in lower-grade glioma and secondary glioblastomas. IDH mutants confer a neomorphic enzyme activity that converts α-ketoglutarate to an oncometabolite D-2-hydroxyglutarate, which impacts cellular epigenetics and metabolism. IDH mutation establishes distinctive patterns in metabolism, cancer biology, and the therapeutic sensitivity of glioma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 408
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32825279",
          "text": "Mutations in isocitrate dehydrogenase (IDH) are commonly observed in lower-grade glioma and secondary glioblastomas. IDH mutants confer a neomorphic enzyme activity that converts α-ketoglutarate to an oncometabolite D-2-hydroxyglutarate, which impacts cellular epigenetics and metabolism.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 288
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21955197",
          "text": "Recently, the isocitrate dehydrogenase (IDH) enzymes have become a focal point for research aimed at understanding the biology of glioma and identifying novel targets for therapy. Following the publication of a landmark genetic sequencing study in 2008, which identified IDH1 as a frequently mutated gene in glioblastoma, much work has been carried out to further characterize the frequency, associations and clinical implications of IDH1/2 mutations. Mutations in IDH genes are thought to occur early in tumorigenesis and define a subgroup of glioma that are characterized by specific metabolic changes and improved prognosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 627
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21955197",
          "text": "Recently, the isocitrate dehydrogenase (IDH) enzymes have become a focal point for research aimed at understanding the biology of glioma and identifying novel targets for therapy. Following the publication of a landmark genetic sequencing study in 2008, which identified IDH1 as a frequently mutated gene in glioblastoma, much work has been carried out to further characterize the frequency, associations and clinical implications of IDH1/2 mutations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 451
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32825279",
          "text": "Mutations in isocitrate dehydrogenase (IDH) are commonly observed in lower-grade glioma and secondary glioblastomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 116
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31263678",
          "text": "Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the Krebs cycle that plays an important role in energy metabolism. In recent years, it has been found that IDH mutations are closely related to the occurrence and development of glioma, and it is a notable potential therapeutic target. First, IDH mutations can produce high levels of 2-hydroxyglutaric acid (2-HG), thereby inhibiting glioma stem cell differentiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 431
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31263678",
          "text": "Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the Krebs cycle that plays an important role in energy metabolism. In recent years, it has been found that IDH mutations are closely related to the occurrence and development of glioma, and it is a notable potential therapeutic target.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 299
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21955197",
          "text": "Recently, the isocitrate dehydrogenase (IDH) enzymes have become a focal point for research aimed at understanding the biology of glioma and identifying novel targets for therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 179
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35769466",
          "text": "The unique immune microenvironment plays a crucial role in the malignant progression of isocitrate dehydrogenase (IDH) mutant gliomas. IDH mutations in glioma can inhibit tumor-associated immune system evasion of NK cell immune surveillance. Meanwhile, mutant IDH can inhibit classical and alternative complement pathways and directly inhibit T-cell responses by metabolizing isocitrate to D-2-Hydroxyglutaric acid (2-HG).",
          "beginSection": "abstract",
          "offsetInBeginSection": 107,
          "endSection": "abstract",
          "offsetInEndSection": 529
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35769466",
          "text": "The unique immune microenvironment plays a crucial role in the malignant progression of isocitrate dehydrogenase (IDH) mutant gliomas. IDH mutations in glioma can inhibit tumor-associated immune system evasion of NK cell immune surveillance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 107,
          "endSection": "abstract",
          "offsetInEndSection": 348
        }
      ],
      "ideal_answer": "",
      "exact_answer": "n/a"
    },
    {
      "id": "66301fcb187cba990d000029",
      "type": "yesno",
      "body": "Is there an association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36565132",
        "http://www.ncbi.nlm.nih.gov/pubmed/3993293",
        "http://www.ncbi.nlm.nih.gov/pubmed/31708335",
        "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
        "http://www.ncbi.nlm.nih.gov/pubmed/31650559",
        "http://www.ncbi.nlm.nih.gov/pubmed/2590130",
        "http://www.ncbi.nlm.nih.gov/pubmed/23225043",
        "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
        "http://www.ncbi.nlm.nih.gov/pubmed/37945525",
        "http://www.ncbi.nlm.nih.gov/pubmed/8024305"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
          "text": "OBJECTIVE\nTo study the association between clinical phenotypes and genotypes in children with Becker muscular dystrophy (BMD)/Duchenne muscular dystrophy (DMD) so as to provide a theoretical basis for disease management, gene therapy, and prenatal diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 258
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
          "text": "OBJECTIVE\nTo study the association between clinical phenotypes and genotypes in children with Becker muscular dystrophy (BMD)/Duchenne muscular dystrophy (DMD) so as to provide a theoretical basis for disease management, gene therapy, and prenatal diagnosis. METHODS\nA retrospective analysis was performed for the clinical data and gene detection results of 52 children with BMD/DMD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 385
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31708335",
          "text": "Psychiatric and neurodevelopmental aspects of Becker muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 72
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31708335",
          "text": "Little is known about the relationship between Becker Muscular Dystrophy (BMD) and mental disorders. This study aimed to clarify whether BMD is a risk factor for psychiatric diseases. We asked genetically or immunohistochemically confirmed BMD patients to participate in the study interview.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31708335",
          "text": "Little is known about the relationship between Becker Muscular Dystrophy (BMD) and mental disorders. This study aimed to clarify whether BMD is a risk factor for psychiatric diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 183
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
          "text": "OBJECTIVE\nTo study the association between clinical phenotypes and genotypes in children with Becker muscular dystrophy (BMD)/Duchenne muscular dystrophy (DMD) so as to provide a theoretical basis for disease management, gene therapy, and prenatal diagnosis. METHODS\nA retrospective analysis was performed for the clinical data and gene detection results of 52 children with BMD/DMD. Multiplex ligation-dependent probe amplification (MLPA) was used to detect the DMD gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 474
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2590130",
          "text": "Forty-three unrelated South Australian boys diagnosed as having either Duchenne or Becker muscular dystrophy were screened for deletions using DNA probes to the dystrophin gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 177
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
          "text": "[A predictive analysis of the association between clinical phenotypes and genotypes in children with Becker muscular dystrophy/Duchenne muscular dystrophy].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 156
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2590130",
          "text": "Forty-three unrelated South Australian boys diagnosed as having either Duchenne or Becker muscular dystrophy were screened for deletions using DNA probes to the dystrophin gene. For the 35 boys with Duchenne muscular dystrophy, the deletion frequency was 43% using a simplified probing strategy based on the probes Cf56a, Cf56b, pERT87-15 and XJ (XJ1.1 or XJ2.3).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 363
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2590130",
          "text": "Forty-three unrelated South Australian boys diagnosed as having either Duchenne or Becker muscular dystrophy were screened for deletions using DNA probes to the dystrophin gene. For the 35 boys with Duchenne muscular dystrophy, the deletion frequency was 43% using a simplified probing strategy based on the probes Cf56a, Cf56b, pERT87-15 and XJ (XJ1.1 or XJ2.3). The corresponding deletion frequency for the eight boys with Becker muscular dystrophy was 38%.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 459
        }
      ],
      "ideal_answer": "Yes, there is an association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy. Particularly, Dp140 and Dp71 genotypes could be linked to these disorders.",
      "exact_answer": "yes"
    },
    {
      "id": "65d375b31930410b1300004b",
      "type": "list",
      "body": "What medication are included in the Juvisync pill?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
        "http://www.ncbi.nlm.nih.gov/pubmed/19046202",
        "http://www.ncbi.nlm.nih.gov/pubmed/23077137",
        "http://www.ncbi.nlm.nih.gov/pubmed/34836863",
        "http://www.ncbi.nlm.nih.gov/pubmed/30936920",
        "http://www.ncbi.nlm.nih.gov/pubmed/29786959",
        "http://www.ncbi.nlm.nih.gov/pubmed/25425754",
        "http://www.ncbi.nlm.nih.gov/pubmed/29403928",
        "http://www.ncbi.nlm.nih.gov/pubmed/22907901",
        "http://www.ncbi.nlm.nih.gov/pubmed/23761972"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
          "text": "BACKGROUND\nThe purpose of this study was to review the current literature and information on the combination product Juvisync™ (sitagliptin + simvastatin), which was approved by the US Food and Drug Administration in October 2011. METHODS\nPubMed (2001-2014) was searched for primary and review articles on sitagliptin, simvastatin, or the combination product.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 361
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
          "text": "BACKGROUND: The purpose of this study was to review the current literature and information on the combination product Juvisync™ (sitagliptin + simvastatin), which was approved by the US Food and Drug Administration in October 2011.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 231
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
          "text": "BACKGROUND\nThe purpose of this study was to review the current literature and information on the combination product Juvisync™ (sitagliptin + simvastatin), which was approved by the US Food and Drug Administration in October 2011.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 230
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
          "text": "CONCLUSION: Juvisync should be used in patients requiring both sitagliptin and simvastatin. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 1448,
          "endSection": "abstract",
          "offsetInEndSection": 1540
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
          "text": "CONCLUSION\nJuvisync should be used in patients requiring both sitagliptin and simvastatin. Both agents have shown good efficacy and acceptable safety profiles.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1454,
          "endSection": "abstract",
          "offsetInEndSection": 1613
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
          "text": "CONCLUSION\nJuvisync should be used in patients requiring both sitagliptin and simvastatin. Both agents have shown good efficacy and acceptable safety profiles. Sitagliptin is a good option for diabetic patients to improve glycemic control with a lower risk of hypoglycemia and weight gain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1454,
          "endSection": "abstract",
          "offsetInEndSection": 1743
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
          "text": "CONCLUSION\nJuvisync should be used in patients requiring both sitagliptin and simvastatin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1454,
          "endSection": "abstract",
          "offsetInEndSection": 1544
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
          "text": "BACKGROUND\nThe purpose of this study was to review the current literature and information on the combination product Juvisync™ (sitagliptin + simvastatin), which was approved by the US Food and Drug Administration in October 2011. METHODS\nPubMed (2001-2014) was searched for primary and review articles on sitagliptin, simvastatin, or the combination product. Drug manufacturing data and product labeling were also used.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 422
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
          "text": "However, caution is needed when coadministering with any drug that may increase simvastatin levels to reduce the risk of myopathy and rhabdomyolysis. CONCLUSION\nJuvisync should be used in patients requiring both sitagliptin and simvastatin. Both agents have shown good efficacy and acceptable safety profiles.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1302,
          "endSection": "abstract",
          "offsetInEndSection": 1613
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
          "text": "Both medications have also demonstrated an acceptable side effect profile. However, caution is needed when coadministering with any drug that may increase simvastatin levels to reduce the risk of myopathy and rhabdomyolysis. CONCLUSION\nJuvisync should be used in patients requiring both sitagliptin and simvastatin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1227,
          "endSection": "abstract",
          "offsetInEndSection": 1544
        }
      ],
      "ideal_answer": "The Juvisync pill contains sitagliptin and simvastatin.",
      "exact_answer": [
        [
          "sitagliptin"
        ],
        [
          "simvastatin"
        ]
      ]
    },
    {
      "id": "66214cc6b9f8b89d7e000003",
      "type": "yesno",
      "body": "Is fish intake a protective factor against colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35158907",
        "http://www.ncbi.nlm.nih.gov/pubmed/15956652",
        "http://www.ncbi.nlm.nih.gov/pubmed/26264963",
        "http://www.ncbi.nlm.nih.gov/pubmed/17425596",
        "http://www.ncbi.nlm.nih.gov/pubmed/18483335",
        "http://www.ncbi.nlm.nih.gov/pubmed/22513196",
        "http://www.ncbi.nlm.nih.gov/pubmed/19169007",
        "http://www.ncbi.nlm.nih.gov/pubmed/19638981",
        "http://www.ncbi.nlm.nih.gov/pubmed/35458225",
        "http://www.ncbi.nlm.nih.gov/pubmed/31252190"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158907",
          "text": "Individuals in the highest (vs. lowest) category of fish consumption had a significantly reduced risk of CRC (SRR 0.94, 95%CI 0.89-0.99). In dose-response meta-analysis, a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in CRC risk (SRR 0.96, 95%CI 0.92-0.99). Preclinical studies (n = 25) identified multiple mechanisms of action of fish and fish components on colorectal carcinogenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 875,
          "endSection": "abstract",
          "offsetInEndSection": 1324
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158907",
          "text": "In dose-response meta-analysis, a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in CRC risk (SRR 0.96, 95%CI 0.92-0.99). Preclinical studies (n = 25) identified multiple mechanisms of action of fish and fish components on colorectal carcinogenesis. Conclusions: Dietary recommendations for cancer prevention should take into account the evidence from epidemiological and preclinical studies that increasing fish consumption may be effective in preventing CRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1013,
          "endSection": "abstract",
          "offsetInEndSection": 1535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158907",
          "text": "In dose-response meta-analysis, a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in CRC risk (SRR 0.96, 95%CI 0.92-0.99). Preclinical studies (n = 25) identified multiple mechanisms of action of fish and fish components on colorectal carcinogenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1013,
          "endSection": "abstract",
          "offsetInEndSection": 1324
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158907",
          "text": "Individuals in the highest (vs. lowest) category of fish consumption had a significantly reduced risk of CRC (SRR 0.94, 95%CI 0.89-0.99). In dose-response meta-analysis, a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in CRC risk (SRR 0.96, 95%CI 0.92-0.99).",
          "beginSection": "abstract",
          "offsetInBeginSection": 875,
          "endSection": "abstract",
          "offsetInEndSection": 1196
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158907",
          "text": "Background: Epidemiological studies on the association between fish consumption and colorectal cancer (CRC) risk have yielded inconsistent results, despite evidence from preclinical studies that long-chain ω-3 polyunsaturated fatty acids inhibit colorectal carcinogenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 272
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158907",
          "text": " Individuals in the highest (vs. lowest) category of fish consumption had a significantly reduced risk of CRC (SRR 0.94, 95%CI 0.89-0.99). In dose-response meta-analysis, a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in CRC risk (SRR 0.96, 95%CI 0.92-0.99)",
          "beginSection": "abstract",
          "offsetInBeginSection": 874,
          "endSection": "abstract",
          "offsetInEndSection": 1195
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158907",
          "text": "Preclinical studies (n = 25) identified multiple mechanisms of action of fish and fish components on colorectal carcinogenesis. Conclusions: Dietary recommendations for cancer prevention should take into account the evidence from epidemiological and preclinical studies that increasing fish consumption may be effective in preventing CRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1197,
          "endSection": "abstract",
          "offsetInEndSection": 1535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158907",
          "text": "Results: Twenty-five prospective epidemiological studies encompassing 25,777 CRC cases were included. Individuals in the highest (vs. lowest) category of fish consumption had a significantly reduced risk of CRC (SRR 0.94, 95%CI 0.89-0.99). In dose-response meta-analysis, a 50-g increment in the daily consumption of fish was associated with a statistically significant 4% reduction in CRC risk (SRR 0.96, 95%CI 0.92-0.99).",
          "beginSection": "abstract",
          "offsetInBeginSection": 773,
          "endSection": "abstract",
          "offsetInEndSection": 1196
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26264963",
          "text": "A strong inverse association was found between freshwater fish intake and colorectal cancer risk. Compared with the lowest quartile, the highest quartile intake showed a risk reduction of 53% (OR 0.47, 95% CI = 0.36-0.60, Ptrend < 0.01) after adjustment for various confounders.",
          "beginSection": "abstract",
          "offsetInBeginSection": 643,
          "endSection": "abstract",
          "offsetInEndSection": 921
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17425596",
          "text": "The consumption of fish and fish products was similarly inversely related to the risk although the association was not statistically significant. These associations were more evident for distal colon cancer; adjusted odds ratio for the highest versus lowest quintile of n-3 PUFA intake was 0.56 (95% confidence interval 0.34-0.92, trend P=0.02). Our findings do not support the hypothesis that consumption of red meat increases colorectal cancer risk but do suggest that high intake of fish may decrease the risk, particularly of distal colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1198,
          "endSection": "abstract",
          "offsetInEndSection": 1748
        }
      ],
      "ideal_answer": "Yes, fish intake is a protective factor against colorectal cancer. Individuals in the highest category of fish consumption had a significantly reduced risk of colorectal cancer (CRC) compared to those in the lowest category. A 50-g increment in daily fish consumption was associated with a 4% reduction in CRC risk.",
      "exact_answer": "yes"
    },
    {
      "id": "6616b259fdcbea915f00005a",
      "type": "summary",
      "body": "What is the exposome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24767943",
        "http://www.ncbi.nlm.nih.gov/pubmed/24906490",
        "http://www.ncbi.nlm.nih.gov/pubmed/26339073",
        "http://www.ncbi.nlm.nih.gov/pubmed/26012316",
        "http://www.ncbi.nlm.nih.gov/pubmed/26168307",
        "http://www.ncbi.nlm.nih.gov/pubmed/35790874",
        "http://www.ncbi.nlm.nih.gov/pubmed/37333730",
        "http://www.ncbi.nlm.nih.gov/pubmed/28669935",
        "http://www.ncbi.nlm.nih.gov/pubmed/35310334",
        "http://www.ncbi.nlm.nih.gov/pubmed/22080817"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24767943",
          "text": "The concept of the Exposome is a compilation of diseases and one's lifetime exposure to chemicals, whether the exposure comes from environmental, dietary, or occupational exposures; or endogenous chemicals that are formed from normal metabolism, inflammation, oxidative stress, lipid peroxidation, infections, and other natural metabolic processes such as alteration of the gut microbiome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 389
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168307",
          "text": "The \"exposome\" is defined as \"the totality of human environmental exposures from conception onward, complementing the genome\" and its holistic approach may advance understanding of disease etiology.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 198
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24767943",
          "text": "The concept of the Exposome is a compilation of diseases and one's lifetime exposure to chemicals, whether the exposure comes from environmental, dietary, or occupational exposures; or endogenous chemicals that are formed from normal metabolism, inflammation, oxidative stress, lipid peroxidation, infections, and other natural metabolic processes such as alteration of the gut microbiom",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 387
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24767943",
          "text": "The concept of the Exposome is a compilation of diseases and one's lifetime exposure to chemicals, whether the exposure comes from environmental, dietary, or occupational exposures; or endogenous chemicals that are formed from normal metabolism, inflammation, oxidative stress, lipid peroxidation, infections, and other natural metabolic processes such as alteration of the gut microbiome. In this review, we have focused on the endogenous exposome, the DNA damage that arises from the production of endogenous electrophilic molecules in our cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 548
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168307",
          "text": "The \"exposome\" is defined as \"the totality of human environmental exposures from conception onward, complementing the genome\" and its holistic approach may advance understanding of disease etiology. We aimed to describe the correlation structure of the exposome during pregnancy to better understand the relationships between and within families of exposure and to develop analytical tools appropriate to exposome data.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 419
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168307",
          "text": "The \"exposome\" is defined as \"the totality of human environmental exposures from conception onward, complementing the genome\" and its holistic approach may advance understanding of disease etiology. We aimed to describe the correlation structure of the exposome during pregnancy to better understand the relationships between and within families of exposure and to develop analytical tools appropriate to exposome data. Estimates on 81 environmental exposures of current health concern were obtained for 728 women enrolled in The INMA (INfancia y Medio Ambiente) birth cohort, in Sabadell, Spain, using biomonitoring, geospatial modeling, remote sensors, and questionnaires.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 674
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24767943",
          "text": "The concept of the Exposome is a compilation of diseases and one's lifetime exposure to chemicals, whether the exposure comes from environmental, dietary, or occupational exposures; or endogenous chemicals that are formed from normal metabolism, inflammation, oxidative stress, lipid peroxidation, infections, and other natural metabolic processes such as alteration of the gut microbiome. In this review, we have focused on the endogenous exposome, the DNA damage that arises from the production of endogenous electrophilic molecules in our cells. It provides quantitative data on endogenous DNA damage and its relationship to mutagenesis, with emphasis on when exogenous chemical exposures that produce identical DNA adducts to those arising from normal metabolism cause significant increases in total identical DNA adducts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 826
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28669935",
          "text": "In 2005, Christopher Wild introduced the concept of the exposome, which encompasses environmental exposures and concomitant biological responses throughout the life course.",
          "beginSection": "abstract",
          "offsetInBeginSection": 138,
          "endSection": "abstract",
          "offsetInEndSection": 310
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35310334",
          "text": "The exposome concept encourages holistic consideration of the non-genetic factors (environmental exposures including lifestyle) that influence an individual's health over their life course.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 189
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35310334",
          "text": "We propose a reattribution of \"exposome\" to exclusively represent the totality of contact with external factors that a biological entity experiences, and introduce the term \"functional exposomics\" to denote the systematic study of exposure-phenotype interaction.",
          "beginSection": "abstract",
          "offsetInBeginSection": 732,
          "endSection": "abstract",
          "offsetInEndSection": 994
        }
      ],
      "ideal_answer": "The exposome is the totality of an individual's exposures over the life course, including environmental, dietary, occupational, and endogenous exposures.",
      "exact_answer": "n/a"
    },
    {
      "id": "66156200fdcbea915f00004d",
      "type": "factoid",
      "body": "What is the gold standard for a diagnosis of narcolepsy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
        "http://www.ncbi.nlm.nih.gov/pubmed/12659360",
        "http://www.ncbi.nlm.nih.gov/pubmed/30803831",
        "http://www.ncbi.nlm.nih.gov/pubmed/20054743",
        "http://www.ncbi.nlm.nih.gov/pubmed/23386370",
        "http://www.ncbi.nlm.nih.gov/pubmed/20477240",
        "http://www.ncbi.nlm.nih.gov/pubmed/35447401",
        "http://www.ncbi.nlm.nih.gov/pubmed/28360551",
        "http://www.ncbi.nlm.nih.gov/pubmed/22078731",
        "http://www.ncbi.nlm.nih.gov/pubmed/28326118"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "It is hard for doctors to correctly and objectively diagnose narcolepsy. Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis. There have been some studies on automatic narcolepsy diagnosis using PSG recordings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 113,
          "endSection": "abstract",
          "offsetInEndSection": 436
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis. There have been some studies on automatic narcolepsy diagnosis using PSG recordings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 186,
          "endSection": "abstract",
          "offsetInEndSection": 436
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis. There have been some studies on automatic narcolepsy diagnosis using PSG recordings. However, the sleep stage information, an important cue for narcolepsy diagnosis, has not been fully utilized.",
          "beginSection": "abstract",
          "offsetInBeginSection": 186,
          "endSection": "abstract",
          "offsetInEndSection": 546
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "It is hard for doctors to correctly and objectively diagnose narcolepsy. Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 113,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 186,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis",
          "beginSection": "abstract",
          "offsetInBeginSection": 186,
          "endSection": "abstract",
          "offsetInEndSection": 350
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30803831",
          "text": "In addition to identifying low cerebrospinal fluid (CSF) hypocretin (orexin) levels, evaluation for narcolepsy requires in-laboratory polysomnography (PSG). Polysomnography is the gold standard for diagnosis of obstructive sleep apnea (OSA) as well as other sleep disorders.",
          "beginSection": "abstract",
          "offsetInBeginSection": 326,
          "endSection": "abstract",
          "offsetInEndSection": 600
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "Narcolepsy is a sleep disorder affecting millions of people worldwide and causes serious public health problems. It is hard for doctors to correctly and objectively diagnose narcolepsy. Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30803831",
          "text": "In addition to identifying low cerebrospinal fluid (CSF) hypocretin (orexin) levels, evaluation for narcolepsy requires in-laboratory polysomnography (PSG). Polysomnography is the gold standard for diagnosis of obstructive sleep apnea (OSA) as well as other sleep disorders. However, the use of home sleep apnea testing (HSAT) to screen for OSA in adults with EDS has increased greatly based on its lower cost, lower technical complexity, and greater convenience, versus PSG.",
          "beginSection": "abstract",
          "offsetInBeginSection": 326,
          "endSection": "abstract",
          "offsetInEndSection": 801
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30803831",
          "text": "Polysomnography is the gold standard for diagnosis of obstructive sleep apnea (OSA) as well as other sleep disorders. However, the use of home sleep apnea testing (HSAT) to screen for OSA in adults with EDS has increased greatly based on its lower cost, lower technical complexity, and greater convenience, versus PSG. The most commonly used, types 3 and 4, portable monitors for HSAT lack capability for electroencephalogram recording, which is necessary for the diagnosis of narcolepsy and other sleep disorders and is provided by PSG.",
          "beginSection": "abstract",
          "offsetInBeginSection": 483,
          "endSection": "abstract",
          "offsetInEndSection": 1020
        }
      ],
      "ideal_answer": "The gold standard for a diagnosis of narcolepsy is a formal sleep study including overnight polysomnography (PSG) recordings at an accredited sleep laboratory.",
      "exact_answer": [
        "PSG recordings"
      ]
    },
    {
      "id": "6630390b187cba990d000035",
      "type": "factoid",
      "body": "Which receptor tyrosine kinase is commonly mutated or amplified in pediatric glioma cases?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35978801",
        "http://www.ncbi.nlm.nih.gov/pubmed/27582545",
        "http://www.ncbi.nlm.nih.gov/pubmed/20889717",
        "http://www.ncbi.nlm.nih.gov/pubmed/22323597",
        "http://www.ncbi.nlm.nih.gov/pubmed/36119525",
        "http://www.ncbi.nlm.nih.gov/pubmed/24157063",
        "http://www.ncbi.nlm.nih.gov/pubmed/19737945",
        "http://www.ncbi.nlm.nih.gov/pubmed/36043552",
        "http://www.ncbi.nlm.nih.gov/pubmed/36685223",
        "http://www.ncbi.nlm.nih.gov/pubmed/16785193"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22323597",
          "text": "Analysis of The Cancer Genome Atlas GBM dataset identified 34 of 463 cases showing independent focal amplification of two or more RTKs, most commonly platelet-derived growth factor receptor α (PDGFRA) and epidermal growth factor receptor (EGFR). Dual-color fluorescence in situ hybridization was performed on eight samples with EGFR and PDGFRA amplification, revealing distinct tumor cell subpopulations amplified for only one RTK; in all cases these predominated over cells amplified for both.",
          "beginSection": "abstract",
          "offsetInBeginSection": 673,
          "endSection": "abstract",
          "offsetInEndSection": 1167
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20889717",
          "text": "However, the incidence of platelet-derived growth factor receptor-α (PDGFRA) gene rearrangement in these tumors is unknown. We investigated the PDGFRA locus in PDGFRA-amplified gliomas and identified two rearrangements, including the first case of a gene fusion between kinase insert domain receptor (KDR) (VEGFRII) and the PDGFRA gene, and six cases of PDGFRA(Δ8, 9), an intragenic deletion rearrangement. The PDGFRA(Δ8, 9) mutant was common, being present in 40% of the glioblastoma multiformes (GBMs) with PDGFRA amplification.",
          "beginSection": "abstract",
          "offsetInBeginSection": 168,
          "endSection": "abstract",
          "offsetInEndSection": 698
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20889717",
          "text": "However, the incidence of platelet-derived growth factor receptor-α (PDGFRA) gene rearrangement in these tumors is unknown. We investigated the PDGFRA locus in PDGFRA-amplified gliomas and identified two rearrangements, including the first case of a gene fusion between kinase insert domain receptor (KDR) (VEGFRII) and the PDGFRA gene, and six cases of PDGFRA(Δ8, 9), an intragenic deletion rearrangement.",
          "beginSection": "abstract",
          "offsetInBeginSection": 168,
          "endSection": "abstract",
          "offsetInEndSection": 574
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35978801",
          "text": "Over 20% of pHGG have been found in sequencing studies to have alterations in platelet derived growth factor-alpha (PDGFRA), making growth factor modeling and inhibition via targeted tyrosine kinases a rich vein of interest. With commonly found alterations in other growth factors, including FGFR, EGFR, VEGFR as well as RET, MET, and ALK, it is necessary to model those receptors, as well.",
          "beginSection": "abstract",
          "offsetInBeginSection": 710,
          "endSection": "abstract",
          "offsetInEndSection": 1100
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35978801",
          "text": "Over 20% of pHGG have been found in sequencing studies to have alterations in platelet derived growth factor-alpha (PDGFRA), making growth factor modeling and inhibition via targeted tyrosine kinases a rich vein of interest.",
          "beginSection": "abstract",
          "offsetInBeginSection": 710,
          "endSection": "abstract",
          "offsetInEndSection": 934
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35978801",
          "text": "Over 20% of pHGG have been found in sequencing studies to have alterations in platelet derived growth factor-alpha (PDGFRA), making growth factor modeling and inhibition via targeted tyrosine kinases a rich vein of interest. With commonly found alterations in other growth factors, including FGFR, EGFR, VEGFR as well as RET, MET, and ALK, it is necessary to model those receptors, as well. Here we review the recent advances in murine modeling and precision targeting of the most important RTKs in their clinical context.",
          "beginSection": "abstract",
          "offsetInBeginSection": 710,
          "endSection": "abstract",
          "offsetInEndSection": 1232
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22323597",
          "text": "Analysis of The Cancer Genome Atlas GBM dataset identified 34 of 463 cases showing independent focal amplification of two or more RTKs, most commonly platelet-derived growth factor receptor α (PDGFRA) and epidermal growth factor receptor (EGFR). Dual-color fluorescence in situ hybridization was performed on eight samples with EGFR and PDGFRA amplification, revealing distinct tumor cell subpopulations amplified for only one RTK; in all cases these predominated over cells amplified for both. Cell lines derived from coamplified tumors exhibited genotype selection under RTK-targeted ligand stimulation or pharmacologic inhibition in vitro.",
          "beginSection": "abstract",
          "offsetInBeginSection": 673,
          "endSection": "abstract",
          "offsetInEndSection": 1315
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22323597",
          "text": "Analysis of The Cancer Genome Atlas GBM dataset identified 34 of 463 cases showing independent focal amplification of two or more RTKs, most commonly platelet-derived growth factor receptor α (PDGFRA) and epidermal growth factor receptor (EGFR).",
          "beginSection": "abstract",
          "offsetInBeginSection": 673,
          "endSection": "abstract",
          "offsetInEndSection": 918
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22323597",
          "text": "Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 162
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20889717",
          "text": "However, the incidence of platelet-derived growth factor receptor-α (PDGFRA) gene rearrangement in these tumors is unknown.",
          "beginSection": "abstract",
          "offsetInBeginSection": 168,
          "endSection": "abstract",
          "offsetInEndSection": 291
        }
      ],
      "ideal_answer": "Platelet derived growth factor-alpha (PDGFRA) is commonly mutated or amplified in pediatric glioma cases.",
      "exact_answer": [
        "PDGFRA"
      ]
    },
    {
      "id": "66300c23187cba990d00001a",
      "type": "yesno",
      "body": "Can procalcitonin be used as a predictor for mortality in paediatric sepsis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36715265",
        "http://www.ncbi.nlm.nih.gov/pubmed/28257335",
        "http://www.ncbi.nlm.nih.gov/pubmed/38046497",
        "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
        "http://www.ncbi.nlm.nih.gov/pubmed/37355942",
        "http://www.ncbi.nlm.nih.gov/pubmed/31135778",
        "http://www.ncbi.nlm.nih.gov/pubmed/22701089",
        "http://www.ncbi.nlm.nih.gov/pubmed/32350044",
        "http://www.ncbi.nlm.nih.gov/pubmed/32567597",
        "http://www.ncbi.nlm.nih.gov/pubmed/26320678"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38046497",
          "text": "Procalcitonin Use for Predicting Mortality and Morbidity of Patients Diagnosed With Sepsis Within the Intensive Care Unit.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 122
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
          "text": "BACKGROUND\nProcalcitonin is useful for the diagnosis of sepsis but its prognostic value regarding mortality is unclear. This prospective observational study was designed to study the prognostic value of procalcitonin in prediction of 28 day mortality in patients of sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38046497",
          "text": "Without a clear marker to diagnose and manage sepsis, procalcitonin has been extensively studied for its usefulness in the management of bacterial infections. These studies, however, have been focused toward how it can be used to help guide when antibiotics should be initiated and de-escalated. There, however, has not been a study on how this biomarker could be used to predict mortality, and morbidity and help guide a need for antibiotic escalation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 203,
          "endSection": "abstract",
          "offsetInEndSection": 656
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
          "text": "BACKGROUND\nProcalcitonin is useful for the diagnosis of sepsis but its prognostic value regarding mortality is unclear. This prospective observational study was designed to study the prognostic value of procalcitonin in prediction of 28 day mortality in patients of sepsis. Fifty-four consecutive patients of sepsis, severe sepsis and septic shock defined using the 2001 Consensus Conference SCCM/ESICM/ACCP/ATS/SIS criteria from medical Intensive Care Unit (ICU) of a tertiary care center in New Delhi, India were enrolled from July 2011 to June 2013.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 552
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
          "text": "BACKGROUND\nProcalcitonin is useful for the diagnosis of sepsis but its prognostic value regarding mortality is unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 119
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28257335",
          "text": "CONCLUSIONS\nResults of this large, prospective multicenter U.S. study indicate that inability to decrease procalcitonin by more than 80% is a significant independent predictor of mortality and may aid in sepsis care.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1580,
          "endSection": "abstract",
          "offsetInEndSection": 1796
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28257335",
          "text": "Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 142
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
          "text": "Procalcitonin as a prognostic marker for sepsis: a prospective observational study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 83
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
          "text": "This prospective observational study was designed to study the prognostic value of procalcitonin in prediction of 28 day mortality in patients of sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 120,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38046497",
          "text": "Without a clear marker to diagnose and manage sepsis, procalcitonin has been extensively studied for its usefulness in the management of bacterial infections. These studies, however, have been focused toward how it can be used to help guide when antibiotics should be initiated and de-escalated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 203,
          "endSection": "abstract",
          "offsetInEndSection": 498
        }
      ],
      "ideal_answer": "Yes, procalcitonin can be used as a predictor for mortality in paediatric sepsis. It can help identify children at higher risk of morbidity and mortality, allowing for appropriate monitoring and treatment.",
      "exact_answer": "yes"
    },
    {
      "id": "66214c5db9f8b89d7e000002",
      "type": "factoid",
      "body": "What is the race with the highest incidence of colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34148614",
        "http://www.ncbi.nlm.nih.gov/pubmed/34325062",
        "http://www.ncbi.nlm.nih.gov/pubmed/15184825",
        "http://www.ncbi.nlm.nih.gov/pubmed/34620630",
        "http://www.ncbi.nlm.nih.gov/pubmed/27294749",
        "http://www.ncbi.nlm.nih.gov/pubmed/15743345",
        "http://www.ncbi.nlm.nih.gov/pubmed/12716038",
        "http://www.ncbi.nlm.nih.gov/pubmed/22052446",
        "http://www.ncbi.nlm.nih.gov/pubmed/36047055",
        "http://www.ncbi.nlm.nih.gov/pubmed/16532978"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15184825",
          "text": "In the United States, African Americans have the highest incidence of colorectal cancer of any racial or ethnic group.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 118
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15184825",
          "text": "In the United States, African Americans have the highest incidence of colorectal cancer of any racial or ethnic group. Compared with whites, African Americans have a younger mean age at colorectal cancer diagnosis and a greater proportion have proximal cancers. Survival in African Americans with colorectal cancer is lower than in whites.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 339
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15184825",
          "text": "In the United States, African Americans have the highest incidence of colorectal cancer of any racial or ethnic group. Compared with whites, African Americans have a younger mean age at colorectal cancer diagnosis and a greater proportion have proximal cancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 261
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15743345",
          "text": "Colorectal cancer in African Americans has an increased incidence and mortality relative to Whites.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15184825",
          "text": "Colorectal cancer in African Americans.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 39
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15743345",
          "text": "Colorectal cancer in African Americans.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 39
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294749",
          "text": "BACKGROUND\nIn the USA, race and socioeconomic status are well-known factors associated with colorectal cancer incidence and mortality rates. These are higher among blacks than whites and other racial/ethnic groups. METHODS\nIn this article, we review opportunities to address disparities in colorectal cancer incidence, mortality, and survivorship among African Americans.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 373
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15184825",
          "text": "Compared with whites, African Americans have a younger mean age at colorectal cancer diagnosis and a greater proportion have proximal cancers. Survival in African Americans with colorectal cancer is lower than in whites.",
          "beginSection": "abstract",
          "offsetInBeginSection": 119,
          "endSection": "abstract",
          "offsetInEndSection": 339
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294749",
          "text": "BACKGROUND\nIn the USA, race and socioeconomic status are well-known factors associated with colorectal cancer incidence and mortality rates. These are higher among blacks than whites and other racial/ethnic groups.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 214
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15743345",
          "text": "Colorectal cancer in African Americans has an increased incidence and mortality relative to Whites. The mean age of CRC development in African Americans is younger than that of Whites.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 184
        }
      ],
      "ideal_answer": "Black Americans have the highest incidence of colorectal cancer.",
      "exact_answer": [
        "Black Americans"
      ]
    },
    {
      "id": "662cfd21187cba990d000009",
      "type": "factoid",
      "body": "LRP6 is a member of what  superfamily of cell-surface receptors?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
        "http://www.ncbi.nlm.nih.gov/pubmed/16390319",
        "http://www.ncbi.nlm.nih.gov/pubmed/9704021",
        "http://www.ncbi.nlm.nih.gov/pubmed/26046396",
        "http://www.ncbi.nlm.nih.gov/pubmed/32076828",
        "http://www.ncbi.nlm.nih.gov/pubmed/37065631",
        "http://www.ncbi.nlm.nih.gov/pubmed/7878005",
        "http://www.ncbi.nlm.nih.gov/pubmed/28696417",
        "http://www.ncbi.nlm.nih.gov/pubmed/10456843",
        "http://www.ncbi.nlm.nih.gov/pubmed/29344294"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
          "text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 95
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
          "text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 96
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
          "text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors. It is required for the activation of the Wnt/β-catenin signalling pathway.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 170
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
          "text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors. It is required for the activation of the Wnt/β-catenin signalling pathway. LRP6 is detected in different tissue types and is involved in numerous biological activities such as cell proliferation, specification, metastatic cancer, and embryonic development.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 352
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32076828",
          "text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptors (LDLRs) family and accumulating evidence points to the critical role of LRP6 in cardiovascular health and homeostasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 229
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26046396",
          "text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor family and has a unique structure, which facilitates its multiple functions as a co-receptor for Wnt/β-catenin signaling and as a ligand receptor for endocytosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 272
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26046396",
          "text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor family and has a unique structure, which facilitates its multiple functions as a co-receptor for Wnt/β-catenin signaling and as a ligand receptor for endocytosis. The role LRP6 plays in metabolic regulation, specifically in the nutrient-sensing pathway, has recently garnered considerable interest.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 408
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32076828",
          "text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptors (LDLRs) family and accumulating evidence points to the critical role of LRP6 in cardiovascular health and homeostasis. In addition to presenting the well-appreciated roles in canonical signaling regulating blood pressure, blood glucose, lipid metabolism, atherosclerosis, cardiac valve disease, cardiac development, Alzheimer's disease and tumorigenesis, LRP6 also inhibits non-canonical Wnt signals that promote arterial smooth muscle cell proliferation and vascular calcification.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 593
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26046396",
          "text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor family and has a unique structure, which facilitates its multiple functions as a co-receptor for Wnt/β-catenin signaling and as a ligand receptor for endocytosis. The role LRP6 plays in metabolic regulation, specifically in the nutrient-sensing pathway, has recently garnered considerable interest. Patients carrying an LRP6 mutation exhibit elevated levels of LDL cholesterol, triglycerides, and fasting glucose, which cooperatively constitute the risk factors of metabolic syndrome and atherosclerosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 614
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32076828",
          "text": "Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptors (LDLRs) family and accumulating evidence points to the critical role of LRP6 in cardiovascular health and homeostasis. In addition to presenting the well-appreciated roles in canonical signaling regulating blood pressure, blood glucose, lipid metabolism, atherosclerosis, cardiac valve disease, cardiac development, Alzheimer's disease and tumorigenesis, LRP6 also inhibits non-canonical Wnt signals that promote arterial smooth muscle cell proliferation and vascular calcification. Noticeably, the role of LRP6 is displayed in cardiometabolic disease, an increasingly important clinical burden with aging and obesity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 729
        }
      ],
      "ideal_answer": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors.",
      "exact_answer": [
        "low-density lipoprotein receptor superfamily"
      ]
    },
    {
      "id": "661686e4fdcbea915f000052",
      "type": "list",
      "body": "List of major risks of intrauterine device.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27771475",
        "http://www.ncbi.nlm.nih.gov/pubmed/36717556",
        "http://www.ncbi.nlm.nih.gov/pubmed/37535968",
        "http://www.ncbi.nlm.nih.gov/pubmed/20120941",
        "http://www.ncbi.nlm.nih.gov/pubmed/7984332",
        "http://www.ncbi.nlm.nih.gov/pubmed/33189897",
        "http://www.ncbi.nlm.nih.gov/pubmed/23535053",
        "http://www.ncbi.nlm.nih.gov/pubmed/36357958",
        "http://www.ncbi.nlm.nih.gov/pubmed/36457635",
        "http://www.ncbi.nlm.nih.gov/pubmed/12516324"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7984332",
          "text": "The major health risks associated with IUD use are perforation of the uterus, pregnancy (both intrauterine and ectopic), and pelvic inflammatory disease. Perforation of the uterus by an IUD is a serious complication and this is possible both during the insertion and later.",
          "beginSection": "abstract",
          "offsetInBeginSection": 151,
          "endSection": "abstract",
          "offsetInEndSection": 424
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7984332",
          "text": "The major health risks associated with IUD use are perforation of the uterus, pregnancy (both intrauterine and ectopic), and pelvic inflammatory disease. Perforation of the uterus by an IUD is a serious complication and this is possible both during the insertion and later. Perforation of the uterus is rare, but potentially fatal.",
          "beginSection": "abstract",
          "offsetInBeginSection": 151,
          "endSection": "abstract",
          "offsetInEndSection": 482
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7984332",
          "text": "The intrauterine device (IUD) is an effective and relatively safe contraceptive. Approximately 15% of women of child-bearing age in Italy use the IUD. The major health risks associated with IUD use are perforation of the uterus, pregnancy (both intrauterine and ectopic), and pelvic inflammatory disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 304
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120941",
          "text": "Intrauterine contraceptive device (IUD) is a safe and effective method of contraception, widely used all over the world. The most common IUD complications include heavy bleeding, painful cramps, expulsion, complete or partial uterine perforation, infertility caused by pelvic inflammatory disease (PID), and an increased risk for septic and spontaneous abortion in cases of pregnancy with an IUD in situ.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120941",
          "text": "Intrauterine contraceptive device (IUD) is a safe and effective method of contraception, widely used all over the world. The most common IUD complications include heavy bleeding, painful cramps, expulsion, complete or partial uterine perforation, infertility caused by pelvic inflammatory disease (PID), and an increased risk for septic and spontaneous abortion in cases of pregnancy with an IUD in situ. A potentially serious complication is the perforation of the uterus, with reported incidence of 0.5-1/1000 insertions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 523
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7984332",
          "text": "The major health risks associated with IUD use are perforation of the uterus, pregnancy (both intrauterine and ectopic), and pelvic inflammatory disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 151,
          "endSection": "abstract",
          "offsetInEndSection": 304
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37535968",
          "text": "OBJECTIVE\nThe APEX-IUD (Association of Perforation and Expulsion of Intrauterine Devices) study evaluated the association of postpartum timing of intrauterine device (IUD) insertion, breastfeeding, heavy menstrual bleeding, and IUD type (levonorgestrel-releasing vs copper) with risks of uterine perforation and IUD expulsion in usual clinical practice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 353
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37535968",
          "text": "OBJECTIVE\nThe APEX-IUD (Association of Perforation and Expulsion of Intrauterine Devices) study evaluated the association of postpartum timing of intrauterine device (IUD) insertion, breastfeeding, heavy menstrual bleeding, and IUD type (levonorgestrel-releasing vs copper) with risks of uterine perforation and IUD expulsion in usual clinical practice. We summarize the clinically important findings to inform counseling and shared decision making.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 449
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120941",
          "text": "The most common IUD complications include heavy bleeding, painful cramps, expulsion, complete or partial uterine perforation, infertility caused by pelvic inflammatory disease (PID), and an increased risk for septic and spontaneous abortion in cases of pregnancy with an IUD in situ. A potentially serious complication is the perforation of the uterus, with reported incidence of 0.5-1/1000 insertions. After perforation, devices have been found in various locations in the pelvis and abdomen.",
          "beginSection": "abstract",
          "offsetInBeginSection": 121,
          "endSection": "abstract",
          "offsetInEndSection": 614
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120941",
          "text": "The most common IUD complications include heavy bleeding, painful cramps, expulsion, complete or partial uterine perforation, infertility caused by pelvic inflammatory disease (PID), and an increased risk for septic and spontaneous abortion in cases of pregnancy with an IUD in situ. A potentially serious complication is the perforation of the uterus, with reported incidence of 0.5-1/1000 insertions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 121,
          "endSection": "abstract",
          "offsetInEndSection": 523
        }
      ],
      "ideal_answer": "The major risks of intrauterine device (IUD) include pregnancy, infection, IUD expulsion, perforation, pelvic inflammatory disease, heavy bleeding, and anemia. The use of Cu-IUD may also increase the risk of bacterial infections and negatively impact the vaginal environment.",
      "exact_answer": [
        [
          "pregnancy"
        ],
        [
          "infection"
        ],
        [
          "IUD expulsion"
        ],
        [
          "perforation"
        ],
        [
          "pelvic inflammatory disease"
        ],
        [
          "heavy bleeding"
        ],
        [
          "anemia"
        ]
      ]
    },
    {
      "id": "66301e04187cba990d000027",
      "type": "factoid",
      "body": "What are episignatures?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
        "http://www.ncbi.nlm.nih.gov/pubmed/35047860",
        "http://www.ncbi.nlm.nih.gov/pubmed/32109418",
        "http://www.ncbi.nlm.nih.gov/pubmed/35887210",
        "http://www.ncbi.nlm.nih.gov/pubmed/35904121",
        "http://www.ncbi.nlm.nih.gov/pubmed/36537268",
        "http://www.ncbi.nlm.nih.gov/pubmed/31029150",
        "http://www.ncbi.nlm.nih.gov/pubmed/32644126",
        "http://www.ncbi.nlm.nih.gov/pubmed/33291301",
        "http://www.ncbi.nlm.nih.gov/pubmed/37249002"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
          "text": "A growing number of genetic syndromes have been associated with unique genomic DNA methylation patterns (called \"episignatures\") that can be used for diagnostic testing and as disease biomarkers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 548,
          "endSection": "abstract",
          "offsetInEndSection": 743
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
          "text": "A growing number of genetic syndromes have been associated with unique genomic DNA methylation patterns (called \"episignatures\") that can be used for diagnostic testing and as disease biomarkers. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 548,
          "endSection": "abstract",
          "offsetInEndSection": 744
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32109418",
          "text": "An expanding number of genetic syndromes have been shown to have unique genomic DNA methylation patterns (called \"episignatures\"). Peripheral blood episignatures can be used for diagnostic testing as well as for the interpretation of ambiguous genetic test results.",
          "beginSection": "abstract",
          "offsetInBeginSection": 182,
          "endSection": "abstract",
          "offsetInEndSection": 447
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35904121",
          "text": "Episignatures are distinct, highly sensitive, and specific biomarkers that have recently been applied in clinical diagnosis of genetic syndromes. Episignatures are contained within the broader disorder-specific genome-wide DNA methylation changes, which can share significant overlap among different conditions. In this study, we performed functional genomic assessment and comparison of disorder-specific and overlapping genome-wide DNA methylation changes related to 65 genetic syndromes with previously described episignatures.",
          "beginSection": "abstract",
          "offsetInBeginSection": 143,
          "endSection": "abstract",
          "offsetInEndSection": 673
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32109418",
          "text": "An expanding number of genetic syndromes have been shown to have unique genomic DNA methylation patterns (called \"episignatures\"). Peripheral blood episignatures can be used for diagnostic testing as well as for the interpretation of ambiguous genetic test results. We present here an approach to episignature mapping in 42 genetic syndromes, which has allowed the identification of 34 robust disease-specific episignatures.",
          "beginSection": "abstract",
          "offsetInBeginSection": 182,
          "endSection": "abstract",
          "offsetInEndSection": 606
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35904121",
          "text": "Episignatures are distinct, highly sensitive, and specific biomarkers that have recently been applied in clinical diagnosis of genetic syndromes. Episignatures are contained within the broader disorder-specific genome-wide DNA methylation changes, which can share significant overlap among different conditions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 143,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35904121",
          "text": "An expanding range of genetic syndromes are characterized by genome-wide disruptions in DNA methylation profiles referred to as episignatures. Episignatures are distinct, highly sensitive, and specific biomarkers that have recently been applied in clinical diagnosis of genetic syndromes. Episignatures are contained within the broader disorder-specific genome-wide DNA methylation changes, which can share significant overlap among different conditions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
          "text": "A growing number of genetic syndromes have been associated with unique genomic DNA methylation patterns (called \"episignatures\") that can be used for diagnostic testing and as disease biomarkers. To further investigate DMD pathophysiology, we assessed the genome-wide DNA methylation profiles of peripheral blood from 36 patients with DMD using the combination of Illumina Infinium Methylation EPIC bead chip array and EpiSign technology. We identified a unique episignature for DMD that whose specificity was confirmed in relation other neurodevelopmental disorders with known episignatures.",
          "beginSection": "abstract",
          "offsetInBeginSection": 548,
          "endSection": "abstract",
          "offsetInEndSection": 1140
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35904121",
          "text": "An expanding range of genetic syndromes are characterized by genome-wide disruptions in DNA methylation profiles referred to as episignatures. Episignatures are distinct, highly sensitive, and specific biomarkers that have recently been applied in clinical diagnosis of genetic syndromes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 288
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
          "text": "A growing number of genetic syndromes have been associated with unique genomic DNA methylation patterns (called \"episignatures\") that can be used for diagnostic testing and as disease biomarkers. To further investigate DMD pathophysiology, we assessed the genome-wide DNA methylation profiles of peripheral blood from 36 patients with DMD using the combination of Illumina Infinium Methylation EPIC bead chip array and EpiSign technology.",
          "beginSection": "abstract",
          "offsetInBeginSection": 548,
          "endSection": "abstract",
          "offsetInEndSection": 986
        }
      ],
      "ideal_answer": "Episignatures are unique genomic DNA methylation patterns that have been associated with a growing number of genetic syndromes. They can be used for diagnostic testing and as disease biomarkers.",
      "exact_answer": [
        "genomic DNA methylation patterns"
      ]
    },
    {
      "id": "66215690b9f8b89d7e00000a",
      "type": "yesno",
      "body": "Is chemotherapy an effective treatment for patients with advance colorectal cancer and poor performance status (ECOG/PS >1)",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
        "http://www.ncbi.nlm.nih.gov/pubmed/32919889",
        "http://www.ncbi.nlm.nih.gov/pubmed/18243010",
        "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
        "http://www.ncbi.nlm.nih.gov/pubmed/17645468",
        "http://www.ncbi.nlm.nih.gov/pubmed/31987521",
        "http://www.ncbi.nlm.nih.gov/pubmed/26318078",
        "http://www.ncbi.nlm.nih.gov/pubmed/29743951",
        "http://www.ncbi.nlm.nih.gov/pubmed/31227648",
        "http://www.ncbi.nlm.nih.gov/pubmed/22322592"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "CONCLUSION\nOur retrospective study suggests that chemotherapy might benefit selected mCRC patients with poor PS. With up-front dose reduction and close monitoring for toxicity, the risk of serious adverse events is minimized.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1724,
          "endSection": "abstract",
          "offsetInEndSection": 1949
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "Our retrospective study suggests that chemotherapy might benefit selected mCRC patients with poor PS. With up-front dose reduction and close monitoring for toxicity, the risk of serious adverse events is minimized.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1730,
          "endSection": "abstract",
          "offsetInEndSection": 1944
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "All deaths were disease-associated. CONCLUSION\nOur retrospective study suggests that chemotherapy might benefit selected mCRC patients with poor PS. With up-front dose reduction and close monitoring for toxicity, the risk of serious adverse events is minimized.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1686,
          "endSection": "abstract",
          "offsetInEndSection": 1949
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "The rates of treatment-related hospitalization were similar across all ECOG groups. All deaths were disease-associated. CONCLUSION\nOur retrospective study suggests that chemotherapy might benefit selected mCRC patients with poor PS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1602,
          "endSection": "abstract",
          "offsetInEndSection": 1836
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "BACKGROUND\nAlthough chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS > 2 remains uncertain, because they are generally excluded from clinical trials. Our objectives were to compare the survival and safety of ECOG PS 3/4 patients who were administered chemotherapy with those who received BSC only. PATIENTS AND METHODS\nWe retrospectively analyzed all consecutive mCRC patients who started first-line chemotherapy at our institution in a 4-year period.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 515
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "BACKGROUND\nAlthough chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS > 2 remains uncertain, because they are generally excluded from clinical trials. Our objectives were to compare the survival and safety of ECOG PS 3/4 patients who were administered chemotherapy with those who received BSC only.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 359
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "BACKGROUND\nAlthough chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS > 2 remains uncertain, because they are generally excluded from clinical trials.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 211
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "CONCLUSION\nOur retrospective study suggests that chemotherapy might benefit selected mCRC patients with poor PS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1724,
          "endSection": "abstract",
          "offsetInEndSection": 1836
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "All deaths were disease-associated. CONCLUSION\nOur retrospective study suggests that chemotherapy might benefit selected mCRC patients with poor PS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1686,
          "endSection": "abstract",
          "offsetInEndSection": 1836
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
          "text": "In addition, ECOG PS 4 or cholestasis had poorer overall survival. Finally, 25% and 53.6% of patients received these treatments in the last 14 and 30 days of life, respectively. CONCLUSION\nIn the present study, palliative multiagent chemotherapy in poor performance status patients with non-molecularly selected colorectal cancer tended to impact tumor symptoms control; however, there is no benefit in OS and a considerable risk of toxicity and treatment-related death.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1243,
          "endSection": "abstract",
          "offsetInEndSection": 1715
        }
      ],
      "ideal_answer": "Yes, chemotherapy is an effective treatment for patients with advanced colorectal cancer and poor performance status (ECOG/PS >1). This is based on a retrospective study that suggests chemotherapy might benefit selected mCRC patients with poor PS. With up-front dose reduction and close monitoring for toxicity, the risk of serious adverse events is minimized.",
      "exact_answer": "yes"
    },
    {
      "id": "663027bb187cba990d000033",
      "type": "summary",
      "body": "How does Pamrevlumab work?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
        "http://www.ncbi.nlm.nih.gov/pubmed/29347981",
        "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
        "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
        "http://www.ncbi.nlm.nih.gov/pubmed/29719620",
        "http://www.ncbi.nlm.nih.gov/pubmed/34797990",
        "http://www.ncbi.nlm.nih.gov/pubmed/36869335",
        "http://www.ncbi.nlm.nih.gov/pubmed/32817130",
        "http://www.ncbi.nlm.nih.gov/pubmed/28610597",
        "http://www.ncbi.nlm.nih.gov/pubmed/24154679"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": " Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF),",
          "beginSection": "abstract",
          "offsetInBeginSection": 227,
          "endSection": "abstract",
          "offsetInEndSection": 338
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF), is in Phase III development for treatment of DMD and other diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 227,
          "endSection": "abstract",
          "offsetInEndSection": 406
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF), is in Phase III development for treatment of DMD and other diseases. METHODS\nMISSION (Study 079; NCT02606136) was an open-label, Phase II, single-arm trial of pamrevlumab in 21 non-ambulatory patients with DMD (aged≥12 years, receiving corticosteroids) who received 35-mg/kg intravenous infusions every 2 weeks for 2 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 227,
          "endSection": "abstract",
          "offsetInEndSection": 663
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF), is in Phase III development for treatment of DMD and other diseases. METHODS\nMISSION (Study 079; NCT02606136) was an open-label, Phase II, single-arm trial of pamrevlumab in 21 non-ambulatory patients with DMD (aged≥12 years, receiving corticosteroids) who received 35-mg/kg intravenous infusions every 2 weeks for 2 years. The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 227,
          "endSection": "abstract",
          "offsetInEndSection": 761
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 151
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "BACKGROUND\nConnective tissue growth factor (CTGF) is a secreted glycoprotein that has a central role in the process of fibrosis. This study was designed to assess the safety, tolerability, and efficacy of pamrevlumab (FG-3019), a fully recombinant human monoclonal antibody against CTGF, in idiopathic pulmonary fibrosis. The aim was to establish whether pamrevlumab could slow, stop, or reverse progression of idiopathic pulmonary fibrosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 441
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "Lack of dystrophin leads to progressive muscle damage and replacement of muscle with fibrotic and adipose tissue. Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF), is in Phase III development for treatment of DMD and other diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 113,
          "endSection": "abstract",
          "offsetInEndSection": 406
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "Lack of dystrophin leads to progressive muscle damage and replacement of muscle with fibrotic and adipose tissue. Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF), is in Phase III development for treatment of DMD and other diseases. METHODS\nMISSION (Study 079; NCT02606136) was an open-label, Phase II, single-arm trial of pamrevlumab in 21 non-ambulatory patients with DMD (aged≥12 years, receiving corticosteroids) who received 35-mg/kg intravenous infusions every 2 weeks for 2 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 113,
          "endSection": "abstract",
          "offsetInEndSection": 663
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "BACKGROUND\nConnective tissue growth factor (CTGF) is a secreted glycoprotein that has a central role in the process of fibrosis. This study was designed to assess the safety, tolerability, and efficacy of pamrevlumab (FG-3019), a fully recombinant human monoclonal antibody against CTGF, in idiopathic pulmonary fibrosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 321
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "This study was designed to assess the safety, tolerability, and efficacy of pamrevlumab (FG-3019), a fully recombinant human monoclonal antibody against CTGF, in idiopathic pulmonary fibrosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 129,
          "endSection": "abstract",
          "offsetInEndSection": 321
        }
      ],
      "ideal_answer": "Pamrevlumab is a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF).",
      "exact_answer": "n/a"
    },
    {
      "id": "662fbec6187cba990d00000f",
      "type": "factoid",
      "body": "What are the clinical indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32468211",
        "http://www.ncbi.nlm.nih.gov/pubmed/35326651",
        "http://www.ncbi.nlm.nih.gov/pubmed/34318754",
        "http://www.ncbi.nlm.nih.gov/pubmed/30306400",
        "http://www.ncbi.nlm.nih.gov/pubmed/25444473",
        "http://www.ncbi.nlm.nih.gov/pubmed/22906288",
        "http://www.ncbi.nlm.nih.gov/pubmed/16944163",
        "http://www.ncbi.nlm.nih.gov/pubmed/35463654",
        "http://www.ncbi.nlm.nih.gov/pubmed/37828491",
        "http://www.ncbi.nlm.nih.gov/pubmed/38041083"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32468211",
          "text": "PURPOSE\nThe purpose of this study was to evaluate the therapeutic efficacy and safety of transarterial chemoembolization (TACE) in the treatment of patients with unresectable colorectal cancer liver metastases (CRCLM) who had failed systemic chemotherapy. In addition, the role of TACE in the treatment of CRCLM is also worth discussing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 337
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32468211",
          "text": "PURPOSE\nThe purpose of this study was to evaluate the therapeutic efficacy and safety of transarterial chemoembolization (TACE) in the treatment of patients with unresectable colorectal cancer liver metastases (CRCLM) who had failed systemic chemotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 255
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32468211",
          "text": "PURPOSE\nThe purpose of this study was to evaluate the therapeutic efficacy and safety of transarterial chemoembolization (TACE) in the treatment of patients with unresectable colorectal cancer liver metastases (CRCLM) who had failed systemic chemotherapy. In addition, the role of TACE in the treatment of CRCLM is also worth discussing. METHODS\nThis single-center retrospective study evaluated the consecutive medical records of patients with CRCLM treated with TACE from June 2014 to June 2018, who had failed at least two lines of prior chemotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30306400",
          "text": "PURPOSE\nTo evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM). METHODS\nWe conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 406
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22906288",
          "text": "OBJECTIVE\nA retrospective clinical study to evaluate the effect of transarterial infusion (TAI) chemotherapy and transarterial chemoembolization (TACE) on liver metastasis after gastric cancer resection. METHODS\nThe study recruited patients who underwent surgical resection for stage T(2)N(2)M(0) gastric adenocarcinoma without liver metastasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 347
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22906288",
          "text": "OBJECTIVE\nA retrospective clinical study to evaluate the effect of transarterial infusion (TAI) chemotherapy and transarterial chemoembolization (TACE) on liver metastasis after gastric cancer resection. METHODS\nThe study recruited patients who underwent surgical resection for stage T(2)N(2)M(0) gastric adenocarcinoma without liver metastasis. Patients chose to receive either TAI or systemic chemotherapy, based on the advantages and disadvantages of each regimen as explained by physicians.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 496
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30306400",
          "text": "PURPOSE\nTo evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 214
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22906288",
          "text": "OBJECTIVE\nA retrospective clinical study to evaluate the effect of transarterial infusion (TAI) chemotherapy and transarterial chemoembolization (TACE) on liver metastasis after gastric cancer resection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 203
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30306400",
          "text": "PURPOSE\nTo evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM). METHODS\nWe conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin (raltitrexed group), and 20 received TACE using FUDR, oxaliplatin, and pirarubicin (FUDR group).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 587
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32468211",
          "text": "The results of subgroup analysis showed that synchronous liver metastasis and extrahepatic metastasis had an effect on the prognosis of patients, while the primary tumor sites (rectum, left, and right colon) had no effect on the prognosis. CONCLUSIONS\nTACE is well tolerated and effective in patients with unresectable chemotherapy refractory CRCLM. Meanwhile, the results of this study also indicated that TACE is still a better treatment for these patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1210,
          "endSection": "abstract",
          "offsetInEndSection": 1671
        }
      ],
      "ideal_answer": "The clinical indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer is unresectable chemotherapy refractory liver metastasis, particularly for larger, intermediate (3-5 cm) lesions.",
      "exact_answer": [
        "unresectable chemotherapy refractory liver metastasis"
      ]
    },
    {
      "id": "663014c8187cba990d000020",
      "type": "summary",
      "body": "What is Alzheimer's disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37264659",
        "http://www.ncbi.nlm.nih.gov/pubmed/37488880",
        "http://www.ncbi.nlm.nih.gov/pubmed/3470778",
        "http://www.ncbi.nlm.nih.gov/pubmed/2649895",
        "http://www.ncbi.nlm.nih.gov/pubmed/1652752",
        "http://www.ncbi.nlm.nih.gov/pubmed/11790632",
        "http://www.ncbi.nlm.nih.gov/pubmed/8321160",
        "http://www.ncbi.nlm.nih.gov/pubmed/7916770",
        "http://www.ncbi.nlm.nih.gov/pubmed/19479823",
        "http://www.ncbi.nlm.nih.gov/pubmed/24255154"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19479823",
          "text": "The histopathological hallmarks of Alzheimer disease are the extracellular amyloid plaques, composed principally of the amyloid beta peptide, and the intracellular neurofibrillary tangles, composed of paired helical filaments of the microtubule-associated protein, tau.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 269
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19479823",
          "text": "The histopathological hallmarks of Alzheimer disease are the extracellular amyloid plaques, composed principally of the amyloid beta peptide, and the intracellular neurofibrillary tangles, composed of paired helical filaments of the microtubule-associated protein, tau. Other histopathological structures involving actin and the actin-binding protein, cofilin, have more recently been recognized.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 396
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255154",
          "text": "This debilitating disease is marked by memory loss, confusion, and loss of cognitive ability. The exact cause of Alzheimer disease is unknown although research suggests that it might result from a combination of factors. The hallmarks of Alzheimer disease are the presence of beta-amyloid plaques and neurofibrillary tangles in the brain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 102,
          "endSection": "abstract",
          "offsetInEndSection": 440
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8321160",
          "text": "Amyloid beta-protein is a major focus in efforts to understand the etiology of Alzheimer disease yet there is little known about the mechanism of its deposition in plaques. I propose deposition of amyloid in neuritic plaques depends on the remains of neurofibrillary tangles after neuronal death.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 296
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8321160",
          "text": "Amyloid beta-protein is a major focus in efforts to understand the etiology of Alzheimer disease yet there is little known about the mechanism of its deposition in plaques. I propose deposition of amyloid in neuritic plaques depends on the remains of neurofibrillary tangles after neuronal death. The interaction of these two lesions means neuritic plaques are not only dependent on neurofibrillary tangles and neuronal death but also dependent on their concurrence.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 466
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19479823",
          "text": "The histopathological hallmarks of Alzheimer disease are the extracellular amyloid plaques, composed principally of the amyloid beta peptide, and the intracellular neurofibrillary tangles, composed of paired helical filaments of the microtubule-associated protein, tau. Other histopathological structures involving actin and the actin-binding protein, cofilin, have more recently been recognized. Here we review new findings about these cytoskeletal pathologies, and, emphasize how plaques, tangles, the actin-containing inclusions and their respective building blocks may contribute to Alzheimer pathogenesis and the primary behavioral symptoms of the disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 661
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11790632",
          "text": "Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 121
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3470778",
          "text": "Amyloid of neurofibrillary tangles of Guamanian parkinsonism-dementia and Alzheimer disease share identical amino acid sequence.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 128
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1652752",
          "text": "Senile plaques are polymorphous beta-amyloid protein deposits found in the brain in Alzheimer disease and normal aging. This beta-amyloid protein is derived from a larger precursor molecule of which neurons are the principal producers in brain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 244
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1652752",
          "text": "Senile plaques are polymorphous beta-amyloid protein deposits found in the brain in Alzheimer disease and normal aging. This beta-amyloid protein is derived from a larger precursor molecule of which neurons are the principal producers in brain. We found that amyloid precursor protein (APP)-immunoreactive neurites were involved in senile plaques and that only a subset of these neurites showed markers for the abnormal filaments characteristic of neurofibrillary pathology.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 474
        }
      ],
      "ideal_answer": "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease. The two main hallmarks of Alzheimer's disease are amyloid beta plaque and neurofibrillary tangles.",
      "exact_answer": "n/a"
    },
    {
      "id": "662fbfc4187cba990d000010",
      "type": "yesno",
      "body": "Is short-course radiation therapy a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35103791",
        "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
        "http://www.ncbi.nlm.nih.gov/pubmed/30977859",
        "http://www.ncbi.nlm.nih.gov/pubmed/31673654",
        "http://www.ncbi.nlm.nih.gov/pubmed/31949387",
        "http://www.ncbi.nlm.nih.gov/pubmed/30964794",
        "http://www.ncbi.nlm.nih.gov/pubmed/34990423",
        "http://www.ncbi.nlm.nih.gov/pubmed/21645867",
        "http://www.ncbi.nlm.nih.gov/pubmed/32873251",
        "http://www.ncbi.nlm.nih.gov/pubmed/36759387"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35103791",
          "text": "Importance\nShort-course radiotherapy and total neoadjuvant therapy (SCRT-TNT) followed by total mesorectal excision (TME) has emerged as a new treatment paradigm for patients with locally advanced rectal adenocarcinoma. However, the economic implication of this treatment strategy has not been compared with that of conventional long-course chemoradiotherapy (LCCRT) followed by TME with adjuvant chemotherapy. Objective\nTo perform a cost-effectiveness analysis of SCRT-TNT vs LCCRT in conjunction with TME for patients with locally advanced rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 558
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35103791",
          "text": "Importance\nShort-course radiotherapy and total neoadjuvant therapy (SCRT-TNT) followed by total mesorectal excision (TME) has emerged as a new treatment paradigm for patients with locally advanced rectal adenocarcinoma. However, the economic implication of this treatment strategy has not been compared with that of conventional long-course chemoradiotherapy (LCCRT) followed by TME with adjuvant chemotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 410
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35103791",
          "text": "Importance\nShort-course radiotherapy and total neoadjuvant therapy (SCRT-TNT) followed by total mesorectal excision (TME) has emerged as a new treatment paradigm for patients with locally advanced rectal adenocarcinoma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 219
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "We review the current clinical literature highlighting the relative merits of short-course radiation, along with modern neoadjuvant strategies that incorporate its use. RECENT FINDINGS\nAs compared to long-course chemoradiation with delayed surgery, short-course radiation with early surgery offers similar oncologic efficacy for locally advanced rectal cancer patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 536
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "PURPOSE OF REVIEW\nFor patients with locally advanced rectal cancer, neoadjuvant hypofractionated short-course radiation remains an underutilized regimen in the USA. We review the current clinical literature highlighting the relative merits of short-course radiation, along with modern neoadjuvant strategies that incorporate its use. RECENT FINDINGS\nAs compared to long-course chemoradiation with delayed surgery, short-course radiation with early surgery offers similar oncologic efficacy for locally advanced rectal cancer patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 536
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "Delaying surgery also offers the opportunity to administer neoadjuvant systemic therapy, which may help increase local-regional tumor response and potentially decrease distant relapse rates, the latter a persisting problem in rectal cancer treatment. Short-course radiation, either with immediate or with delayed surgery, represents an appealing treatment alternative to long-course chemoradiation for patients with locally advanced rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 683,
          "endSection": "abstract",
          "offsetInEndSection": 1130
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "We review the current clinical literature highlighting the relative merits of short-course radiation, along with modern neoadjuvant strategies that incorporate its use. RECENT FINDINGS\nAs compared to long-course chemoradiation with delayed surgery, short-course radiation with early surgery offers similar oncologic efficacy for locally advanced rectal cancer patients. Delaying surgery after short-course radiation decreases post-operative complications as compared to early surgery and improves tumor downstaging.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 682
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "Short-course radiation, either with immediate or with delayed surgery, represents an appealing treatment alternative to long-course chemoradiation for patients with locally advanced rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 934,
          "endSection": "abstract",
          "offsetInEndSection": 1130
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "RECENT FINDINGS\nAs compared to long-course chemoradiation with delayed surgery, short-course radiation with early surgery offers similar oncologic efficacy for locally advanced rectal cancer patients. Delaying surgery after short-course radiation decreases post-operative complications as compared to early surgery and improves tumor downstaging. Delaying surgery also offers the opportunity to administer neoadjuvant systemic therapy, which may help increase local-regional tumor response and potentially decrease distant relapse rates, the latter a persisting problem in rectal cancer treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 336,
          "endSection": "abstract",
          "offsetInEndSection": 933
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "Delaying surgery after short-course radiation decreases post-operative complications as compared to early surgery and improves tumor downstaging. Delaying surgery also offers the opportunity to administer neoadjuvant systemic therapy, which may help increase local-regional tumor response and potentially decrease distant relapse rates, the latter a persisting problem in rectal cancer treatment. Short-course radiation, either with immediate or with delayed surgery, represents an appealing treatment alternative to long-course chemoradiation for patients with locally advanced rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 537,
          "endSection": "abstract",
          "offsetInEndSection": 1130
        }
      ],
      "ideal_answer": "Yes, short-course radiation therapy is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer. This is because short-course radiation therapy followed by total mesorectal excision (TME) incurs lower cost and improves quality-adjusted life years (QALYs) compared with conventional long-course chemoradiation therapy followed by TME and adjuvant chemotherapy.",
      "exact_answer": "yes"
    },
    {
      "id": "66301f5a187cba990d000028",
      "type": "yesno",
      "body": "Are there any episignatures for Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
        "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
        "http://www.ncbi.nlm.nih.gov/pubmed/37637209",
        "http://www.ncbi.nlm.nih.gov/pubmed/18974549",
        "http://www.ncbi.nlm.nih.gov/pubmed/35646370",
        "http://www.ncbi.nlm.nih.gov/pubmed/23746543",
        "http://www.ncbi.nlm.nih.gov/pubmed/6866009",
        "http://www.ncbi.nlm.nih.gov/pubmed/18022230",
        "http://www.ncbi.nlm.nih.gov/pubmed/3440453",
        "http://www.ncbi.nlm.nih.gov/pubmed/31089101"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
          "text": "The discovery of the DNA methylation episignature for Duchenne muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 82
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
          "text": "To further investigate DMD pathophysiology, we assessed the genome-wide DNA methylation profiles of peripheral blood from 36 patients with DMD using the combination of Illumina Infinium Methylation EPIC bead chip array and EpiSign technology. We identified a unique episignature for DMD that whose specificity was confirmed in relation other neurodevelopmental disorders with known episignatures. By modeling the DMD episignature, we developed a new DMD episignature biomarker and provided novel insights into the molecular pathogenesis of this disorder, which have the potential to advance more effective, personalized approaches to DMD care.",
          "beginSection": "abstract",
          "offsetInBeginSection": 744,
          "endSection": "abstract",
          "offsetInEndSection": 1387
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
          "text": "To further investigate DMD pathophysiology, we assessed the genome-wide DNA methylation profiles of peripheral blood from 36 patients with DMD using the combination of Illumina Infinium Methylation EPIC bead chip array and EpiSign technology. We identified a unique episignature for DMD that whose specificity was confirmed in relation other neurodevelopmental disorders with known episignatures.",
          "beginSection": "abstract",
          "offsetInBeginSection": 744,
          "endSection": "abstract",
          "offsetInEndSection": 1140
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
          "text": "Duchenne Muscular Dystrophy (DMD) is an X-linked recessive neuromuscular disorder characterized by progressive muscle weakness due to loss of function mutations in the dystrophin gene. Variation in clinical presentation, the rate of disease progression, and treatment responsiveness have been observed amongst DMD patients, suggesting that factors beyond the loss of dystrophin may contribute to DMD pathophysiology. Epigenetic mechanisms are becoming recognized as important factors implicated in the etiology and progression of various diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 547
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37637209",
          "text": "Duchenne muscular dystrophy is an X-linked monogenic disease caused by mutations in the dystrophin gene (DMD) characterized by progressive muscle weakness, leading to loss of ambulation and decreased life expectancy. Since the current standard of care for Duchenne muscular dystrophy is to merely treat symptoms, there is a dire need for treatment modalities that can correct the underlying genetic mutations. While several gene replacement therapies are being explored in clinical trials, one emerging approach that can directly correct mutations in genomic DNA is base editing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 579
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
          "text": "A growing number of genetic syndromes have been associated with unique genomic DNA methylation patterns (called \"episignatures\") that can be used for diagnostic testing and as disease biomarkers. To further investigate DMD pathophysiology, we assessed the genome-wide DNA methylation profiles of peripheral blood from 36 patients with DMD using the combination of Illumina Infinium Methylation EPIC bead chip array and EpiSign technology. We identified a unique episignature for DMD that whose specificity was confirmed in relation other neurodevelopmental disorders with known episignatures.",
          "beginSection": "abstract",
          "offsetInBeginSection": 548,
          "endSection": "abstract",
          "offsetInEndSection": 1140
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35646370",
          "text": "A 1-year-old Chinese patient was diagnosed with early-onset Duchenne muscular dystrophy. Next-generation gene sequencing was conducted and the Sanger method was used to validate sequencing. We identified a novel nonsense mutation (c.6283C>T) in DMD that caused the replacement of native arginine at codon 2095 with a premature termination codon (p.R2095X), which may have had a pathogenic effect against dystrophin in our patient's muscle cell membranes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 180,
          "endSection": "abstract",
          "offsetInEndSection": 634
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37637209",
          "text": "Duchenne muscular dystrophy is an X-linked monogenic disease caused by mutations in the dystrophin gene (DMD) characterized by progressive muscle weakness, leading to loss of ambulation and decreased life expectancy. Since the current standard of care for Duchenne muscular dystrophy is to merely treat symptoms, there is a dire need for treatment modalities that can correct the underlying genetic mutations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 409
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6866009",
          "text": "Motor neuron abnormalities have been implicated in the pathogenesis of Duchenne muscular dystrophy. Evidence concerning the effect of injury on motor neurons of human Duchenne muscular dystrophy (DMD) is lacking. We report a DMD patient having, in addition, an obstetric paresis on his left arm.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 295
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37637209",
          "text": "Duchenne muscular dystrophy is an X-linked monogenic disease caused by mutations in the dystrophin gene (DMD) characterized by progressive muscle weakness, leading to loss of ambulation and decreased life expectancy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 216
        }
      ],
      "ideal_answer": "Yes, there is an episignature for Duchenne Muscular Dystrophy (DMD). A unique DNA methylation episignature for DMD was discovered and confirmed to be specific to this disorder, providing novel insights into its molecular pathogenesis.",
      "exact_answer": "yes"
    },
    {
      "id": "6621506cb9f8b89d7e000007",
      "type": "list",
      "body": "What are the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32418154",
        "http://www.ncbi.nlm.nih.gov/pubmed/28185757",
        "http://www.ncbi.nlm.nih.gov/pubmed/31553708",
        "http://www.ncbi.nlm.nih.gov/pubmed/20563851",
        "http://www.ncbi.nlm.nih.gov/pubmed/32098826",
        "http://www.ncbi.nlm.nih.gov/pubmed/24666267",
        "http://www.ncbi.nlm.nih.gov/pubmed/29470838",
        "http://www.ncbi.nlm.nih.gov/pubmed/33611888",
        "http://www.ncbi.nlm.nih.gov/pubmed/21305640",
        "http://www.ncbi.nlm.nih.gov/pubmed/22427190"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20563851",
          "text": "To evaluate the KRAS, BRAF, EGFR, and HER2 gene status in colorectal cancer by novel techniques and evaluate whether anti-HER2 therapies could be offered in the treatment of these patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 189
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31553708",
          "text": "Background Colorectal cancer is a successful model of genetic biomarker development in oncology. Currently, several predictive or prognostic genetic alterations have been identified and are used in clinical practice. The RAS gene family, which includes KRAS and NRAS act as predictors for anti-epithelial growth factor receptor treatment (anti-EGFR), and it has been suggested that NRAS mutations also play a role in prognosis: patients harboring NRAS alterations have a significantly shorter survival compared to those with wild type tumours.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 543
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24666267",
          "text": "The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 153
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20563851",
          "text": "HER2, but not EGFR gene amplification, was frequently observed in KRAS and BRAF wild type colorectal cancer patients. These data indicate that HER2 amplification could be one of the genes to be considered in the therapeutic management of colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1092,
          "endSection": "abstract",
          "offsetInEndSection": 1348
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20563851",
          "text": "To evaluate the KRAS, BRAF, EGFR, and HER2 gene status in colorectal cancer by novel techniques and evaluate whether anti-HER2 therapies could be offered in the treatment of these patients. There are conflicting data on the prevalence of BRAF mutations and EGFR and HER2 gene amplification in colorectal KRAS wild type patients. In our study we tried to evaluate these expressions and their relationship to future treatment assays.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 431
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24666267",
          "text": "The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways in colorectal cancer is uncertain, which led us to systematically review the impact of alterations in KRAS (outside of exon 2), NRAS, BRAF, PIK3CA and PTEN in relation to the clinical benefit from anti-EGFR treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 223,
          "endSection": "abstract",
          "offsetInEndSection": 539
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20563851",
          "text": "To evaluate the KRAS, BRAF, EGFR, and HER2 gene status in colorectal cancer by novel techniques and evaluate whether anti-HER2 therapies could be offered in the treatment of these patients. There are conflicting data on the prevalence of BRAF mutations and EGFR and HER2 gene amplification in colorectal KRAS wild type patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 328
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24666267",
          "text": "CONCLUSIONS\nMeta-analysis suggests that mutations in KRAS exons 3 and 4, NRAS, BRAF and PIK3CA and non-functional PTEN predict resistance to anti-EGFR therapies and demonstrates that biomarker analysis beyond KRAS exon 2 should be implemented for prediction of clinical benefit from anti-EGFR antibodies in metastatic colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1440,
          "endSection": "abstract",
          "offsetInEndSection": 1776
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24666267",
          "text": "BACKGROUND\nIn metastatic colorectal cancer, mutation testing for KRAS exon 2 is widely implemented to select patients with wild-type tumors for treatment with the monocloncal anti-EGFR antibodies cetuximab and panitumumab. The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways in colorectal cancer is uncertain, which led us to systematically review the impact of alterations in KRAS (outside of exon 2), NRAS, BRAF, PIK3CA and PTEN in relation to the clinical benefit from anti-EGFR treatment. METHODS\nIn total, 22 studies that include 2395 patients formed the basis for a meta-analysis on alterations in KRAS exons 3 and 4, NRAS, BRAF, and PIK3CA and PTEN and outcome of anti-EGFR treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 740
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24666267",
          "text": "The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways in colorectal cancer is uncertain, which led us to systematically review the impact of alterations in KRAS (outside of exon 2), NRAS, BRAF, PIK3CA and PTEN in relation to the clinical benefit from anti-EGFR treatment. METHODS\nIn total, 22 studies that include 2395 patients formed the basis for a meta-analysis on alterations in KRAS exons 3 and 4, NRAS, BRAF, and PIK3CA and PTEN and outcome of anti-EGFR treatment. Odds ratios for objective response rate (ORR) and hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS) were calculated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 223,
          "endSection": "abstract",
          "offsetInEndSection": 888
        }
      ],
      "ideal_answer": "The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice include testing for EGFR, KRAS, NRAS, BRAF, HER2, DNA repair pathway proteins, and NTRK fusions. These tests provide clinically actionable information for targeted therapy and are essential for determining the most effective treatment plan.",
      "exact_answer": [
        [
          "EGFR"
        ],
        [
          "KRAS"
        ],
        [
          "NRAS"
        ],
        [
          "BRAF"
        ],
        [
          "HER2"
        ],
        [
          "DNA repair pathway proteins"
        ],
        [
          "NTRK"
        ]
      ]
    },
    {
      "id": "66301c47187cba990d000025",
      "type": "list",
      "body": "What are the most common issues that need to be addressed in adults with Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37724986",
        "http://www.ncbi.nlm.nih.gov/pubmed/19945914",
        "http://www.ncbi.nlm.nih.gov/pubmed/37406964",
        "http://www.ncbi.nlm.nih.gov/pubmed/30275253",
        "http://www.ncbi.nlm.nih.gov/pubmed/27757431",
        "http://www.ncbi.nlm.nih.gov/pubmed/29254382",
        "http://www.ncbi.nlm.nih.gov/pubmed/37344421",
        "http://www.ncbi.nlm.nih.gov/pubmed/30275250",
        "http://www.ncbi.nlm.nih.gov/pubmed/25608128",
        "http://www.ncbi.nlm.nih.gov/pubmed/24785967"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37724986",
          "text": "Adults living with Duchenne muscular dystrophy: old and new challenges in a cohort of 19 patients in their third to fifth decade.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 129
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30275253",
          "text": "Primary Care and Emergency Department Management of the Patient With Duchenne Muscular Dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 97
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19945914",
          "text": "Optimum management of Duchenne muscular dystrophy (DMD) requires a multidisciplinary approach that focuses on anticipatory and preventive measures as well as active interventions to address the primary and secondary aspects of the disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 240
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19945914",
          "text": "Optimum management of Duchenne muscular dystrophy (DMD) requires a multidisciplinary approach that focuses on anticipatory and preventive measures as well as active interventions to address the primary and secondary aspects of the disorder. Implementing comprehensive management strategies can favourably alter the natural history of the disease and improve function, quality of life, and longevity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 399
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19945914",
          "text": "Optimum management of Duchenne muscular dystrophy (DMD) requires a multidisciplinary approach that focuses on anticipatory and preventive measures as well as active interventions to address the primary and secondary aspects of the disorder. Implementing comprehensive management strategies can favourably alter the natural history of the disease and improve function, quality of life, and longevity. Standardised care can also facilitate planning for multicentre trials and help with the identification of areas in which care can be improved.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27757431",
          "text": "This literature is discussed to give an overview of the current management of scoliosis within Duchenne Muscular Dystrophy. Importantly, improvements in respiratory care, the use of steroids and improving surgical techniques have allowed patients to maintain quality of life and improved life expectancy in this patient group.",
          "beginSection": "abstract",
          "offsetInBeginSection": 197,
          "endSection": "abstract",
          "offsetInEndSection": 523
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37406964",
          "text": "The lack of dystrophin plays a pathophysiological role in the development of dilated cardiomyopathy in Duchenne muscular dystrophy. Currently, no consensus exists on specific pharmacological therapy guidelines for these patients; however, it centers around the guidelines for heart failure management. This systematic review investigated 12 randomized control trials dating back to 2005 in the pharmacotherapy of patients with dilated cardiomyopathy Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 225,
          "endSection": "abstract",
          "offsetInEndSection": 703
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30275253",
          "text": "Primary care providers (PCPs) are usually the first point of contact with the health care system for patients with Duchenne muscular dystrophy (DMD), and patients often present to emergency departments in which providers have little experience in dealing with this condition.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 275
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37406964",
          "text": "Currently, no consensus exists on specific pharmacological therapy guidelines for these patients; however, it centers around the guidelines for heart failure management. This systematic review investigated 12 randomized control trials dating back to 2005 in the pharmacotherapy of patients with dilated cardiomyopathy Duchenne muscular dystrophy. This review specifically included angiotensin-converting enzyme inhibitors, aldosterone receptor blockers, angiotensin receptor/neprilysin inhibitors, beta-blockers, and mineralocorticoid receptor antagonists.",
          "beginSection": "abstract",
          "offsetInBeginSection": 357,
          "endSection": "abstract",
          "offsetInEndSection": 913
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37724986",
          "text": "BACKGROUND AND PURPOSE\nAdvances in multidisciplinary care are extending overall survival in Duchenne muscular dystrophy (DMD) patients. Our research objective was to delineate the clinical characteristics of this particular cohort and identify novel challenges associated with the disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 289
        }
      ],
      "ideal_answer": "The most common issues that need to be addressed in adults with Duchenne Muscular Dystrophy include emergency management, safety of pharmacological treatments for psychiatric symptoms, chronic pain management, and caregivers burden.",
      "exact_answer": [
        [
          "emergency management"
        ],
        [
          "pharmacological treatment safety"
        ],
        [
          "chronic pain management"
        ],
        [
          "caregivers burden"
        ]
      ]
    },
    {
      "id": "6621510eb9f8b89d7e000008",
      "type": "list",
      "body": "What histological features are described in colorectal tumors with BRAF mutation?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
        "http://www.ncbi.nlm.nih.gov/pubmed/32047231",
        "http://www.ncbi.nlm.nih.gov/pubmed/27198569",
        "http://www.ncbi.nlm.nih.gov/pubmed/16381005",
        "http://www.ncbi.nlm.nih.gov/pubmed/27404270",
        "http://www.ncbi.nlm.nih.gov/pubmed/30370522",
        "http://www.ncbi.nlm.nih.gov/pubmed/17143472",
        "http://www.ncbi.nlm.nih.gov/pubmed/12717242",
        "http://www.ncbi.nlm.nih.gov/pubmed/27914130",
        "http://www.ncbi.nlm.nih.gov/pubmed/34341259"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes. Mutations in BRAF were mutually exclusive with mutations in KRAS but showed no clear association with the presence of TP53 mutation. CONCLUSION\nBRAF mutation identifies a colorectal cancer subgroup with distinctive phenotypic properties independent of microsatellite instability status and thus could be a valuable marker for studies into the clinical properties of these tumors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 877,
          "endSection": "abstract",
          "offsetInEndSection": 1475
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 876,
          "endSection": "abstract",
          "offsetInEndSection": 1092
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 877,
          "endSection": "abstract",
          "offsetInEndSection": 1093
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes. Mutations in BRAF were mutually exclusive with mutations in KRAS but showed no clear association with the presence of TP53 mutation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 877,
          "endSection": "abstract",
          "offsetInEndSection": 1226
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "They were 5-10-fold more frequent in tumors with infiltrating lymphocytes, location in the proximal colon, poor histological grade and mucinous appearance (P < 0.002 for each). Tumors with BRAF mutation were also 10-fold more likely to show microsatellite instability and frequent DNA methylation (P < 0.0001) compared to tumors without this mutation. The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 525,
          "endSection": "abstract",
          "offsetInEndSection": 1093
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "They were 5-10-fold more frequent in tumors with infiltrating lymphocytes, location in the proximal colon, poor histological grade and mucinous appearance (P < 0.002 for each). Tumors with BRAF mutation were also 10-fold more likely to show microsatellite instability and frequent DNA methylation (P < 0.0001) compared to tumors without this mutation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 525,
          "endSection": "abstract",
          "offsetInEndSection": 876
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "Tumors with BRAF mutation were also 10-fold more likely to show microsatellite instability and frequent DNA methylation (P < 0.0001) compared to tumors without this mutation. The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 702,
          "endSection": "abstract",
          "offsetInEndSection": 1093
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32047231",
          "text": "Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 185
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "RESULTS\nMutations in BRAF were identified in 8% (23/275) of colorectal cancers. They were 5-10-fold more frequent in tumors with infiltrating lymphocytes, location in the proximal colon, poor histological grade and mucinous appearance (P < 0.002 for each). Tumors with BRAF mutation were also 10-fold more likely to show microsatellite instability and frequent DNA methylation (P < 0.0001) compared to tumors without this mutation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 445,
          "endSection": "abstract",
          "offsetInEndSection": 876
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "The aim of the present study was to evaluate the clinical, pathological and molecular phenotype of colorectal tumors with BRAF mutations. RESULTS\nMutations in BRAF were identified in 8% (23/275) of colorectal cancers. They were 5-10-fold more frequent in tumors with infiltrating lymphocytes, location in the proximal colon, poor histological grade and mucinous appearance (P < 0.002 for each).",
          "beginSection": "abstract",
          "offsetInBeginSection": 305,
          "endSection": "abstract",
          "offsetInEndSection": 701
        }
      ],
      "ideal_answer": "Colorectal tumors with BRAF mutation are characterized by infiltrating lymphocytes, poor grade, and mucinous histological features. These features remain consistent regardless of microsatellite instability and methylator phenotypes.",
      "exact_answer": [
        [
          "infiltrating lymphocytes"
        ],
        [
          "poor grade"
        ],
        [
          "mucinous"
        ]
      ]
    },
    {
      "id": "662e44e9187cba990d00000b",
      "type": "yesno",
      "body": "Is vaccination against all arboviruses indicated for pregnant women?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
        "http://www.ncbi.nlm.nih.gov/pubmed/23151167",
        "http://www.ncbi.nlm.nih.gov/pubmed/34462162",
        "http://www.ncbi.nlm.nih.gov/pubmed/14739654",
        "http://www.ncbi.nlm.nih.gov/pubmed/21777636",
        "http://www.ncbi.nlm.nih.gov/pubmed/33096597",
        "http://www.ncbi.nlm.nih.gov/pubmed/31616947",
        "http://www.ncbi.nlm.nih.gov/pubmed/15701552",
        "http://www.ncbi.nlm.nih.gov/pubmed/14638392",
        "http://www.ncbi.nlm.nih.gov/pubmed/12782056"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
          "text": "Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines. Recommendations on use of these vaccines in pregnancy vary. Other arboviral vaccines have been licensed but are not indicated for use in pregnant travelers (e.g., dengue vaccines) or are in development (e.g., chikungunya, Zika vaccines).",
          "beginSection": "abstract",
          "offsetInBeginSection": 287,
          "endSection": "abstract",
          "offsetInEndSection": 718
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
          "text": "Some arboviral infections can be of particular concern for pregnant women or their fetuses. Vaccination is one preventive measure that can reduce the risk for infection. Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 117,
          "endSection": "abstract",
          "offsetInEndSection": 480
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
          "text": "Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines. Recommendations on use of these vaccines in pregnancy vary.",
          "beginSection": "abstract",
          "offsetInBeginSection": 287,
          "endSection": "abstract",
          "offsetInEndSection": 540
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
          "text": "Vaccination is one preventive measure that can reduce the risk for infection. Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines. Recommendations on use of these vaccines in pregnancy vary.",
          "beginSection": "abstract",
          "offsetInBeginSection": 209,
          "endSection": "abstract",
          "offsetInEndSection": 540
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
          "text": "Vaccination is one preventive measure that can reduce the risk for infection. Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 209,
          "endSection": "abstract",
          "offsetInEndSection": 480
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
          "text": "Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines.",
          "beginSection": "abstract",
          "offsetInBeginSection": 287,
          "endSection": "abstract",
          "offsetInEndSection": 480
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14739654",
          "text": "Although there is a safe, inexpensive and efficacious vaccine against yellow fever, vaccination against other flavivirus diseases is less successful. There is no licensed vaccine against dengue fever and current vaccines against tick-borne encephalitis (TBE) and Japanese encephalitis are expensive and require several injections. Furthermore novel vaccines containing only virus envelope proteins may raise fears over antibody mediated enhancement (ADE) of disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 466
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14739654",
          "text": "Although there is a safe, inexpensive and efficacious vaccine against yellow fever, vaccination against other flavivirus diseases is less successful. There is no licensed vaccine against dengue fever and current vaccines against tick-borne encephalitis (TBE) and Japanese encephalitis are expensive and require several injections.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 330
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
          "text": "Other arboviral vaccines have been licensed but are not indicated for use in pregnant travelers (e.g., dengue vaccines) or are in development (e.g., chikungunya, Zika vaccines).",
          "beginSection": "abstract",
          "offsetInBeginSection": 541,
          "endSection": "abstract",
          "offsetInEndSection": 718
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
          "text": "Other arboviral vaccines have been licensed but are not indicated for use in pregnant travelers (e.g., dengue vaccines) or are in development (e.g., chikungunya, Zika vaccines). This review describes arboviral vaccines for travelers, focusing on women who are pregnant and those planning travel during pregnancy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 541,
          "endSection": "abstract",
          "offsetInEndSection": 853
        }
      ],
      "ideal_answer": "No, vaccination against all arboviruses is not indicated for pregnant women. While vaccines for Japanese encephalitis, yellow fever, and tick-borne encephalitis can be used, recommendations vary. Other arboviral vaccines, such as those for dengue and Zika, are not indicated for use in pregnant travelers or are still in development.",
      "exact_answer": "no"
    },
    {
      "id": "662fc4b1187cba990d000016",
      "type": "list",
      "body": "What are the mechanisms of action of regorafenib on tumor cells?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31715423",
        "http://www.ncbi.nlm.nih.gov/pubmed/26419617",
        "http://www.ncbi.nlm.nih.gov/pubmed/28954993",
        "http://www.ncbi.nlm.nih.gov/pubmed/29262623",
        "http://www.ncbi.nlm.nih.gov/pubmed/32052681",
        "http://www.ncbi.nlm.nih.gov/pubmed/26399347",
        "http://www.ncbi.nlm.nih.gov/pubmed/24763611",
        "http://www.ncbi.nlm.nih.gov/pubmed/33753566",
        "http://www.ncbi.nlm.nih.gov/pubmed/29359239",
        "http://www.ncbi.nlm.nih.gov/pubmed/32397371"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31715423",
          "text": "Additionally, it inhibits molecular escape pathways to VEGF inhibition (e.g., FGF, PIGF, and PDGF signaling), enabling its continuous antiangiogenic effect even in tumors resistant to VEGF inhibitors. Furthermore, regorafenib has the important effect of enhancing anti-tumor immunity via macrophage modulation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 731,
          "endSection": "abstract",
          "offsetInEndSection": 1041
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31715423",
          "text": "Additionally, it inhibits molecular escape pathways to VEGF inhibition (e.g., FGF, PIGF, and PDGF signaling), enabling its continuous antiangiogenic effect even in tumors resistant to VEGF inhibitors. Furthermore, regorafenib has the important effect of enhancing anti-tumor immunity via macrophage modulation. Based on this concept, clinical trials have been recently launched for the development of a combination strategy with immune checkpoint inhibitors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 731,
          "endSection": "abstract",
          "offsetInEndSection": 1189
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31715423",
          "text": "The dual blockade of VEGF receptors and TIE2 can lead to both additive anti-angiogenesis effects and the suggestive unique regulation of vessel stability. Additionally, it inhibits molecular escape pathways to VEGF inhibition (e.g., FGF, PIGF, and PDGF signaling), enabling its continuous antiangiogenic effect even in tumors resistant to VEGF inhibitors. Furthermore, regorafenib has the important effect of enhancing anti-tumor immunity via macrophage modulation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 576,
          "endSection": "abstract",
          "offsetInEndSection": 1041
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954993",
          "text": "In addition to endothelial cells, cancer cells express the three receptors, suggesting that the antiangiogenic inhibitors affect tumor cells. In fact, we previously demonstrated that regorafenib directly acted on human colorectal cancer cells and accelerated their apoptosis resistance and migration capability. Thus, we here elucidated how regorafenib induced the malignant phenotypes in colorectal cancer cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 394,
          "endSection": "abstract",
          "offsetInEndSection": 807
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954993",
          "text": "Thus, the antiangiogenic agents, such as regorafenib, simultaneously target those receptors on vascular endothelial cells. In addition to endothelial cells, cancer cells express the three receptors, suggesting that the antiangiogenic inhibitors affect tumor cells. In fact, we previously demonstrated that regorafenib directly acted on human colorectal cancer cells and accelerated their apoptosis resistance and migration capability.",
          "beginSection": "abstract",
          "offsetInBeginSection": 271,
          "endSection": "abstract",
          "offsetInEndSection": 705
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954993",
          "text": "In addition to endothelial cells, cancer cells express the three receptors, suggesting that the antiangiogenic inhibitors affect tumor cells. In fact, we previously demonstrated that regorafenib directly acted on human colorectal cancer cells and accelerated their apoptosis resistance and migration capability.",
          "beginSection": "abstract",
          "offsetInBeginSection": 394,
          "endSection": "abstract",
          "offsetInEndSection": 705
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954993",
          "text": "Tumor angiogenesis is regulated by multiple signaling pathways, including VEGF and VEGF receptor (VEGF-R), FGF and FGF receptor (FGF-R), and PDGF and PDGF receptor (PDGF-R) pathways. Thus, the antiangiogenic agents, such as regorafenib, simultaneously target those receptors on vascular endothelial cells. In addition to endothelial cells, cancer cells express the three receptors, suggesting that the antiangiogenic inhibitors affect tumor cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 88,
          "endSection": "abstract",
          "offsetInEndSection": 535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954993",
          "text": "Thus, the antiangiogenic agents, such as regorafenib, simultaneously target those receptors on vascular endothelial cells. In addition to endothelial cells, cancer cells express the three receptors, suggesting that the antiangiogenic inhibitors affect tumor cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 271,
          "endSection": "abstract",
          "offsetInEndSection": 535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954993",
          "text": "Recently, inhibition of tumor angiogenesis has become an important anti-cancer therapy. Tumor angiogenesis is regulated by multiple signaling pathways, including VEGF and VEGF receptor (VEGF-R), FGF and FGF receptor (FGF-R), and PDGF and PDGF receptor (PDGF-R) pathways. Thus, the antiangiogenic agents, such as regorafenib, simultaneously target those receptors on vascular endothelial cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 393
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954993",
          "text": "In fact, we previously demonstrated that regorafenib directly acted on human colorectal cancer cells and accelerated their apoptosis resistance and migration capability. Thus, we here elucidated how regorafenib induced the malignant phenotypes in colorectal cancer cells. To identify the responsible receptor among the regorafenib-targeting proangiogenic receptors, we examined the effects of a potent selective inhibitor for VEGF-R, FGF-R or PDGF-R on apoptosis resistance and migration capability.",
          "beginSection": "abstract",
          "offsetInBeginSection": 536,
          "endSection": "abstract",
          "offsetInEndSection": 1035
        }
      ],
      "ideal_answer": "Regorafenib has multiple mechanisms of action on tumor cells. It inhibits RAF1, blocks VEGF receptors and TIE2, and interferes with FGF, PIGF, and PDGF signaling. Additionally, it modulates macrophages.",
      "exact_answer": []
    },
    {
      "id": "661d5fe1eac11fad33000024",
      "type": "list",
      "body": "What are the types of Polycystic Kidney Disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24584572",
        "http://www.ncbi.nlm.nih.gov/pubmed/16767405",
        "http://www.ncbi.nlm.nih.gov/pubmed/30523303",
        "http://www.ncbi.nlm.nih.gov/pubmed/8005596",
        "http://www.ncbi.nlm.nih.gov/pubmed/33474686",
        "http://www.ncbi.nlm.nih.gov/pubmed/36362756",
        "http://www.ncbi.nlm.nih.gov/pubmed/12832752",
        "http://www.ncbi.nlm.nih.gov/pubmed/28473970",
        "http://www.ncbi.nlm.nih.gov/pubmed/10328473",
        "http://www.ncbi.nlm.nih.gov/pubmed/25753522"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30523303",
          "text": "Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are cilia-related disorders and the two main forms of monogenic cystic kidney diseases. ADPKD is a common disease that mostly presents in adults, whereas ARPKD is a rarer and often more severe form of polycystic kidney disease (PKD) that usually presents perinatally or in early childhood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 93,
          "endSection": "abstract",
          "offsetInEndSection": 493
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30523303",
          "text": "Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are cilia-related disorders and the two main forms of monogenic cystic kidney diseases. ADPKD is a common disease that mostly presents in adults, whereas ARPKD is a rarer and often more severe form of polycystic kidney disease (PKD) that usually presents perinatally or in early childhood. Cell biological and clinical research approaches have expanded our knowledge of the pathogenesis of ADPKD and ARPKD and revealed some mechanistic overlap between them.",
          "beginSection": "abstract",
          "offsetInBeginSection": 93,
          "endSection": "abstract",
          "offsetInEndSection": 661
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30523303",
          "text": "Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are cilia-related disorders and the two main forms of monogenic cystic kidney diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 93,
          "endSection": "abstract",
          "offsetInEndSection": 291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33474686",
          "text": "Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are characterized by bilateral cystic kidney disease leading to progressive kidney function decline. These diseases also have distinct liver manifestations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 267
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33474686",
          "text": "Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are characterized by bilateral cystic kidney disease leading to progressive kidney function decline. These diseases also have distinct liver manifestations. The range of clinical presentation and severity of both ADPKD and ARPKD is much wider than was once recognized.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 379
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33474686",
          "text": "Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are characterized by bilateral cystic kidney disease leading to progressive kidney function decline.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 211
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30523303",
          "text": "Cystic kidneys are common causes of end-stage renal disease, both in children and in adults. Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are cilia-related disorders and the two main forms of monogenic cystic kidney diseases. ADPKD is a common disease that mostly presents in adults, whereas ARPKD is a rarer and often more severe form of polycystic kidney disease (PKD) that usually presents perinatally or in early childhood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 493
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28473970",
          "text": "In pediatric patients, the term polycystic kidney disease (PKD) commonly refers to two specific hereditary diseases, autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD).",
          "beginSection": "abstract",
          "offsetInBeginSection": 152,
          "endSection": "abstract",
          "offsetInEndSection": 380
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30523303",
          "text": "Cystic kidneys are common causes of end-stage renal disease, both in children and in adults. Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are cilia-related disorders and the two main forms of monogenic cystic kidney diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28473970",
          "text": "Cystic kidney diseases comprise a varied collection of hereditary disorders, where renal cysts comprise a major element of their pleiotropic phenotype. In pediatric patients, the term polycystic kidney disease (PKD) commonly refers to two specific hereditary diseases, autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD). Remarkable progress has been made in understanding the complex molecular and cellular mechanisms of renal cyst formation in ARPKD and ADPKD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 521
        }
      ],
      "ideal_answer": "There are two types of Polycystic Kidney Disease (PKD): Autosomal Recessive Polycystic Kidney Disease (ARPKD) and Autosomal Dominant Polycystic Kidney Disease (ADPKD). While ARPKD usually presents in childhood, early onset can also occur in ADPKD.",
      "exact_answer": [
        [
          "ARPKD"
        ],
        [
          "ADPKD"
        ]
      ]
    },
    {
      "id": "66214f52b9f8b89d7e000005",
      "type": "yesno",
      "body": "Is tumor expression of Topoisomerase I a biomarker of response to irinotecan in colorectal cancer patients therapy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
        "http://www.ncbi.nlm.nih.gov/pubmed/22108516",
        "http://www.ncbi.nlm.nih.gov/pubmed/29261002",
        "http://www.ncbi.nlm.nih.gov/pubmed/30881507",
        "http://www.ncbi.nlm.nih.gov/pubmed/20371676",
        "http://www.ncbi.nlm.nih.gov/pubmed/27577551",
        "http://www.ncbi.nlm.nih.gov/pubmed/15996331",
        "http://www.ncbi.nlm.nih.gov/pubmed/28880238",
        "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
        "http://www.ncbi.nlm.nih.gov/pubmed/24966994"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
          "text": "CONCLUSION\nPatients with resected CRC expressing Topo I seem to benefit from irinotecan-containing adjuvant chemotherapy. However randomised prospective trials are needed to confirm these results.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1469,
          "endSection": "abstract",
          "offsetInEndSection": 1665
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
          "text": "Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 182
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
          "text": "BACKGROUND\nThymidylate synthase (TS) and Topoisomerase I (Topo I) are significant biomarkers in colorectal cancer (CRC). We aimed to study the expression of TS and Topo I in patients with resected CRC who received adjuvant chemotherapy and correlated it with clinical outcome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 276
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
          "text": "BACKGROUND\nThymidylate synthase (TS) and Topoisomerase I (Topo I) are significant biomarkers in colorectal cancer (CRC). We aimed to study the expression of TS and Topo I in patients with resected CRC who received adjuvant chemotherapy and correlated it with clinical outcome. METHODS\nAll patients diagnosed with CRC between 1989 and 2007 and treated with adjuvant chemotherapy within Hellenic Cooperative Oncology Group's (HeCOG) protocols, were identified.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 460
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29261002",
          "text": "Topoisomerase 1 (TOPO-1) and carboxylesterase 2 (CES-2) are found to play crucial roles in the pathogenesis of various cancers. The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown. In the current study, we assessed the expression of TOPO-1 and CES-2 in mCRC and analyzed its potential relevance to irinotecan based therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 422
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29261002",
          "text": "Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 131
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29261002",
          "text": "The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown. In the current study, we assessed the expression of TOPO-1 and CES-2 in mCRC and analyzed its potential relevance to irinotecan based therapy. A total of 98 patients with mCRC were included in this study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 128,
          "endSection": "abstract",
          "offsetInEndSection": 484
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29261002",
          "text": "Topoisomerase 1 (TOPO-1) and carboxylesterase 2 (CES-2) are found to play crucial roles in the pathogenesis of various cancers. The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 279
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29261002",
          "text": "The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown. In the current study, we assessed the expression of TOPO-1 and CES-2 in mCRC and analyzed its potential relevance to irinotecan based therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 128,
          "endSection": "abstract",
          "offsetInEndSection": 422
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
          "text": "CONCLUSION\nPatients with resected CRC expressing Topo I seem to benefit from irinotecan-containing adjuvant chemotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1469,
          "endSection": "abstract",
          "offsetInEndSection": 1590
        }
      ],
      "ideal_answer": "Yes, tumor expression of Topoisomerase I is a biomarker of response to irinotecan in colorectal cancer patients therapy. The context states that patients with resected colorectal cancer (CRC) expressing Topoisomerase I (Topo I) seem to benefit from irinotecan-containing adjuvant chemotherapy.",
      "exact_answer": "yes"
    },
    {
      "id": "662f401b187cba990d00000e",
      "type": "yesno",
      "body": "Is Vitamin D deficiency associated with sepsis mortality?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
        "http://www.ncbi.nlm.nih.gov/pubmed/26800186",
        "http://www.ncbi.nlm.nih.gov/pubmed/35715206",
        "http://www.ncbi.nlm.nih.gov/pubmed/36769240",
        "http://www.ncbi.nlm.nih.gov/pubmed/37892385",
        "http://www.ncbi.nlm.nih.gov/pubmed/29184435",
        "http://www.ncbi.nlm.nih.gov/pubmed/25179041",
        "http://www.ncbi.nlm.nih.gov/pubmed/27632669",
        "http://www.ncbi.nlm.nih.gov/pubmed/19710612",
        "http://www.ncbi.nlm.nih.gov/pubmed/26120004"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26800186",
          "text": "Conclusions Vitamin D deficiency detected upon ICU admission was not associated with 90-day mortality in patients with severe sepsis or septic shock. Key messages In severe sepsis and septic shock, a vitamin D deficiency upon ICU admission was not associated with increased mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1145,
          "endSection": "abstract",
          "offsetInEndSection": 1429
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
          "text": "However, past studies have reported inconsistent results regarding the association between vitamin D deficiency and mortality in patients with sepsis, and early-stage data regarding septic shock are limited. This study aimed to determine the relationship between vitamin D deficiency on admission to the emergency department (ED) and mortality in patients with septic shock.",
          "beginSection": "abstract",
          "offsetInBeginSection": 106,
          "endSection": "abstract",
          "offsetInEndSection": 480
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26800186",
          "text": "Vitamin D deficiency at admission is not associated with 90-day mortality in patients with severe sepsis or septic shock: Observational FINNAKI cohort study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 157
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
          "text": "However, past studies have reported inconsistent results regarding the association between vitamin D deficiency and mortality in patients with sepsis, and early-stage data regarding septic shock are limited. This study aimed to determine the relationship between vitamin D deficiency on admission to the emergency department (ED) and mortality in patients with septic shock. METHODS\nWe analyzed prospectively collected data on adult patients with septic shock who were treated with protocol-driven resuscitation bundle therapy in the ED between September 2019 and February 2021.",
          "beginSection": "abstract",
          "offsetInBeginSection": 106,
          "endSection": "abstract",
          "offsetInEndSection": 686
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
          "text": "However, past studies have reported inconsistent results regarding the association between vitamin D deficiency and mortality in patients with sepsis, and early-stage data regarding septic shock are limited.",
          "beginSection": "abstract",
          "offsetInBeginSection": 106,
          "endSection": "abstract",
          "offsetInEndSection": 313
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
          "text": "CONCLUSIONS\nVitamin D deficiency was prevalent in patients with septic shock visiting the ED and was associated with mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1497,
          "endSection": "abstract",
          "offsetInEndSection": 1624
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
          "text": "Vitamin D deficiency was prevalent in patients with septic shock visiting the ED and was associated with mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1504,
          "endSection": "abstract",
          "offsetInEndSection": 1619
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
          "text": "BACKGROUND\nVitamin D is an important immune modulator and is associated with susceptibility to infection. However, past studies have reported inconsistent results regarding the association between vitamin D deficiency and mortality in patients with sepsis, and early-stage data regarding septic shock are limited. This study aimed to determine the relationship between vitamin D deficiency on admission to the emergency department (ED) and mortality in patients with septic shock.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 480
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26800186",
          "text": "Conclusions Vitamin D deficiency detected upon ICU admission was not associated with 90-day mortality in patients with severe sepsis or septic shock.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1145,
          "endSection": "abstract",
          "offsetInEndSection": 1294
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26800186",
          "text": "Introduction Low levels of vitamin D have been associated with increased mortality in patients that are critically ill. This study explored whether vitamin D levels were associated with 90-day mortality in severe sepsis or septic shock.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 236
        }
      ],
      "ideal_answer": "Yes, Vitamin D deficiency is associated with sepsis mortality. The study found that Vitamin D deficiency was prevalent in patients with septic shock visiting the ED and was associated with mortality.",
      "exact_answer": "yes"
    },
    {
      "id": "66214b9cb9f8b89d7e000001",
      "type": "list",
      "body": "Which countries have a higher incidence of colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35397795",
        "http://www.ncbi.nlm.nih.gov/pubmed/34831918",
        "http://www.ncbi.nlm.nih.gov/pubmed/22964866",
        "http://www.ncbi.nlm.nih.gov/pubmed/22310896",
        "http://www.ncbi.nlm.nih.gov/pubmed/27239121",
        "http://www.ncbi.nlm.nih.gov/pubmed/11151903",
        "http://www.ncbi.nlm.nih.gov/pubmed/29900136",
        "http://www.ncbi.nlm.nih.gov/pubmed/32963484",
        "http://www.ncbi.nlm.nih.gov/pubmed/26110595",
        "http://www.ncbi.nlm.nih.gov/pubmed/9536601"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35397795",
          "text": "Taiwan (province of China; 62·0 [48·9-80·0] per 100 000), Monaco (60·7 [48·5-73·6] per 100 000), and Andorra (56·6 [42·8-71·9] per 100 000) had the highest age-standardised incidence rates, while Greenland (31·4 [26·0-37·1] per 100 000), Brunei (30·3 [26·6-34·1] per 100 000), and Hungary (28·6 [23·6-34·0] per 100 000) had the highest age-standardised mortality rates. From 1990 through 2019, a substantial rise in incidence rates was observed in younger adults (age <50 years), particularly in high Socio-demographic Index (SDI) countries. Globally, a diet low in milk (15·6%), smoking (13·3%), a diet low in calcium (12·9%), and alcohol use (9·9%) were the main contributors to colorectal cancer DALYs in 2019.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1623,
          "endSection": "abstract",
          "offsetInEndSection": 2336
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35397795",
          "text": "Taiwan (province of China; 62·0 [48·9-80·0] per 100 000), Monaco (60·7 [48·5-73·6] per 100 000), and Andorra (56·6 [42·8-71·9] per 100 000) had the highest age-standardised incidence rates, while Greenland (31·4 [26·0-37·1] per 100 000), Brunei (30·3 [26·6-34·1] per 100 000), and Hungary (28·6 [23·6-34·0] per 100 000) had the highest age-standardised mortality rates.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1620,
          "endSection": "abstract",
          "offsetInEndSection": 1989
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35397795",
          "text": "Taiwan (province of China; 62·0 [48·9-80·0] per 100 000), Monaco (60·7 [48·5-73·6] per 100 000), and Andorra (56·6 [42·8-71·9] per 100 000) had the highest age-standardised incidence rates, while Greenland (31·4 [26·0-37·1] per 100 000), Brunei (30·3 [26·6-34·1] per 100 000), and Hungary (28·6 [23·6-34·0] per 100 000) had the highest age-standardised mortality rates.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1623,
          "endSection": "abstract",
          "offsetInEndSection": 1992
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35397795",
          "text": "Taiwan (province of China; 62·0 [48·9-80·0] per 100 000), Monaco (60·7 [48·5-73·6] per 100 000), and Andorra (56·6 [42·8-71·9] per 100 000) had the highest age-standardised incidence rates, while Greenland (31·4 [26·0-37·1] per 100 000), Brunei (30·3 [26·6-34·1] per 100 000), and Hungary (28·6 [23·6-34·0] per 100 000) had the highest age-standardised mortality rates. From 1990 through 2019, a substantial rise in incidence rates was observed in younger adults (age <50 years), particularly in high Socio-demographic Index (SDI) countries.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1623,
          "endSection": "abstract",
          "offsetInEndSection": 2164
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22964866",
          "text": "BACKGROUND\nColorectal cancer (CRC) is the most common cancer in Taiwan. Colorectal cancer screening can prevent or detect cancer early, but the acceptance rate in rural southern Taiwan is unknown.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 196
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22964866",
          "text": "BACKGROUND\nColorectal cancer (CRC) is the most common cancer in Taiwan.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 71
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22964866",
          "text": "BACKGROUND\nColorectal cancer (CRC) is the most common cancer in Taiwan. Colorectal cancer screening can prevent or detect cancer early, but the acceptance rate in rural southern Taiwan is unknown. OBJECTIVE\nThe purpose of this study was to explore the prevalence of CRC screening and related factors in rural south Taiwan.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 324
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22310896",
          "text": "BACKGROUND\nThe risk of metachronous colorectal cancer in patients with colorectal cancer is higher than the rate of sporadic colorectal cancer in the average population. We conducted a large-scale, population-based study, with many more clinical cases than in previously published studies, to calculate the incidence of metachronous colorectal cancer. METHODS\nThis is a retrospective study based on data obtained from the Taiwan Cancer Registry from 1988 to 2007.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 465
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22964866",
          "text": "Colorectal cancer screening can prevent or detect cancer early, but the acceptance rate in rural southern Taiwan is unknown.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 196
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35397795",
          "text": "The global age-standardised incidence rate increased from 22·2 (95% UI 21·3-23·0) per 100 000 to 26·7 (24·6-28·9) per 100 000, whereas the age-standardised mortality rate decreased from 14·3 (13·5-14·9) per 100 000 to 13·7 (12·6-14·5) per 100 000 and the age-standardised DALY rate decreased from 308·5 (294·7-320·7) per 100 000 to 295·5 (275·2-313·0) per 100 000 from 1990 through 2019. Taiwan (province of China; 62·0 [48·9-80·0] per 100 000), Monaco (60·7 [48·5-73·6] per 100 000), and Andorra (56·6 [42·8-71·9] per 100 000) had the highest age-standardised incidence rates, while Greenland (31·4 [26·0-37·1] per 100 000), Brunei (30·3 [26·6-34·1] per 100 000), and Hungary (28·6 [23·6-34·0] per 100 000) had the highest age-standardised mortality rates.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1235,
          "endSection": "abstract",
          "offsetInEndSection": 1992
        }
      ],
      "ideal_answer": "Taiwan, Monaco, and Andorra have a higher incidence of colorectal cancer.",
      "exact_answer": [
        [
          "Taiwan"
        ],
        [
          "Monaco"
        ],
        [
          "Andorra"
        ]
      ]
    },
    {
      "id": "66302978187cba990d000034",
      "type": "list",
      "body": "What are the primary and secondary endpoints of Pamrevlumab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
        "http://www.ncbi.nlm.nih.gov/pubmed/31564850",
        "http://www.ncbi.nlm.nih.gov/pubmed/27649492",
        "http://www.ncbi.nlm.nih.gov/pubmed/24381380",
        "http://www.ncbi.nlm.nih.gov/pubmed/23219352",
        "http://www.ncbi.nlm.nih.gov/pubmed/34918368",
        "http://www.ncbi.nlm.nih.gov/pubmed/28483654",
        "http://www.ncbi.nlm.nih.gov/pubmed/28618190",
        "http://www.ncbi.nlm.nih.gov/pubmed/19940277",
        "http://www.ncbi.nlm.nih.gov/pubmed/31575509"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "METHODS\nMISSION (Study 079; NCT02606136) was an open-label, Phase II, single-arm trial of pamrevlumab in 21 non-ambulatory patients with DMD (aged≥12 years, receiving corticosteroids) who received 35-mg/kg intravenous infusions every 2 weeks for 2 years. The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC). Secondary endpoints included other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging.",
          "beginSection": "abstract",
          "offsetInBeginSection": 409,
          "endSection": "abstract",
          "offsetInEndSection": 948
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC). Secondary endpoints included other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging. RESULTS\nFifteen patients completed the trial.",
          "beginSection": "abstract",
          "offsetInBeginSection": 664,
          "endSection": "abstract",
          "offsetInEndSection": 996
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC). Secondary endpoints included other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging.",
          "beginSection": "abstract",
          "offsetInBeginSection": 664,
          "endSection": "abstract",
          "offsetInEndSection": 948
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "Secondary endpoints included other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging. RESULTS\nFifteen patients completed the trial.",
          "beginSection": "abstract",
          "offsetInBeginSection": 762,
          "endSection": "abstract",
          "offsetInEndSection": 996
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "Secondary endpoints included other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging. RESULTS\nFifteen patients completed the trial. Annual change from baseline (SE) in ppFVC was -4.2 (0.7) (95% CI -5.5, -2.8).",
          "beginSection": "abstract",
          "offsetInBeginSection": 762,
          "endSection": "abstract",
          "offsetInEndSection": 1074
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "Secondary endpoints included other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging.",
          "beginSection": "abstract",
          "offsetInBeginSection": 762,
          "endSection": "abstract",
          "offsetInEndSection": 948
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "METHODS\nMISSION (Study 079; NCT02606136) was an open-label, Phase II, single-arm trial of pamrevlumab in 21 non-ambulatory patients with DMD (aged≥12 years, receiving corticosteroids) who received 35-mg/kg intravenous infusions every 2 weeks for 2 years. The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 409,
          "endSection": "abstract",
          "offsetInEndSection": 761
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF), is in Phase III development for treatment of DMD and other diseases. METHODS\nMISSION (Study 079; NCT02606136) was an open-label, Phase II, single-arm trial of pamrevlumab in 21 non-ambulatory patients with DMD (aged≥12 years, receiving corticosteroids) who received 35-mg/kg intravenous infusions every 2 weeks for 2 years. The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 227,
          "endSection": "abstract",
          "offsetInEndSection": 761
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging.",
          "beginSection": "abstract",
          "offsetInBeginSection": 790,
          "endSection": "abstract",
          "offsetInEndSection": 947
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31564850",
          "text": "All participants underwent a pulmonary function test (forced expiratory volume in first second/forced vital capacity, FEV1/FVC; percentage value of predicted FEV1, FEV1%pred), a respiratory muscle strength test (maximal inspiratory pressure, MIP; maximal expiratory pressure, MEP), and an isokinetic test of dominant upper limb after a 24-hr interval (peak torque, PT; PT/body weight, PT/BW; total work, TW; endurance ratio, ER). Results\nA total of 88 patients with stable COPD (age: 65.5±8.7 years) were recruited, of which 73% (64 patients) were male. In the multiple stepwise regression analysis, sex remained as significant impactors in the final model for FEV1%pred (adjusted R2=0.243, P<0.001).",
          "beginSection": "abstract",
          "offsetInBeginSection": 592,
          "endSection": "abstract",
          "offsetInEndSection": 1294
        }
      ],
      "ideal_answer": "The primary endpoint of Pamrevlumab is the change from baseline in percent predicted forced vital capacity (ppFVC). The secondary endpoints include other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging.",
      "exact_answer": [
        [
          "ppFVC"
        ],
        [
          "pulmonary function tests"
        ],
        [
          "upper limb function"
        ],
        [
          "strength assessments"
        ],
        [
          "MRI changes"
        ]
      ]
    },
    {
      "id": "66099ac8fdcbea915f00001f",
      "type": "list",
      "body": "What are the mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22722830",
        "http://www.ncbi.nlm.nih.gov/pubmed/24913799",
        "http://www.ncbi.nlm.nih.gov/pubmed/24553387",
        "http://www.ncbi.nlm.nih.gov/pubmed/37336286",
        "http://www.ncbi.nlm.nih.gov/pubmed/28982154",
        "http://www.ncbi.nlm.nih.gov/pubmed/30980281",
        "http://www.ncbi.nlm.nih.gov/pubmed/24812410",
        "http://www.ncbi.nlm.nih.gov/pubmed/26036643",
        "http://www.ncbi.nlm.nih.gov/pubmed/19943202",
        "http://www.ncbi.nlm.nih.gov/pubmed/33436306"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722830",
          "text": "The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood. Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK).",
          "beginSection": "abstract",
          "offsetInBeginSection": 435,
          "endSection": "abstract",
          "offsetInEndSection": 976
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553387",
          "text": "Heterogeneous and concomitant mutations in KRAS and NRAS were also detected in plasma samples from patients who developed resistance to anti-EGFR antibodies. A mouse xenotransplant from a CRC patient who responded and subsequently relapsed upon EGFR therapy showed exquisite sensitivity to combinatorial treatment with MEK and EGFR inhibitors. Collectively, these results identify genetically distinct mechanisms that mediate secondary resistance to anti-EGFR therapies, all of which reactivate ERK signaling.",
          "beginSection": "abstract",
          "offsetInBeginSection": 968,
          "endSection": "abstract",
          "offsetInEndSection": 1477
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722830",
          "text": "A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers. After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 434
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722830",
          "text": "A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 315
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553387",
          "text": "Colorectal cancers (CRCs) that are sensitive to the anti-epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab almost always develop resistance within several months of initiating therapy. We report the emergence of polyclonal KRAS, NRAS, and BRAF mutations in CRC cells with acquired resistance to EGFR blockade. Regardless of the genetic alterations, resistant cells consistently displayed mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) activation, which persisted after EGFR blockade.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 556
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722830",
          "text": "Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK).",
          "beginSection": "abstract",
          "offsetInBeginSection": 536,
          "endSection": "abstract",
          "offsetInEndSection": 976
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24913799",
          "text": "Molecular profiling of clinical specimens confirmed that genetic alterations of genes in the EGFR-RAS-RAF-MEK signaling pathway and of receptor tyrosine kinases are mechanisms of acquired resistance to anti-EGFR antibodies. The escape from anti-EGFR blockade appears to converge on the (re)activation of MEK-ERK or AKT as revealed in preclinical studies. Circulating tumor DNA and patient derived xenografts have proven useful tools to monitor patients for resistance to anti-EGFR therapy and test combination therapies to overcome or reverse resistance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 660,
          "endSection": "abstract",
          "offsetInEndSection": 1214
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553387",
          "text": "Colorectal cancers (CRCs) that are sensitive to the anti-epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab almost always develop resistance within several months of initiating therapy. We report the emergence of polyclonal KRAS, NRAS, and BRAF mutations in CRC cells with acquired resistance to EGFR blockade.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 335
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24913799",
          "text": "Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies used as therapies for metastatic colorectal cancer patients. Intrinsic mechanisms of resistance, such as RAS mutations, can prevent patients from having a response with clinical benefit. The clinical efficacy of EGFR targeted antibodies is limited by the development of acquired (secondary) resistance, which typically occurs within 3-12 months from the start of therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 473
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722830",
          "text": "Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers. After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug. The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 129,
          "endSection": "abstract",
          "offsetInEndSection": 535
        }
      ],
      "ideal_answer": "Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment is primarily driven by molecular alterations in the EGFR-RAS-RAF-MEK signaling pathway, particularly KRAS mutations, MEK-ERK reactivation, and AKT reactivation. These genetic alterations can be detected non-invasively and often precede radiographic progression.",
      "exact_answer": [
        [
          "KRAS mutations"
        ],
        [
          "MEK-ERK reactivation"
        ],
        [
          "AKT reactivation"
        ]
      ]
    },
    {
      "id": "661d19d5eac11fad33000007",
      "type": "yesno",
      "body": "Can the neonatal Pediatric Sepsis Biomarker Risk Model (nPERSEVERE) accurately predict mortality in neonatal sepsis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
        "http://www.ncbi.nlm.nih.gov/pubmed/23025259",
        "http://www.ncbi.nlm.nih.gov/pubmed/27997530",
        "http://www.ncbi.nlm.nih.gov/pubmed/36605131",
        "http://www.ncbi.nlm.nih.gov/pubmed/28991832",
        "http://www.ncbi.nlm.nih.gov/pubmed/34560770",
        "http://www.ncbi.nlm.nih.gov/pubmed/37656048",
        "http://www.ncbi.nlm.nih.gov/pubmed/26380313",
        "http://www.ncbi.nlm.nih.gov/pubmed/30600951",
        "http://www.ncbi.nlm.nih.gov/pubmed/32617051"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "We derived a new decision tree that is neonate specific (nPERSEVERE) with improved performance compared to IL-8 (sensitivity 100%, specificity 86%, negative predictive value 100%, AUC 0.95, p < 0.0001). CONCLUSIONS\nIL-8 and nPERSEVERE demonstrated good prognostic performance in a small cohort of neonates with sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 831,
          "endSection": "abstract",
          "offsetInEndSection": 1151
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "We derived a new decision tree that is neonate specific (nPERSEVERE) with improved performance compared to IL-8 (sensitivity 100%, specificity 86%, negative predictive value 100%, AUC 0.95, p < 0.0001). CONCLUSIONS\nIL-8 and nPERSEVERE demonstrated good prognostic performance in a small cohort of neonates with sepsis. Moving toward precision medicine in sepsis, our study proposes an important tool for clinical trial prognostic enrichment that needs to be validated in larger studies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 831,
          "endSection": "abstract",
          "offsetInEndSection": 1319
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "Biomarkers estimating baseline mortality risk for neonatal sepsis: nPERSEVERE: neonate-specific sepsis biomarker risk model.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 124
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "Amongst PERSEVERE II biomarkers, IL-8 showed good prognostic performance for mortality prediction with a cutoff of 300 pg/mL (sensitivity 100%, specificity 65%, negative predictive value 100%, AUC 0.87, p 0.0003). We derived a new decision tree that is neonate specific (nPERSEVERE) with improved performance compared to IL-8 (sensitivity 100%, specificity 86%, negative predictive value 100%, AUC 0.95, p < 0.0001). CONCLUSIONS\nIL-8 and nPERSEVERE demonstrated good prognostic performance in a small cohort of neonates with sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 617,
          "endSection": "abstract",
          "offsetInEndSection": 1151
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "Amongst PERSEVERE II biomarkers, IL-8 showed good prognostic performance for mortality prediction with a cutoff of 300 pg/mL (sensitivity 100%, specificity 65%, negative predictive value 100%, AUC 0.87, p 0.0003). We derived a new decision tree that is neonate specific (nPERSEVERE) with improved performance compared to IL-8 (sensitivity 100%, specificity 86%, negative predictive value 100%, AUC 0.95, p < 0.0001).",
          "beginSection": "abstract",
          "offsetInBeginSection": 617,
          "endSection": "abstract",
          "offsetInEndSection": 1033
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23025259",
          "text": "The pediatric sepsis biomarker risk model.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 42
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "IMPACT\nPrognostic and predictive biomarker research is lacking in the newborn intensive care unit. Biomarkers can be used at the time of evaluation for neonatal sepsis (blood culture acquisition) to identify neonates with high baseline mortality risk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1322,
          "endSection": "abstract",
          "offsetInEndSection": 1573
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "RESULTS\nIn a cohort of 59 neonates with a mortality rate of 15.3%, PERSEVERE II was 67% sensitive and 59% specific for mortality, p 0.27. Amongst PERSEVERE II biomarkers, IL-8 showed good prognostic performance for mortality prediction with a cutoff of 300 pg/mL (sensitivity 100%, specificity 65%, negative predictive value 100%, AUC 0.87, p 0.0003). We derived a new decision tree that is neonate specific (nPERSEVERE) with improved performance compared to IL-8 (sensitivity 100%, specificity 86%, negative predictive value 100%, AUC 0.95, p < 0.0001).",
          "beginSection": "abstract",
          "offsetInBeginSection": 479,
          "endSection": "abstract",
          "offsetInEndSection": 1033
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "BACKGROUND\nPrognostic biomarker research neonatal sepsis is lacking. We assessed the utility of a validated pediatric prognostic tool called PERSEVERE II that uses decision tree methodology to predict mortality at discharge in neonates who experienced sepsis. METHODS\nProspective study in a dual-center cohort of neonates with sepsis admitted between June 2020 and December 2021.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 381
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "BACKGROUND\nPrognostic biomarker research neonatal sepsis is lacking. We assessed the utility of a validated pediatric prognostic tool called PERSEVERE II that uses decision tree methodology to predict mortality at discharge in neonates who experienced sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 259
        }
      ],
      "ideal_answer": "Yes, the neonatal Pediatric Sepsis Biomarker Risk Model (nPERSEVERE) can accurately predict mortality in neonatal sepsis. It demonstrated improved performance compared to IL-8 with a sensitivity of 100%, specificity of 86%, and AUC of 0.95.",
      "exact_answer": "yes"
    },
    {
      "id": "662fc0bc187cba990d000011",
      "type": "yesno",
      "body": "Can calcium dietary supplementation reduce the risk of colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26675033",
        "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
        "http://www.ncbi.nlm.nih.gov/pubmed/19116875",
        "http://www.ncbi.nlm.nih.gov/pubmed/8922297",
        "http://www.ncbi.nlm.nih.gov/pubmed/12467133",
        "http://www.ncbi.nlm.nih.gov/pubmed/37621239",
        "http://www.ncbi.nlm.nih.gov/pubmed/15252846",
        "http://www.ncbi.nlm.nih.gov/pubmed/19064518",
        "http://www.ncbi.nlm.nih.gov/pubmed/18843026",
        "http://www.ncbi.nlm.nih.gov/pubmed/8827015"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
          "text": "CONCLUSIONS\nDaily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. The long latency associated with the development of colorectal cancer, along with the seven-year duration of the trial, may have contributed to this null finding.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1444,
          "endSection": "abstract",
          "offsetInEndSection": 1762
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
          "text": "CONCLUSIONS\nDaily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. The long latency associated with the development of colorectal cancer, along with the seven-year duration of the trial, may have contributed to this null finding. Ongoing follow-up will assess the longer-term effect of this intervention.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1444,
          "endSection": "abstract",
          "offsetInEndSection": 1837
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
          "text": "CONCLUSIONS\nDaily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1444,
          "endSection": "abstract",
          "offsetInEndSection": 1599
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
          "text": "There were no significant treatment interactions with baseline characteristics. CONCLUSIONS\nDaily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1362,
          "endSection": "abstract",
          "offsetInEndSection": 1599
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
          "text": " Daily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. The long latency associated with the development of colorectal cancer, along with the seven-year duration of the trial, may have contributed to this null finding. Ongoing follow-up will assess the longer-term effect of this intervention.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1450,
          "endSection": "abstract",
          "offsetInEndSection": 1832
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
          "text": "There were no significant treatment interactions with baseline characteristics. CONCLUSIONS\nDaily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. The long latency associated with the development of colorectal cancer, along with the seven-year duration of the trial, may have contributed to this null finding.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1362,
          "endSection": "abstract",
          "offsetInEndSection": 1762
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
          "text": "The frequency of colorectal-cancer screening and abdominal symptoms was similar in the two groups. There were no significant treatment interactions with baseline characteristics. CONCLUSIONS\nDaily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1263,
          "endSection": "abstract",
          "offsetInEndSection": 1599
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
          "text": "BACKGROUND\nHigher intake of calcium and vitamin D has been associated with a reduced risk of colorectal cancer in epidemiologic studies and polyp recurrence in polyp-prevention trials. However, randomized-trial evidence that calcium with vitamin D supplementation is beneficial in the primary prevention of colorectal cancer is lacking. METHODS\nWe conducted a randomized, double-blind, placebo-controlled trial involving 36,282 postmenopausal women from 40 Women's Health Initiative centers: 18,176 women received 500 mg of elemental calcium as calcium carbonate with 200 IU of vitamin D3 [corrected] twice daily (1000 mg of elemental calcium and 400 IU of vitamin D3) and 18,106 received a matching placebo for an average of 7.0 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 738
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
          "text": "However, randomized-trial evidence that calcium with vitamin D supplementation is beneficial in the primary prevention of colorectal cancer is lacking. METHODS\nWe conducted a randomized, double-blind, placebo-controlled trial involving 36,282 postmenopausal women from 40 Women's Health Initiative centers: 18,176 women received 500 mg of elemental calcium as calcium carbonate with 200 IU of vitamin D3 [corrected] twice daily (1000 mg of elemental calcium and 400 IU of vitamin D3) and 18,106 received a matching placebo for an average of 7.0 years. The incidence of pathologically confirmed colorectal cancer was the designated secondary outcome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 185,
          "endSection": "abstract",
          "offsetInEndSection": 836
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
          "text": "However, randomized-trial evidence that calcium with vitamin D supplementation is beneficial in the primary prevention of colorectal cancer is lacking. METHODS\nWe conducted a randomized, double-blind, placebo-controlled trial involving 36,282 postmenopausal women from 40 Women's Health Initiative centers: 18,176 women received 500 mg of elemental calcium as calcium carbonate with 200 IU of vitamin D3 [corrected] twice daily (1000 mg of elemental calcium and 400 IU of vitamin D3) and 18,106 received a matching placebo for an average of 7.0 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 185,
          "endSection": "abstract",
          "offsetInEndSection": 738
        }
      ],
      "ideal_answer": "No, daily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. However, high calcium intake had a greater protective effect against tumors of the distal colon and rectal cancer vs. proximal colon. Additionally, calcium consumption was inversely related to colorectal cancer risk in Korean population where national average calcium intake level is relatively lower than Western countries.",
      "exact_answer": "no"
    },
    {
      "id": "66300ee7187cba990d00001c",
      "type": "factoid",
      "body": "What is the prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
        "http://www.ncbi.nlm.nih.gov/pubmed/7194435",
        "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
        "http://www.ncbi.nlm.nih.gov/pubmed/7032457",
        "http://www.ncbi.nlm.nih.gov/pubmed/1743411",
        "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
        "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
        "http://www.ncbi.nlm.nih.gov/pubmed/25660133",
        "http://www.ncbi.nlm.nih.gov/pubmed/19385447",
        "http://www.ncbi.nlm.nih.gov/pubmed/29305139"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "text": "The literature shows that about 30-40% of DMD subjects have intellectual disability. In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsive disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 109,
          "endSection": "abstract",
          "offsetInEndSection": 396
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "text": "The literature shows that about 30-40% of DMD subjects have intellectual disability. In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsive disorder. Duchenne muscular dystrophy is not just a muscle disorder, but also a disease that affects the brain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 109,
          "endSection": "abstract",
          "offsetInEndSection": 498
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "text": "BACKGROUND\nDuchenne muscular dystrophy (DMD) is the most frequent and severe form of the dystrophinopathies. The literature shows that about 30-40% of DMD subjects have intellectual disability. In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsive disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 396
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "text": "BACKGROUND\nDuchenne muscular dystrophy (DMD) is the most frequent and severe form of the dystrophinopathies. The literature shows that about 30-40% of DMD subjects have intellectual disability.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 193
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "In this study, we set out to reject the hypothesis that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur no more often than expected by chance. Two index cases and six additional boys with concomitant Duchenne muscular dystrophy and autism spectrum disorder were identified in a muscular dystrophy clinic that approximates the total number of Duchenne muscular dystrophy boys (158) in the state of Massachusetts. The rate of prevalence (6 of 158) was compared with the prevalence rate of autism spectrum disorder in boys in the general population (1.6 in 1,000).",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 769
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
          "text": "The school-age group showed no significant differences in general intellectual abilities. However, our data identified that boys with Duchenne muscular dystrophy experience mild cognitive dysfunction across multiple domains, including visual memory, and verbal and nonverbal executive functioning. Parental reports of 11 boys with the disorder revealed high rates of general behavioral problems (54.5%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 291,
          "endSection": "abstract",
          "offsetInEndSection": 694
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
          "text": "Parental reports of 11 boys with the disorder revealed high rates of general behavioral problems (54.5%). The cognitive profile of boys with Duchenne muscular dystrophy in South Africa is similar to that described elsewhere in the world.",
          "beginSection": "abstract",
          "offsetInBeginSection": 589,
          "endSection": "abstract",
          "offsetInEndSection": 826
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
          "text": "However, our data identified that boys with Duchenne muscular dystrophy experience mild cognitive dysfunction across multiple domains, including visual memory, and verbal and nonverbal executive functioning. Parental reports of 11 boys with the disorder revealed high rates of general behavioral problems (54.5%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 381,
          "endSection": "abstract",
          "offsetInEndSection": 694
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "The rate of prevalence (6 of 158) was compared with the prevalence rate of autism spectrum disorder in boys in the general population (1.6 in 1,000). We rejected the hypothesis that Duchenne muscular dystrophy and autism spectrum disorder co-occurrence was likely to be explained by chance (P = .006). We identify a previously unrecognized association of Duchenne muscular dystrophy with autism spectrum disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 620,
          "endSection": "abstract",
          "offsetInEndSection": 1033
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
          "text": "Parental reports of 11 boys with the disorder revealed high rates of general behavioral problems (54.5%). The cognitive profile of boys with Duchenne muscular dystrophy in South Africa is similar to that described elsewhere in the world. Behavioral problems in our cohort were higher than previously reported.",
          "beginSection": "abstract",
          "offsetInBeginSection": 589,
          "endSection": "abstract",
          "offsetInEndSection": 898
        }
      ],
      "ideal_answer": "The prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy is 22%.",
      "exact_answer": [
        "22%"
      ]
    },
    {
      "id": "660999bffdcbea915f00001b",
      "type": "yesno",
      "body": "Is treatment with acetyl salicylic acid indicated to prevent colorectal adenomas?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12621132",
        "http://www.ncbi.nlm.nih.gov/pubmed/11493722",
        "http://www.ncbi.nlm.nih.gov/pubmed/36084548",
        "http://www.ncbi.nlm.nih.gov/pubmed/12621133",
        "http://www.ncbi.nlm.nih.gov/pubmed/930630",
        "http://www.ncbi.nlm.nih.gov/pubmed/20085565",
        "http://www.ncbi.nlm.nih.gov/pubmed/35653338",
        "http://www.ncbi.nlm.nih.gov/pubmed/17111262",
        "http://www.ncbi.nlm.nih.gov/pubmed/22789400",
        "http://www.ncbi.nlm.nih.gov/pubmed/28431950"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12621132",
          "text": "A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 105
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12621132",
          "text": "Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1767,
          "endSection": "abstract",
          "offsetInEndSection": 1915
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11493722",
          "text": "Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 85
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11493722",
          "text": "Salicylic acid is responsible for the anti-inflammatory action of aspirin, and may cause the reduced risk of colorectal cancer observed in those who take aspirin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 223,
          "endSection": "abstract",
          "offsetInEndSection": 385
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11493722",
          "text": "Salicylic acid is responsible for the anti-inflammatory action of aspirin, and may cause the reduced risk of colorectal cancer observed in those who take aspirin. Yet salicylic acid and other salicylates occur naturally in fruits and plants, while diets rich in these are believed to reduce the risk of colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 223,
          "endSection": "abstract",
          "offsetInEndSection": 544
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11493722",
          "text": "This unique drug belongs to a family of compounds called the salicylates, the simplest of which is salicylic acid, the principal metabolite of aspirin. Salicylic acid is responsible for the anti-inflammatory action of aspirin, and may cause the reduced risk of colorectal cancer observed in those who take aspirin. Yet salicylic acid and other salicylates occur naturally in fruits and plants, while diets rich in these are believed to reduce the risk of colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 71,
          "endSection": "abstract",
          "offsetInEndSection": 544
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11493722",
          "text": "This unique drug belongs to a family of compounds called the salicylates, the simplest of which is salicylic acid, the principal metabolite of aspirin. Salicylic acid is responsible for the anti-inflammatory action of aspirin, and may cause the reduced risk of colorectal cancer observed in those who take aspirin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 71,
          "endSection": "abstract",
          "offsetInEndSection": 385
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12621132",
          "text": "CONCLUSIONS\nDaily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1760,
          "endSection": "abstract",
          "offsetInEndSection": 1920
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36084548",
          "text": "The development of a breakthrough preventive method for colorectal cancer is urgently needed. Aspirin has recently been attracting attention as a cancer preventive drug, and its inhibitory effects on the development of various cancers have been reported in several large prospective studies. However, the underlying molecular mechanisms have not yet been elucidated in detail.",
          "beginSection": "abstract",
          "offsetInBeginSection": 118,
          "endSection": "abstract",
          "offsetInEndSection": 494
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36084548",
          "text": "The development of a breakthrough preventive method for colorectal cancer is urgently needed. Aspirin has recently been attracting attention as a cancer preventive drug, and its inhibitory effects on the development of various cancers have been reported in several large prospective studies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 118,
          "endSection": "abstract",
          "offsetInEndSection": 409
        }
      ],
      "ideal_answer": "Yes, treatment with acetyl salicylic acid (aspirin) is indicated to prevent colorectal adenomas in patients with previous colorectal cancer.",
      "exact_answer": "yes"
    }
  ]
}